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ABSTRACT 
 
Background: Naloxone, an opioid antagonist, offers a powerful tool for 
preventing opioid overdose deaths. Because studies have shown opioid overdose 
education and naloxone distribution (OEND) programs to be a safe, feasible, and 
effective intervention, several policymakers and public health agencies have advocated 
for broader access to this life-saving medication. Community health centers (CHCs) are a 
promising location for expanding naloxone access. This investigation examined the 
experience of CHC-based HIV primary care teams with a variety of overdose education 
and naloxone access (OENA) strategies in order to inform future dissemination efforts.  
Methods: A mixed methods study was conducted with eight CHCs located in 
Massachusetts communities experiencing high opioid overdose fatality rates. Individual 
and group interviews with 29 clinic staff members; clinic and participant surveys; and 
document review were used to elucidate the OENA strategies. The Consolidated 
Framework for Implementation Research guided the data collection process and 
subsequent analysis, which revealed several factors supporting or hindering 
  ix 
implementation of OENA activities in CHC primary care settings. 
Results: Operating in a facilitative state policy environment, the CHCs utilized a 
mix of approaches to OENA: providing clinic-based services, issuing prescriptions, 
utilizing pharmacy standing orders, and making referrals to existing community-based 
OEND programs. With prescribers having limited time and competing priorities, nurses, 
health educators, and other staff played a prominent role in OENA. Pharmacies also 
served as important access points for patients and community residents. Several strategies 
were used to engage patients, including active outreach, partnerships with external 
organizations, and efforts to destigmatize substance use disorders. Clinic staff 
participation was enhanced through leadership support for harm reduction approaches, 
ongoing training, peer modeling, and information sharing.  
Conclusions: This study demonstrated that OENA can be integrated into CHC 
primary care services, adapted to the clinic context, and modified as needed. Successful 
implementation required a systems-level response, grounded in a team-based care model 
and a consideration of patient needs. The process for naloxone reimbursement needs to be 
determined to minimize CHC or patient barriers and ensure sustainability. Clinic training 
and technical assistance plans should be customized according to the staff members’ 
potential roles and their stage of readiness. 
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CHAPTER 1: INTRODUCTION 
The purpose of this study is to identify strategies that support the implementation 
of opioid overdose education and naloxone access (OENA) in community health center 
(CHC) primary care settings in order to help stem the escalation in opioid overdose 
fatalities. Qualitative methods were employed to understand the implementation 
experience, based on individual and group interviews with staff at eight CHC HIV 
primary care programs in the Commonwealth of Massachusetts. The research findings 
will contribute to models for expanding access to this urgently needed, effective, and life-
saving intervention in these settings.  
This chapter provides a brief overview of the background for this study and the 
research methods, which are presented in greater depth in Chapter 2 (Literature Review) 
and Chapter 3 (Research Design and Methods). The chapter starts with an overview of 
recent data on opioid overdose fatalities, followed by a problem statement and the 
research aims. Next, a description of the study rationale and the potential role of this 
research in informing public health practice are described, followed by a summary of the 
dissertation chapters.  
Background and Context 
Deaths from drug overdoses in the United States (U.S.) have more than doubled 
since the 1990s.
1
 Drug overdoses are now the leading cause of accidental death, and have 
surpassed deaths from motor vehicular injuries among adults aged 25–64 nationally in 
2009
2
 and in 35 states and the District of Columbia as of 2013.
3
 Opioids, including both 
prescription opioids and heroin, are responsible for the steep increase, with prescription 
  
2 
opioids causing nearly twice as many deaths as heroin, even though heroin-related 
overdose deaths have more than tripled since 2010.
4
 Nearly 80% of people who recently 
started using heroin previously used prescription opioids— prescribed or not5— and 
switched to or also use heroin which is a cheaper and more accessible drug.
6–9
 
The increase in opioid overdose fatalities has led to national recognition of opioid 
overdose as a major public health issue.
10–12
 Notably, both U.S. presidential candidates 
put the opioid crisis at the top of their 2016 campaign agendas, though they proposed 
vastly different policies.
13
 Furthermore, several state health officials have called for an 
emergency response due to the surge in opioid overdoses.
14–17
 Public health and political 
leaders have recognized that comprehensive, long-term change is needed to address the 
complexities of addiction, but that in the short-term, proven strategies to prevent harm 
and death from opioid overdoses are needed.
18,19
 The expansion of one such strategy in 
CHC primary care settings, called overdose education and naloxone distribution (OEND) 
in community settings, is the focus of this research.  
Naloxone— commonly referred to by its brand name, Narcan™— is an opioid 
antagonist that immediately reverses an overdose upon administration.
20
 It has been the 
standard of care for reversing opioid overdoses by emergency department (ED) and 
emergency medical services (EMS) personnel since 1971.
21
 Numerous studies have 
shown OEND to be a safe, feasible, and effective intervention in community (non-
clinical) settings where persons who inject drugs (PWID) are assisted through harm 
reduction and substance use treatment programs.
22,22–25
 Over 15 years of OEND program 
experience demonstrates that following a brief education session, laypersons who witness 
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an opioid overdose can effectively identify overdose signs and administer intranasal 
naloxone.
26,27
 National public health agencies 
28–32
 and professional associations
33–36
 also 
endorse broad access to naloxone in an effort to curb overdose fatalities. 
Building on the success of community-based OEND programs, there is a need to 
broaden the provision of naloxone to persons who use opioids but do not inject them, 
access harm reduction services, or perceive themselves to be at risk of an opioid 
overdose, including those prescribed chronic opioid therapy for pain management and 
their household members. The latter group is especially significant, as more than half of 
overdose deaths in the U.S. involve a prescription opioid.
4
 Clearly, with the feasibility 
and effectiveness of OEND having been established, there is an urgent need to expand 
access to life-saving naloxone for these individuals as well.  
OEND is an effective intervention that is ripe for widespread dissemination in 
routine primary care clinical care settings.
37
 There has been a recent call to expand access 
to naloxone through clinical care settings, including primary care and pain management 
centers where patients receive long-term care and opioid prescriptions.
38,33,37,39–44
 
Recognizing the need for opioid safety initiatives in clinical care settings, the Substance 
Abuse and Mental Health Services Administration (SAMHSA)
30
 and the Centers for 
Disease Control and Prevention (CDC)
45
 recommend co-prescribing naloxone for 
patients receiving chronic opioid therapy for non-cancer pain management. Furthermore, 
the expanded use of medication-assisted treatment (MAT) programs in primary care 
settings
46
 points to the need for OEND for patients receiving treatment for substance use 
disorder, in accordance with SAMHSA and American Society of Addiction Medicine 
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(ASAM) guidelines.
47,48
 Online training programs, such as Prescribe to Prevent, offer 
prescriber education on OEND.
49,50
 SAMHSA has also created a toolkit for prescribers 
and pharmacists with important information to support implementation.
30
 
Primary care-based OENA interventions can build on lessons learned from 
community-based OEND programs. Some studies have documented barriers to overdose 
education and naloxone prescribing in clinical care settings, including low provider 
awareness of the benefits; discomfort discussing overdose because of the stigma 
surrounding addiction; concern about layperson use of naloxone; complications involved 
in payment, reimbursement, and stocking of naloxone; and competing clinical 
priorities.
39,40,51–55
 While there are some documented clinic-based OENA initiatives in the 
U.S.,
25,41,56
 there is minimal information available about actual implementation 
experience.
37
  
To understand the implementation experience among community health center 
(CHC) primary care programs, this study examined the perspective of CHC HIV primary 
care teams. A meta-analysis found that people living with HIV (PLWH), specifically 
those who inject drugs, are 1.7 times more likely to die from an opioid overdose 
compared to those without HIV.
57
 The specific overdose risk factors for PLWH are not 
clear, though the  literature has suggested several explanations for this increased risk, 
including biological mechanisms as a result of a compromised immune system, increased 
risk-taking behaviors, psychiatric comorbidities, structural factors such as lack of access 
to substance use treatment, homelessness, and incarceration,
57
 plus opioid prescribing 
practices for pain management.
58,59
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Because of the HIV transmission risk of injection drug use, HIV primary care 
providers have been on the front lines of addressing HIV and substance use 
comorbidities. These providers are ideally placed to screen for opioid overdose risk, 
conduct overdose education, prescribe or distribute naloxone, and link or offer persons in 
need of opioid treatment services. CHCs have long focused on addressing HIV and 
substance use comorbidities and implementing innovations in care delivery. Many are 
located within communities affected by the opioid crisis. Given this background, these 
sites can serve as implementation models for other CHC primary care settings. Further-
more, the prevention and treatment response to HIV can serve as a model for how to 
respond to the opioid overdose crisis, including the use of harm reduction approaches, 
clinic-based treatment interventions,
60
 interdisciplinary team models,
61
 and the 
involvement of persons infected and affected by HIV in program decision-making.
62
  
This study focused on clinical care teams that provide routine primary care to 
PLWH at community health centers (CHCs) that were implementing various OENA 
strategies. Massachusetts CHCs were selected as the study setting type for three reasons. 
First, CHCs are located within many of the communities hardest hit by the opioid 
epidemic, and have been at the forefront of addressing public health challenges faced by 
their communities. In Massachusetts, these seemed to be the settings spearheading OEND 
activities. Second, CHCs have received additional state and federal funding to expand 
clinic-based opioid treatment services to patients, thus offering opportunities for both 
current and future OEND implementation.
63,64
 Finally, given the reach of CHC primary 
care settings to persons with and without HIV, findings from these sites are likely to have 
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broader applicability and transferability.  
The Commonwealth of Massachusetts has a policy environment that would likely 
support CHC OENA efforts. Unintentional opioid overdose death rates in the state have 
been rising and stood at 25.8 deaths per 100,000 residents in 2015, a 32% increase from 
the rate of 19.5 deaths per 100,000 in 2014. The 1,574 opioid-related overdose deaths in 
Massachusetts were the highest ever and 2016 data indicate that the numbers deaths are 
continuing to climb.
65
 Both the current and prior Governors have prioritized an urgent 
response, culminating in an action plan by Governor Baker with more than 65 
recommendations proposed by an appointed task force.
15,66
  
One of these recommendations was to build on Massachusetts’ pioneering 
community-based OEND work
67
 by increasing access to naloxone,
68
 including use of 
pharmacy standing orders for naloxone distribution.
69
 Other facilitating policies were 
issued, including guidelines to integrate naloxone provision into state buprenorphine 
treatment programs
70
 and co-prescribing with chronic opioid therapy.
71
 In addition, the 
Commonwealth has several laws in place to support the prescribing and use of naloxone 
by third parties. State-negotiated purchasing agreement resulted in low naloxone cost, 
allowing municipalities increased access to naloxone. Innovative initiatives, including 
several with city police departments, also began in 2015.
72
 New state legislation related 
to first-time opioid prescribing, use of the prescription monitoring program (PMP), and 
treatment referral for persons who overdose was put into place in 2016.
73
 This supportive 
policy context set the stage for this study.  
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Problem Statement 
Both at the national and state levels, policymakers and healthcare professionals 
are seeking to identify promising strategies to reduce the growing number of opioid 
overdoses.
66,74
 Multi-sector, comprehensive strategies are needed to prevent and address 
the complexities of opioid addiction, but in the short term, naloxone offers a safe, 
effective means to reduce deaths from opioid overdose.
49
 Among persons at high risk of 
opioid overdose are PLWH,
57
 both those with an opioid use disorder and those prescribed 
chronic opioid therapy for pain management. CHC primary care settings are opportune 
places for expanding access to this life-saving intervention. Despite the promise, primary 
care settings are underutilized venues for overdose education and naloxone prescribing.
37
 
A better understanding of the strategies and factors that support CHC primary care 
OENA implementation is urgently needed. 
Study Purpose and Research Aims 
The scope of this study was limited to understanding the implementation of 
OENA at CHCs, examined through the lens of clinical care teams providing primary care 
to PLWH at different CHCs in Massachusetts, and with a specific focus on contextual 
factors that affect implementation. The study did not pilot or evaluate an intervention; 
rather, it explored the implementation process, successes, and challenges experienced 
through individual and group interviews with HIV primary care team members. In short, 
the study involved a retrospective and current assessment of “real-world” implementation 
of this relatively new clinic-based innovation.
37
 It is important to emphasize that while 
the study was initiated with the HIV care team members, findings often represented 
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activities conducted across the broader CHC or focused on other populations and not just 
PLWH because of the way in which primary care was integrated at the study sites. 
This study was guided by the following three aims: 
1. To document how opioid OENA strategies are delivered within community health 
center primary care settings; 
2. To identify factors that influence implementation of OENA in this setting, 
examining the intervention, individual, outer setting, inner setting, and process 
domains; and 
3. To determine which strategies are likely to enhance the implementation of OENA 
in community health center primary care settings. 
Research Approach 
Given the nascent stage of OEND in primary care clinical settings, qualitative 
methods were well-suited to address the research aims, as these methods made it possible 
to identify contextual factors that facilitate or hinder such initiatives within CHC settings. 
Surveys were completed by clinic staff to characterize the study participants and clinical 
settings. Observation and review of relevant documents (i.e., posters, EMR templates) 
provided further context to the study findings. All study activities were approved by the 
Boston University Medical Center (BUMC) Institutional Review Board (IRB).  
The study began with three interviews and one focus group with physicians at a 
large, urban HIV clinic in Massachusetts to pilot test the tools and identify barriers and 
facilitators to overdose education and naloxone prescribing in this setting. The 
Consolidated Framework for Implementation Research (CFIR) was selected to guide 
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development of the data collection tools and data analysis. The CFIR is comprised of 
multiple constructs from other health services implementation models, plus factors that 
influence the adoption, implementation, and spread of healthcare delivery practices.
75,76
 
A purposive sampling of eight CHCs in Massachusetts involved in overdose 
prevention and naloxone access activities made it possible to explore different strategies 
and the variety of contextual factors that influenced their implementation. A total of 17 
individual or group interview sessions were conducted with 29 CHC staff members, 
beginning with the HIV medical director or program manager, and then moving to the 
nurses, pharmacists, case managers, and/or health educators identified by the clinical 
team leader or program manager. Relevant documents and observational data were 
collected in conjunction with the interviews. Clinic and participant surveys were 
completed for each study site to describe the study context and the participants. Multiple 
perspectives from different HIV clinics, coupled with the use of different data sources, 
made it possible to triangulate and cross-validate the data.
77
  
Constructs from the CFIR were used to code the data using NVivo 11.0 software
77
 
with certain constructs emerging as predominant from the analysis across the 
framework’s intervention, outer setting, individual, inner setting, and process domains.75 
Throughout the study, content experts and practitioners were consulted to ensure the 
relevance and transferability of the findings.
78
  
Rationale and Significance 
This study seeks to identify strategies for providing opioid overdose education 
and naloxone to patients, and to examine the factors that facilitate or impede their 
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implementation in primary care CHC settings that serve PLWH. Getting naloxone into 
the hands of persons at risk of experiencing or witnessing an opioid overdose offers a 
low-cost, effective way to prevent death. CHC primary care settings have the potential to 
reach persons who may not have access to community-based OEND services, including 
those receiving opioid treatment or prescription opioids. OENA interventions in CHCs 
are essential given increasing use of office-based opioid treatment.
63
 In addition, 
prescription opioids account for the majority of opioid-related deaths.
29
 Primary care 
providers prescribe the most opioids,
79
 and up to one in four patients prescribed chronic 
opioids for non-cancer pain management in primary care settings have experienced an 
opioid use disorder.
80
 At this time, the implementation experience of OENA in CHC 
primary care settings remains unexplored. 
Several studies have identified barriers and facilitators to opioid overdose 
education and naloxone prescribing in various clinical settings, and many of these articles 
revealed provider-level barriers that impede implementation.
37,44,39,25,40,53,55,54
 In contrast, 
this study, for the first time for this topic, examines the full range of critical factors 
known to influence innovation implementation in healthcare settings through a 
comprehensive implementation science framework.
75
 Additionally, the study highlights 
actual implementation experience within CHCs rather than anticipated barriers and 
facilitators. This practice-based experience can support effective replication in other 
primary care clinical settings. 
The timing of this project is also significant, given the attention to the opioid 
epidemic from national and state policymakers, and the recommendation to offer 
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naloxone to patients receiving substance use disorder treatment (i.e., buprenorphine) and 
chronic opioid therapy.
45,81
 Expanding naloxone access is one part of the comprehensive, 
state-based initiatives aimed at decreasing opioid overdose deaths, and this study can 
facilitate an understanding of how to best implement and scale-up this priority activity in 
CHCs reaching PLWH and other individuals at risk of an opioid overdose. 
Summary of Chapters 
This dissertation is comprised of five chapters. Chapter 2 provides a review of the 
literature that describes the opioid epidemic and opioid overdose risk, both in general and 
among PLWH in particular. A summary of OENA programs in community and clinical 
settings is presented, including identified models and barriers to implementation. The 
political and programmatic context of OEND activities in Massachusetts is described 
next to set the stage for the study setting. Chapter 3 outlines the research methodology 
that was employed. The chapter includes a description of the study sample, the 
recruitment process, data collection tools, and data analysis methods. The study setting is 
also described, including survey data summarizing clinic and participant characteristics.  
Chapter 4 describes the qualitative analysis findings along with relevant 
descriptive data from the clinic and participant surveys, organized according to constructs 
from the implementation science framework (CFIR) that emerged from the analysis. This 
chapter addresses the three research aims. Finally, Chapter 5 discusses the findings in 
light of the literature and recommends strategies for future practice and research. To 
conclude, limitations to the study design are assessed. 
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CHAPTER 2: BACKGROUND AND LITERATURE REVIEW 
This chapter summarizes the need for a public health response to prevent opioid 
overdose deaths in the U.S. A brief overview of the rising trends in opioid overdose 
fatalities in both the U.S. and the Commonwealth of Massachusetts, the study setting, is 
provided. Opioid overdose causes and risk factors, both in general and for PLWH, are 
then presented. Both national and Massachusetts’ policy and programmatic responses to 
avert opioid overdose deaths are summarized.  
A review of the literature assessing community-based OEND activities offers 
valuable guidance to help shape future initiatives in CHC primary care settings. Clinic-
based models for OENA, in general, as well as available resources, are then described. 
Barriers to implementation in various clinical settings identified in the literature are 
highlighted, followed by program findings from community-based OEND programs 
related to these barriers.  
Opioid Overdose Explained 
Deaths from drug poisonings (also referred to as drug overdoses) have more than 
doubled in the U.S. since the 1990s.
1
 This increase in overdose deaths, primarily caused 
by opioids, has led to national recognition of opioid overdose as a major public health 
issue.
10,29
 Most overdoses are not fatal, but unfortunately are not rare among people who 
use drugs.
82
 Two different studies reported that 25% and 28% of study participants 
respectively reported a past overdose.
83,84
  Another study reported that 57% of people 
who use drugs in an urban area had witnessed at least one overdose among a peer who 
used drugs.
85
 Knowledge of what constitutes an opioid and leads to opioid overdose is 
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necessary background for addressing this issue. 
Both opiates and opioids are referred to as “opioids.” Opiates are drugs naturally 
derived from the poppy plant (i.e., morphine and heroin), and opioids are synthetic or 
semisynthetic formulations (i.e., prescription painkillers such as hydrocodone, 
oxycodone, fentanyl, and methadone). All opioids bind to receptors in the brain that 
alleviate pain and produce feelings of euphoria.
86
 For that reason, prescription opioids 
play a vital role in the clinical management of pain following surgery, illness, or injury. 
Prescription opioids used in ways other than as prescribed lead to similar effects 
as heroin.
87
 While many people believe prescription opioids to be safe because they are 
prescribed by a medical provider, the physiologic effects and highly addictive properties 
of these medications can lead to misuse, abuse, and dependence.
88–90
 When taken over 
time, opioids create— that is, a need for more or stronger opioids in order to achieve the 
initial effect and eventually to prevent painful symptoms of withdrawal.
91
 
The brain receptors that opioids bind to, resulting in pain relief or a sense of 
euphoria, also control breathing. An overdose occurs when high concentrations of opioids 
bombard these receptors or when opioids are combined with other drugs or alcohol, 
leading to depressed respiratory function.
92
 An overdose is rarely instantaneous, and 
typically happens over a few minutes to hours. During an overdose, a person’s respiratory 
rate decreases, blood pressure drops, and the heart rate decreases. This leads to 
unconsciousness; the victim cannot be awakened, and a blue tone to the skin, lips, and 
fingernail beds develops. Oxygen deprivation can result in cardiac arrest and anoxic brain 
injury, eventually leading to death.
93
 Non-fatal overdoses can lead to long-term 
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morbidities included renal failure, pneumonia, and cognitive impairment.
92,94
  
The mechanisms of opioid overdose are also well understood. As noted earlier, 
opioid abuse can lead to tolerance. Periods of abstinence, such as following drug 
treatment or incarceration, result in decreased tolerance, and therefore use of the same 
dosage of opioids taken previously can lead to overdose. The combination of opioids with 
other medications or alcohol can also depress respiratory rate.
95
 In fact, the majority of 
people who die of a prescription opioid overdose had ingested another drug as well, most 
often a benzodiazepine.
3,95,96
 The increase in heroin adulteration with the synthetic opioid 
fentanyl, led to a surges in opioid overdose deaths beginning in 2013.
97
  
Trends in Opioid Misuse, Abuse, and Overdose 
Drug overdose fatalities surpassed deaths from motor vehicular injuries as the 
leading cause of injury death among adults aged 25–64, both nationally beginning in 
2009
2
 and in 35 states and the District of Columbia as of 2013.
3
  In 2014, 47,055 drug 
overdose deaths occurred in the U.S.— a record high. From 2000 to 2014, the age-
adjusted drug overdose death rate increased from 6.2 per 100,000 persons to 14.7 per 
100,000.
97
 The majority (61% or 28,647) of these deaths were opioid-related, and about 
half (more than 14,000) involved prescription opioids.
4
  
Figure 1 below shows that the age-adjusted rate of opioid-related overdose deaths 
tripled from 2000 to 2014, with a sharp 14% increase from 2013 to 2014, from 7.9 to 9.0 
deaths per 100,000 persons.
97
 This contributed to a drastic increase between 2013 and 
2014 in the number (N=3,073 more deaths) and rate (6.5% higher) of overall drug 
overdose deaths. Massachusetts, the setting of the current study, was one of 14 states that 
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experienced a statistically significant increase in the rate of drug overdose deaths during 
this time period.
97
  
Figure 1. Age-adjusted Rate of Drug Overdose Deaths and Drug Overdose Deaths  
Involving Opioids— U.S., 2000–2014 
 
 
Source: Centers for Disease Control and Prevention. MMWR, 2016.  
 
Figure 2 depicts the rising national trend in drug overdose fatalities caused by 
prescription opioids and heroin.
97
 A dramatic increase in overdose deaths from 2013 to 
2014 (1.0 to 1.8 per 100,000) due to synthetic opioids such as fentanyl, but not including 
methadone, contributed to this spike. Overdose death rates due to natural and 
semisynthetic opioids such as morphine and oxycodone also increased from 2013 to 
2014; they were the greatest contributor to opioid overdose deaths at 3.8 per 100,000 
persons in 2014, up from 3.5 per 100,000 in 2013. Heroin overdose death rates climbed 
by 26% from 2.7 deaths per 100,000 in 2013 to 3.4 deaths per 100,000 in 2014.
97
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Figure 2. Drug Overdose Death Rates Involving Opioids, by Type of Opioid—  
U.S., 2000–2014 
 
Source: Centers for Disease Control and Prevention. MMWR, 2016.  
 
From 1999 to 2014, the highest prescription opioid death rates were among males, 
people aged 25 to 54 years, and non-Hispanic whites and American Indian/Alaskan 
Natives.
4
  While more men die from prescription opioid overdoses, the percentage 
increase in women’s deaths from 1999 to 2012 was more than 400% compared to a 265% 
increase in men’s deaths. This rise in prescription opioid deaths among women has been 
associated with increased prescribing to women.
98
 For heroin-related overdose deaths, 
non-Hispanic whites aged 18 to 44 years experienced the highest overdose death rates.
99
  
The number of prescriptions for opioids in the U.S. has increased over the past ten 
years,
5
 correlating with the surge in fatal overdoses.
100,101
  Non-medical use of 
prescription opioids plays a major role in the overdose death epidemic.
102
 Prescription 
opioids are among the most commonly abused substances in the U.S.
5
 In 2015, more than 
12 million people in the U.S. reported misusing prescription opioids, and over 2 million 
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people reported a prescription opioid use disorder.
103
 Around one in four people who 
receive long-term prescription opioids for non-cancer pain in primary care settings 
experience an opioid use disorder.
80
 Nearly seven out of ten people who reported using 
opioids for non-medical purposes in the prior year obtained the painkillers from a friend 
or relative, 80% of whom got their prescription opioids from just one doctor (Figure 3).
5
 
So while the majority of prescription opioids were in fact prescribed, they often ended up 
being used by people and in ways other than what was prescribed.  
Figure 3. Source of Prescription Opioids, Most Recent Non-medical Use in Past Year, Users 
12 Years and Older— U.S., 2012–2013  
 
 
Source: SAMHSA. Results from the 2013 National Survey on Drug Use and Health: Summary of 
National Findings, 2015.  
 
While previously thought to be separate epidemics, a tight link between 
prescription opioid use and initiation of heroin use has been demonstrated.
88,101,104
 An 
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analysis of the SAMHSA 2011 National Survey on Drug Use and Health data showed 
that among persons 19–49 years of age, nearly 80% who used heroin in the past year used 
prescription opioids non-medically before starting heroin.
105
 This connection is 
unidirectional; only one percent of people recently misusing prescription opioids had 
previously used heroin.
7
 Even though only a small percentage (3.6%) of first-time 
prescription opioid users subsequently started using heroin within five years,
7
 these 
findings do help explain the increase in heroin overdose deaths seen since 2010.
106
  
Several studies help explain the “twin epidemics”107 of prescription opioid and 
heroin addiction. In one study, 39% of heroin injectors reported prior addiction to 
prescription opioids.
108
 In three studies, nearly half of the young adults who injected 
heroin reported abusing prescription opioids before turning to heroin. Their reported 
reasons for switching to heroin included ease of access and affordability compared to 
prescription opioids.
109,110,8,111
 Creation of an abuse-deterrent formulation of the 
prescription painkiller OxyContin has also been associated with switching to heroin.
110
 
Some researchers have hypothesized that increased legislative scrutiny of opioid 
prescribing practices has led to increased uptake in heroin use,
112,113
 though a review of 
deaths from 28 states found that decreases in prescription opioid overdose deaths did not 
correspond with increases in heroin overdose deaths.
114
  
A 2016 CDC analysis revealed the role of polysubstance among people who use 
heroin, with prescription opioid abuse or dependence being the most common. In fact, the 
percentage of people who use heroin with prescription opioid abuse or dependence 
increased from 20.7% in 2002–2004 to 45.2% in 2011–2013.9  It is paramount that 
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overdose prevention strategies take into account the complex interplay between 
prescription opioids and heroin.  
The Study Context: Opioid Overdose Trends in Massachusetts 
Similar to the national trend, the Commonwealth of Massachusetts has 
experienced a continued and sharp increase in opioid overdose mortality (Figure 4).
65
 In 
fact, in 2015 Massachusetts faced a record high number of deaths from unintentional 
opioid overdoses, with 1,574 confirmed cases— a dramatic 43% increase from 2013 (918 
deaths) and a 20% increase from 2014 (1,316 deaths). Every county in the state has 
experienced opioid overdose deaths. Unfortunately, the uptick in deaths does not appear 
to be abating; the number of unintentional opioid-related deaths during the first 9 months 
of 2016 (n=1,005) was higher than what was seen during the same time period in 2015.
65
  
Figure 4: Rate of Unintentional/Undetermined
1 
Opioid
2
-Related Deaths— Massachusetts 
Residents, 2000–2015 
 
Source: Massachusetts Department of Public Health. Data Brief: Opioid-related Overdose Deaths 
Among Massachusetts Residents, November 2016.  
 
In 2014, the Massachusetts opioid overdose death rate of 19.5 deaths per 100,000 
residents exceeded the national rate of 9.0 deaths per 100,000 persons.
97
 In 2015, the 
state’s death rate rose to 25.8 per 100,000, the highest rate that the Commonwealth has 
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ever experienced, and an increase of 32% from 2014.
65
 Similarly, EMS responses to 
opioid-related transports almost doubled between 2013 and 2015.
115
   
Similar to the national trend, the state’s dramatic increases in Schedule II opioid 
prescribing from 2001 to 2011 (88% increase) correlates with increasing opioid-related 
fatalities during that same period.
116
 Toxicology tests have revealed the frequency of 
polysubstance use among people who succumb to an opioid overdose, and the increase in 
fentanyl-related deaths. Among the toxicology screens available from opioid-related 
deaths in 2016, nearly three-quarters (74%) revealed the presence of fentanyl. Heroin was 
present in over half (53%) of the opioid-related deaths. Benzodiazepines and cocaine 
were present in about half and 30% respectively.
65
 
Similar to the national trend, the majority (75%) of unintentional opioid deaths 
were among males and white non-Hispanic (82%) and Hispanic (12%) persons. The toll 
of this epidemic on young adults has been enormous: 58% of opioid deaths in the state 
were among persons aged 25 to 44 years of age compared to only 5% of all deaths in the 
state in 2016.
117
 Opioid-related EMS transports in the state also increased by 18% in the 
first two quarters of 2016 compared to that time period in 2015. Incidents where EMS 
personnel administered naloxone also increased, as did the frequency at which naloxone 
had to be administered more than once, indicating the potency of opioids used.
118
 
Risk Factors for Opioid Overdose  
There are several factors that increase a person’s overdose risk as summarized in 
Table 1.
21,37,41,49,119,120
 As noted above, a person who has used opioids is at risk of an 
overdose following drug treatment or incarceration because of decreased tolerance. 
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Persons with a history of substance abuse, past overdose history, and mental illness are 
also at increased risk of overdose. Patients seeking prescription opioids from multiple 
providers contribute to a significant percentage of overdoses, as many of these patients 
are using opioids for non-medical purposes.
29,121,122
 Use of opioids along with sedatives, 
such as benzodiazepines, antidepressants, and alcohol, greatly increases opioid overdose 
risk.
123,124
 Along with mental health disorders, diseases of the respiratory, circulatory, and 
hepatic systems present additional risks for overdose due to pulmonary and liver 
dysfunction.
94,125
 
The risk of overdose is not limited to those who use heroin or misuse or abuse 
prescription opioids. Complex medication regimens, often managed by different 
providers, can put patients on long-term opioid medication at risk. Higher opioid dosages 
have been associated with higher opioid overdose death rates.
126,127
 This finding is 
particularly concerning given that a report identified an increase of 20% from the period 
of 1999–2002 and 2002–2012 in the percentage of people who were prescribed an opioid 
more potent than morphine.
128
 For this reason, clinic-based OENA programs recommend 
targeting both patients who use opioids as prescribed and those who may be using opioids 
for non-medical reasons.
25
  
Table 1. Patient Risk Factors for Opioid Overdose  
a) History of non-medical use of prescription opioids or heroin 
b) Previous overdose history 
c) Prescribed high-dose opioid prescriptions (>50 mg morphine equivalent/day) 
d) Rotated from one opioid to another 
e) Use of opioids with antidepressants, benzodiazepines, or alcohol 
f) Starting methadone or buprenorphine for addiction treatment 
g) Use of opioids in patients with a respiratory illness or who smoke 
h) Use of opioids in patients with chronic renal, hepatic, or pulmonary disease  
i) Release from a drug detox program or prison following opioid use abstinence  
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Increased Overdose Risk for PLWH 
In 2014, injection drug use was the risk group for an estimated 6% of incident 
HIV infections in the U.S.
129 
Similarly, in Massachusetts, injection drug use was the risk 
group for 7% of persons with incident HIV infections from 2011–2013. In Massachusetts, 
as of January 2015, 18% of the state’s approximately 23,000 PLWH identified injection 
drug use as a risk factor, but about half of all deaths among PLWH were among that 
group.
130
  
While HIV infection is not listed as a specific risk factor in Table 1, opioid 
overdose is a major cause of non-HIV related death among PLWH.
57,131,132
 A brief 
overview of some of these risk factors appears in Table 2.
49,57,131
 Compared to persons 
who use drugs without HIV, those with HIV infection are 1.7 times more likely to die 
from an opioid overdose.
57
  A national study examining causes of death among U.S. 
HIV-seropositive women from 1995 to 2004 found that mortality from non-AIDS causes 
increased over the ten years, with deaths from trauma and intentional or unintentional 
self-harm causing the greatest non-AIDS related mortality, most frequently due to 
overdose.
133
  
Given the connection between injection drug use and overdose, OEND programs 
have prioritized working with HIV-prevention programs designed to reach PWID, 
including syringe access programs,
134
 as PWID are at risk for both HIV transmission and 
overdose. The Massachusetts Overdose Prevention Pilot started as a joint initiative 
between the Massachusetts Department of Public Health (DPH) Bureau of Substance 
Abuse Services and the Office of HIV/AIDS. In the program guide, the DPH specifically 
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identified HIV as a risk factor for opioid overdose among those using opioids, both non-
medically and as prescribed.
135
 The International Eurasian Harm Reduction Network and 
Open Society Foundations implore programs reaching PLWH to integrate opioid 
overdose prevention and naloxone prescribing into their services.
136
  
HIV providers, nurses, and other clinical care team members have been on the 
frontlines of addressing HIV and its comorbidities, including substance use disorder, 
mental health disorder, hepatitis C virus, and other chronic diseases. Along with this 
comes the need to address the risk of a potential overdose, particularly for patients who 
were diagnosed with an opioid use disorder and/or prescribed long-term opioid therapy 
for chronic pain management.  
Table 2: Opioid Overdose Risk Factors for PLWH 
 Past or current use of heroin 
 Non-medical use of prescription opioids 
 Prescribed long-acting opioids for chronic pain management 
 Diagnosed with conditions or comorbidities known to increase risk of overdose 
 Use of opioids with other prescription medications associated with increased risk of 
overdose 
 
It is important to note that there are several explanations for PLWH increased risk 
of overdose, as described in a systematic review and met-analysis of 27 studies, including 
biological, behavioral, and structural mechanisms. Several co-infections, including 
hepatitis C virus, occur frequently among PWID.
137
 As PLWH are living longer due to 
anti-retroviral therapy (ART), the combination of HIV and other chronic conditions are 
likely to compromise long-term health. For example, persons with both HIV and diabetes 
are at significantly increased risk of progressive chronic kidney diseases compared to 
those with only HIV or only diabetes.
138
 Many of these comorbidities can compromise 
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the metabolic and respiratory systems
57
 and can increase the likelihood of an overdose as 
well as lessen the chances of survival from an overdose.
135
   
Immune system functioning among PLWH has also been thought to affect 
overdose risk. One study among a cohort of women with HIV in the U.S. reported an 
association between the level of HIV and overdose/traumatic death.
133
 Another study 
found that the risk of overdose is reduced by 5.7% if ART is initiated early rather than 
deferred.
139
 
A meta-analysis of studies revealed several other causal factors thought to be 
associated with increased risk. These included structural factors such as poor access to 
medication-assisted therapy, homelessness, and poverty. Incarceration release has also 
been found to increase the risk of overdose among persons who contracted HIV through 
injection drug use because they have not taken opioids for a period of time and so are 
more severely affected by a dosage level they may have taken in the past.
39
  
Opioid prescribing patterns for PLWH with mental health disorders may 
exacerbate overdose risk. Mental health disorders— which can occur frequently among 
PLWH.
140,141— have also been linked with opioid misuse and overdose.126 Co-
prescribing of sedating medications, such as benzodiazepines for anxiety, exacerbate 
overdose risk.
142
 In one study, chronic co-prescribing of sedating medications occurred in 
6% of PLWH prescribed opioids. Of greatest concern, patients at the highest risk of 
overdose were the ones who received an opioid prescription with a sedating medication 
co-prescription: those over 50 years of age, receiving public insurance, and experiencing 
depression and anxiety.
143
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Pain commonly occurs among PLWH
140
 with prevalence ranging from 25% to 
80%.
141
 Even with the use of ART to restore immunologic function, PLWH are at 
increased risk of age-related morbidities and mortality compared to HIV-seronegative 
persons.
144,145
 As more and more people are living longer with HIV, chronic pain 
management is a key component to clinical care management.
146
  Pain related to HIV 
comorbidities, such as peripheral neuropathy,
146
 is a commonly reported condition among 
PLWH.
147
 A few studies in clinical care settings found that PLWH were more likely to be 
prescribed opioids at a higher dose,
58
 over a longer period of time,
59
 and into older age
148
 
compared to non-HIV infected patients. Studies have shown chronic opioid prescribing 
rates among PLWH to be 8%,
59
 10%,
58
 and 17%.
143
  
Opioid prescribing among PLWH with a history of substance use disorder 
introduces additional complications. Among PLWH, pain is reported more frequently by 
persons with a history of substance use,
149
 but a review of the literature found that HIV 
providers offered lower rates of pain treatment for PLWH with substance use histories. 
This could lead to opioid misuse through self-medication.
141
 Alternatively, persons with a 
history of or current substance use disorder may have decreased tolerance for pain, thus 
leading to earlier initiation and potentially more potent opioid use. A study examining 
pain and prescription opioid use among 2,267 HIV-infected persons from 1996 to 1997 
reported heightened risk of pain and misuse of opioids among those with a history of 
substance use disorder.
150
  
To put these data in context, for PLWH with an opioid use disorder, provision of 
buprenorphine treatment has been shown to improve quality of life and mental health.
151
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Both buprenorphine and methadone treatment have resulted in improved HIV treatment 
adherence and improved health outcomes.
152–155
 Thus, MAT plays an important role in 
decreasing opioid overdose risk.  
These findings point to the need for strategies in healthcare settings to prevent 
opioid overdose and overdose deaths among PLWH.
57,131
 While multiple strategies are 
needed, clinical care settings providing routine care to PLWH have an opportunity to 
integrate opioid overdose education and naloxone provision into routine care and thereby 
minimize the risks of a potential overdose.  
Cost of Opioid Overdose 
In addition to the soaring number of preventable deaths, fatal and non-fatal opioid 
overdoses take a toll on the healthcare system and ultimately create both direct and 
indirect societal costs. In 2010, there were nearly 136,000 ED visits in the U.S. due to 
opioid overdoses. Unfortunately, this number does not represent the full extent of 
overdose cases: for some non-fatal overdoses, emergency medical help is never called 
and in other cases, an overdose is fatal before emergency help arrives. An analysis of 
relevant ED visits found that 68% of the overdoses involved prescription opioids, while 
heroin accounted for 16%. About half of the opioid overdose patients evaluated in an ED 
were then admitted for inpatient hospital care.
125
  
In Massachusetts, the opioid epidemic is taking a toll on the state’s substance use 
treatment and healthcare systems. Nearly half of those who sought publicly-funded 
substance use treatment in the state in 2013 listed opioids as their primary or secondary 
drug of choice; 40% of these people were between the ages of 13–29 years.156 That year, 
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opioid overdoses also contributed to more than 2,000 hospital stays and 4,570 ED 
visits.
157
 
The burden of overdose among patients insured by the Medicaid system has also 
been documented.
158
 A CDC study of Washington state’s prescription opioid overdose 
deaths from 2004–2007 found that 45.4% of the victims were Medicaid enrollees.159 
Given the costs of opioid overdose, Project Lazarus in North Carolina expanded its 
opioid overdose prevention program to include the state’s regional Medicaid program, 
thus integrating opioid safety into the clinical program’s broader pain management 
initiative.
25,160
 Advocacy with state Medicaid programs has been recommended to 
enhance clinic-based overdose education and naloxone prescribing.
161
 
A cost analysis from 2009 estimated the economic toll of opioid overdose in the 
U.S. at $20.4 billion a year— with $2.2 billion attributed to emergency department and 
inpatient medical costs and the remaining to absenteeism and lost productivity. The 
researchers concluded that a single opioid overdose costs society $37,274, with the 
majority of the estimated total cost being associated with deaths from overdose. 
Therefore, interventions that prevent and reverse opioid overdoses should have the 
greatest immediate impact on reducing these societal costs.
162
  
Policy Recommendations to Prevent Opioid Overdose 
In response to the rise in opioid overdose deaths, several federal government 
agencies, including the U.S. Office of National Drug Control Policy,
163
 U.S. Department 
of Health and Human Services,
18
 and the CDC
19
 have recommended several strategies to 
reduce the number of opioid overdose deaths. In 2016, the U.S. Surgeon General 
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implored physicians to sign a pledge to enhance pain management education, promote 
screening for substance use disorder and referral to treatment, and recognize that 
addiction is a chronic disease.
164
  
While the national policy agenda drives funding, states play a critical role in the 
opioid epidemic response. States enforce their laws and regulations regarding controlled 
substances, licensure, opioid prescribing, and naloxone access; oversee state programs 
such as Medicaid; and fund substance use treatment programs. These policies influence 
the level of access to prescription opioids, substance use treatment services, and 
naloxone.
165–167
 Importantly, the focus on state-level initiatives allows for data-driven, 
community-based responses to the opioid epidemic, as demonstrated by Project 
Lazarus.
160
  
In recognition of the state role, SAMHSA and the CDC have set out to support 
state-based policy initiatives focused on decreasing opioid overdose fatalities through 
targeted funding and policy guidance.
168,169
 An overview of the national policy 
recommendations, many of which are focused on state action, frames the broader context 
of this research. 
1. Training on safe opioid prescribing practices. Federal agencies recommend 
enhanced education for prescribers on opioid prescribing and safety. For example, 
states could stipulate that prescribers are required to complete training about the 
risks of opioid prescribing before getting their controlled substance registration 
and prescribing authority from the U.S. Drug Enforcement Agency. Providing 
education for medical professionals is a first step in increasing awareness about 
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the risks of opioid overdose and strategies to prevent overdose deaths.  
Some states have developed training resources for primary care providers
170,171
 
and prescribers. Several states have legislation requiring such training prior to 
opioid prescribing certification.
49
 Massachusetts, for example, passed a law 
requiring prescribers to complete continuing education related to opioid 
prescribing and associated risks of abuse.
73
  
2. Enforcement of safe prescribing practices. Several state governmental agencies 
and other entities developed clinical practice guidelines.
71,172–174
 Then, in March 
2016, the CDC published Guidelines for Prescribing Opioids for Chronic Pain. 
These evidence-based guidelines detailed: 1) when to initiate or continue opioids 
for chronic pain; 2) opioid selection, dosage, duration, follow-up, and 
discontinuation; and 3) assessing risk and addressing harms of opioid use.”45 
Alongside these, some states enacted opioid prescribing legislation, such as in 
Massachusetts which was the first state in the U.S. to limit first-time opioid adult 
prescriptions to a 7-day supply, and all minor prescriptions to a 7-day supply.
73
  
Increased regulatory action against medical providers who do not follow 
evidence-based opioid prescribing guidelines aim to minimize the availability of 
for-profit pain management clinics (i.e., “pill mills”).163 Several states have laws 
to monitor the establishment and operation of pain clinics, legislation which has 
been shown to reduce prescription opioid overdose deaths in Florida.
175
 
3. Use of Prescription Monitoring Programs (PMP). PMPs store and share 
information about controlled medication prescriptions for authorized prescribers 
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and pharmacists. Use is intended to help prevent patients from obtaining opioid 
prescriptions from multiple prescribers, though the impact of PMP on lowering 
overdose rates has not yet been determined.
176
 As of September 2016, all 50 U.S. 
states, the District of Columbia, and one U.S. Territory have operational PMPs in 
place.
177
 In Massachusetts, a law was passed that requires prescribers to check the 
PMP before prescribing a Schedule 2 or 3 narcotic and then to update the PMP 
within 24 hours.
73
  
4. Proper prescription opioid storage and disposal. Efforts to promote proper 
storage and disposal of prescription opioids minimize the likelihood of 
unintentional poisoning and non-medical use. Approaches to minimize diversion 
of prescription opioids are essential given that nearly 70% of people who used 
prescription opioids for non-medical reasons in the past year got them from a 
friend or relative.
5
 In a survey, 30% of Massachusetts and 17% of national 
respondents reported saving their prescription opioids for future use, raising 
safety concerns about drug diversion and accidental ingestion.
178
 Most community 
police stations offer safe prescription drug disposal.
179
 Such initiatives, still to be 
evaluated, aim to protect friends, family, and others sharing a household with 
someone who has a current or past opioid prescription.  
5. Access to opioid MAT services. Research has shown that patients in opioid 
treatment programs have improved health outcomes including reduced opioid use 
and decreased overdose deaths.
180,181
 For this reason, it is important to increase 
the availability of accessible MAT. Recognition of the role of opioid treatment, 
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specifically methadone and buprenorphine therapies, has led to a call for 
expanded services;
182
 primary care settings are a targeted venue for expanded 
buprenorphine treatment.
183
  
6. Expanded access to overdose education and naloxone. Provision of effective, 
proven harm reduction strategies is needed to prevent overdose and reduce 
overdose fatalities. OEND programs, described in detail below, have played an 
important role in reducing the number of opioid overdose deaths. SAMHSA 
released the Opioid Overdose Prevention Toolkit, which provides guidance to 
local governments, communities, and prescribers for implementing opioid 
overdose prevention and response policies and programs.
30
  
Summary of Massachusetts Policy and Program Context 
Along with the national context, it is important to understand the Massachusetts 
policy and program context for this study. Since 2014 the Commonwealth’s leadership 
has prioritized a broad-spectrum response to the rising and record high number of opioid 
overdose fatalities in the state.
15,66
 The dramatic increase in opioid overdose deaths in 
2013 led former Governor Deval Patrick to declare a public health emergency in March 
2014,
15 
precipitating release of “Opioid Overdose Response Strategies in Massachusetts” 
in that April.
184
 Current Governor Charlie Baker also placed opioid addiction on his 
political agenda before he entered office in January 2015.
17
 An overview of the program 
and policy response to opioid overdose provides useful context for this dissertation 
research. Several significant activities in the Commonwealth’s response to the opioid 
crisis are presented in Table 3.
41,67,185–187
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Table 3: Summary of Massachusetts Opioid Overdose Response Milestones 
Year Activity 
2005 Boston EMT use of intranasal naloxone 
2006 Two city health department OEND pilot programs operate through syringe access 
programs 
2007 Standing order to distribute naloxone through community public health programs; 
Expansion of office-based opioid treatment program to 14 CHCs through DPH 
2010 State police and fire department staff equipped with intranasal naloxone 
2011 Involvement of opioid addicted caregiver support group with OEND  
2012 Passage of Good Samaritan and patient and prescriber protection laws (Chapter 192 
of the Act of 2012) 
2014 Governor Patrick declares Public Health Emergency 
2014 Standing order for OEND at authorized pharmacy retailers 
2015 Governor Baker creates Opioid Addiction Working Group 
2015 Expansion of OEND pilot program to first responders and bystanders throughout 
state 
Creation of police department initiatives (i.e., Police Assistance in Addiction and 
Recovery Initiative; The Angel Program in Gloucester; and Arlington Outreach 
Initiative) 
2016 Passage of opioid bill An Act relative to substance use, treatment, education, and 
prevention inclusive of screening, prescribing, education, referral to treatment, and 
civil liability protections for persons who use naloxone 
 
Massachusetts’ pioneering OEND activities have been shown to reduce opioid 
overdose deaths
27
 and serve as a national model.
41,67
 In 2005, Boston EMS responded to 
the high number of overdoses by equipping Boston EMTs with intranasal naloxone.
67
 
The following year, two OEND pilot programs operating out of the Boston and 
Cambridge health departments distributed naloxone through syringe access programs. In 
2007, the Massachusetts DPH expanded OEND activities to four community organiza-
tions through a DPH-issued standing order, which authorized persons who met certain 
criteria to distribute naloxone. From 2007 to the present, the OEND program has 
operated under existing Commonwealth law (Massachusetts General Law-MGL c. 94C 
and DPH/Drug Control Program regulations at 105 CMR 700.000) through the 
Massachusetts DPH’s Commissioner’s Office and the DPH’s Bureau of Substance Abuse 
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Services and the Office of HIV/AIDS.
135
 This set the stage for the program’s expansion.41  
Over time, OEND program activities expanded from HIV prevention program 
sites (e.g., syringe access programs) to homeless shelters, EDs, methadone clinics, and 
residential drug treatment programs, resulting in 21 agencies conducting OEND in 2015. 
The DPH also funds the purchase of naloxone rescue kits for first responders in 23 
municipalities and for 16 chapters of the Learn to Cope caregiver support network.
188
 As 
of 2015, statewide OEND activities resulted in the training of 32,000 bystanders and first 
responders and over 5,000 reported opioid overdose reversals.
67
 A state policy allows 
adults to purchase naloxone at retail pharmacies with a standing order; currently, there 
are approximately 1,200 pharmacies with standing orders across the state.
189
 Also of note, 
local police departments have played a role in distributing naloxone as part of their 
innovative opioid addiction treatment and recovery initiative, such as the Gloucester 
Police Department’s Angel Initiative which has served as a model for police departments 
across the U.S.
187
 Clearly, coordination of efforts between policymakers, public health 
departments, law enforcement agencies, medical providers, and pharmacies is 
necessary.
190
 
Upon taking office, current Governor Baker built on former Governor Patrick’s 
efforts
191
 and convened a 16-person Opioid Addiction Working Group. In a 
recommendations report released in July 2015,
68,157
 the Working Group proposed more 
than 65 recommendations that resulted in Governor Baker creating an Action Plan
66
 with 
activities focused on the following four areas: 
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 Prevention: education for the general public, parents, students, and prescribers 
about the risks of opioid use;  
 Targeted interventions: activities including mandatory PMP use by prescribers; 
analysis of data to target overdose death “hot spots” across the state; increased co-
prescribing of naloxone with prescription opioids; lowered prices for naloxone 
through bulk purchasing; and promotion of the Good Samaritan law; 
 Treatment: expanded substance use treatment services through partnerships with 
several state agencies (e.g., Department of Corrections and Division of Insurance) 
and their federal counterparts to enhance treatment access; and 
 Recovery: strengthened recovery support services after treatment. 
As part of this plan, on March 14, 2016, Governor Baker signed an opioid bill with 
legislation
73
 that included limiting first-time opioid prescriptions for seven days and all 
prescriptions for those under the age of 18 to seven days; use of PMP before prescribing, 
prescriber continuing education on opioid prescribing and addiction; and increased 
referral to treatment for persons who experience an overdose.
73
 
 Perhaps due to a combination of the widespread opioid crisis and the media 
attention, public concern about the opioid crisis is high in Massachusetts. In April 2015, a 
poll found that 71% of Massachusetts residents, compared to 45% of residents nationally, 
reported that heroin use is an extreme or very serious problem. Sixty percent of residents 
thought prescription painkiller abuse is an extremely or very serious problem, compared 
to about half of all Americans surveyed. Almost one-half of Massachusetts residents 
surveyed thought prescription painkiller abuse is getting worse, compared to 39% 
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nationally.
178
  
Community and Clinic-based Overdose Education and Naloxone Programs 
As described above, addressing the complexities of the opioid overdose crisis 
requires a comprehensive response. Use of the opioid antagonist naloxone hydrochloride, 
commonly known as naloxone or by its brand name, Narcan®, has been shown to be a 
feasible, effective, and inexpensive tool for reducing opioid overdose fatalities.  
Clinical practice experience related to opioid OENA is limited, focusing primarily 
on prescribing, but community-based OEND programs have built a strong foundation for 
future interventions in healthcare settings. The next section describes OEND programs, 
lessons learned from past experience in community settings, models for clinic-based 
activities, and barriers to implementation in clinical care settings.  
Naloxone: The Opioid Overdose Antagonist 
Several U.S. public health agencies, including the Office of National Drug 
Control Policy, CDC, SAMHSA, National Institutes of Health, and the U.S. Food and 
Drug Administration (FDA)
28–32
 encourage the adoption of overdose prevention 
interventions and naloxone distribution. In addition, several professional associations, 
such as the American Medical Association, American Public Health Association, 
American Pharmacists Association, and American Academy of Clinical Toxicology 
33–36
 
advocate widespread distribution of  naloxone, as does the World Health Organization 
and the Global Fund to Fight AIDS, Tuberculosis, and Malaria.
192,193
  
For over 45 years, naloxone has been the standard of care for reversing potentially 
fatal opioid overdoses in EDs and by EMS personnel. Administered intramuscularly, 
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intravenously, subcutaneously, or nasally, naloxone quickly binds to opioid receptors and 
blocks the effects of the opioid. Typically, naloxone reverses an opioid overdose in less 
than two minutes and restores normal respiratory function. It only works if an opioid is 
present, and has no effect on non-opioid overdoses (e.g., from cocaine or alcohol).
21
 
Naloxone is non-addictive. It causes few adverse reactions, other than withdrawal 
symptoms immediately after administration. A review of Massachusetts OEND program 
data found that 49% of persons experienced withdrawal symptoms following naloxone 
use.
185
 Furthermore, because naloxone is a short-acting drug, a secondary overdose due to 
a long-acting prescription opioid may quickly occur after the naloxone’s effect subsides. 
Thus, it is important that emergency medical services (EMS) are called at the first signs 
of an overdose and that the victim be monitored until help arrives.
32,194,195
  
In most U.S. states and cities, naloxone is administered by EMS personnel and 
hospital-based providers.
196
 Administration of naloxone with a syringe and needle carries 
a risk of blood-borne disease transmission and therefore can be a barrier for use by non-
medical bystanders. To increase ease of use and safety, a nasal spray atomizer was 
introduced in 1999 for “off-label” naloxone use, particularly by EMS personnel.197  The 
FDA approved an auto-injector device for naloxone administration in April 2014,
198
 and 
approved a single-step intranasal naloxone device in November 2015.
199
  
Several studies conducted in emergency medical settings have demonstrated the 
safety and effectiveness of nasal administration. Given this, intranasal naloxone has been 
the standard of care for use in pre-hospital and community settings.
21,200,201
 National and 
state policymakers have called on all first responders, including law enforcement and 
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firefighters, to use naloxone to reverse opioid overdoses whenever they are the first ones 
to arrive after a 911 call.
202,203
 As of April 2016, 971 law enforcement departments in 38 
states and the District of Columbia carry naloxone.
204
 
Naloxone has been shown to be a cost-effective intervention. A 2013 study of a 
U.S.-based naloxone distribution program for PWID found that naloxone prevented about 
6% of overdose deaths, with one death prevented for every 227 kits distributed. OEND 
produced a savings ranging from $438 to $14,000 per Quality Adjusted Life Year gained. 
These findings prove that 
OEND is a cost-effective 
intervention, even with 
conservative assumptions 
applied to the cost model.
205
  
The present study is 
focused on the provision of 
overdose education and 
naloxone rescue kits, pictured in 
Image 1.
206
 Typically, in 
community distribution 
programs, a naloxone rescue kit includes two vials of naloxone, mucosal atomizer 
devices, an educational insert, and optional supplies such as rubber gloves and a mask for 
rescue breathing.
206
 With the FDA’s approval of the single-step naloxone spray device in 
2015, prior acquisition of a mucosal atomizer device and pre-assembly of the intranasal 
Image 1. Naloxone Rescue Kit 
Source: Harm Reduction Coalition, 2015.   
 
 
 
 
 
 
 
Source: Harm Reduction 
Coalition.http://harmreduction.org/issues/ overdose-
prevention/tools-best-practices/od-kit-materials. 
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spray device by a bystander is no longer necessary with this formualtion.
199
 The single-
step spray device has a stronger dosage and comes at a higher price, so the feasibility and 
acceptability of its use is currently being explored for community distribution programs.  
Naloxone requires a prescription. However, several city and state health 
departments have created physician-signed standing orders to facilitate broader 
distribution. Through a standing order, a designated physician authorizes distribution of 
naloxone by select programs or personnel meeting specified criteria.
207
 Such standing 
orders have facilitated naloxone distribution by first responders, pharmacists, registered 
nurses, and harm reduction program staff,
41,135,208
 though have been shown to be difficult 
to implement in an ED setting.
209
  
Community-based OEND Programs 
Recognizing that drug overdose fatalities are preventable and typically occur in 
the presence of another person, several community-based organizations and health 
departments began implementing OEND programs in 1996. Different studies have 
reported the percentage of PWID who have witnessed a drug overdose (between 24% and 
94%), noting that it is those at highest risk of overdose who are most likely to witness 
another person’s overdose.82 Therefore, OEND programs have targeted PWID and their 
friends, peers, and family members. 
In an effort to scale-up naloxone use, 644 sites from 140 organizations in 30 states 
and the District of Columbia collectively distributed 152,283 naloxone rescue kits from 
1996–2014. Programs targeting those who use heroin and opioids non-medically— such 
as drug treatment, methadone, and syringe access programs— were early adopters of 
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OEND programs. Through these programs, emergency responders, but also opioid-using 
individuals and their family members and support network, were equipped to administer 
naloxone. Expansion of OEND programs has grown rapidly in recent years: from 2010 to 
2014, there was a 243% increase in the number of sites providing naloxone across the 
U.S.,
134
 resulting in nearly 26,500 overdose reversals.
26
  
Overdose education messages focus on the signs of opioid overdose and how to 
respond, including how to administer naloxone. Table 4 outlines the specific content for 
an overdose prevention and response training program, based on the experience of 
community programs.
49,210,211
 Trainings for peers or non-medical staff educators, ranging 
from 15 to 60 minutes in duration,
41,212
 prepare them to dispense a naloxone rescue kit to 
a friend, family member, or peer who may be likely to witness an overdose. SAMHSA’s 
Opioid Overdose Toolkit provides further support to community OEND program 
development and implementation.
30
 
Table 4: Key Components of Opioid Overdose Education  
1. Risk factors for overdose 
2. Preventing overdose 
3. Signs of an opioid overdose 
4. When to call 911 for help 
5. How to rescue breathe 
6. How to administer naloxone 
7. Importance of staying with victim until emergency medical help arrives 
 
Several studies of programs have found OEND to be a feasible intervention 
targeted to potential bystanders,
22
 PWID,
23,56,213,214
 people on methadone treatment,
215
 ED 
patients,
216
 and formerly incarcerated individuals who inject drugs.
217
 OEND has also 
demonstrated effectiveness in reducing overdose fatalities, primarily in community 
settings with harm reduction programs. An observational study of a seven-year OEND 
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program in Massachusetts measured changes in opioid overdose death rates across 
communities that had no, low, and high naloxone rescue kit distribution rates. Compared 
to communities with no naloxone distribution, there was a 27% and 46% decrease in 
death rates among low- and high-level communities, respectively.  
OEND program experience in Chicago,
218
 Baltimore, San Francisco, North 
Carolina, New York, and New Mexico also suggest that OEND programs will decrease 
opioid overdose deaths.
219
 Preliminary findings from Project Lazarus have shown 
promise in reducing opioid overdose rates from prescription opioid misuse and abuse. 
25
 
From 2009–2010, overdose fatality rates in that program’s catchment area decreased 
from 46.6 per 100,000 to 29.0 per 100,000.
25
 
Interestingly, a national spatial analysis of naloxone distribution sites found that 
they were located in areas with higher drug arrest and overdose deaths rates, and 
therefore noted that “alternative delivery methods…to reach individuals in other areas 
with less concentrated risk”220 are needed. In another study, interviews with primary care 
patients on chronic opioid therapy who were prescribed naloxone found that most 
patients had neither received nor heard about naloxone before getting a prescription, even 
in a city with a high concentration of OEND sites.
221
 Given these issues, CHCs are 
emerging as an important venue for expanding awareness of and access to naloxone in a 
greater number and wider range of communities.  
The number and type of OEND programs has increased dramatically since their 
inception in 1996. From 2010 to 2014, the number of organizations reporting OEND 
activities to the Harm Reduction Coalition increased by 183%, from 48 to 136. 
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Community-based programs have used different distribution models. Of the 136 
organizations that participated in a Coalition survey on OEND activities, 44.1% of the 
programs utilized non-medical staff via standing orders. Others utilized medical staff 
(36.0%) to distribute naloxone or had medical providers write prescriptions to be filled at 
a pharmacy (28.7%) or arranged for pharmacists to distribute the medication directly 
through a standing order or collaborative practice agreement (8.8%). Many of these 
programs (n=33) utilized more than one delivery model.
26
 New naloxone distribution 
models continue to emerge, including the innovative Gloucester, Massachusetts Police 
Department’s Angel Initiative that includes naloxone distribution as one element of its 
treatment access program.
222
  
Expanding OENA in Clinical Settings 
With the feasibility and effectiveness of OEND having been established, there is 
an urgent need to expand access to naloxone in order to curb the rise in opioid deaths. 
OEND programs have reached PWID and members of their social network largely 
through harm reduction programs. Alongside these community interventions, there is also 
a need for interventions that can reach people at risk of opioid overdose who may not 
inject drugs, access harm reduction services, or perceive themselves to be at risk of 
overdose. Furthermore, clinic-based naloxone access initiatives have the potential to 
expand the geographic reach of OEND programming— which is a pressing need for 
addressing the current scale of the opioid overdose death crisis.
223
  
To date, primary care settings have been underutilized for naloxone access, 
despite the major role that prescription opioids play in overdose fatalities.
210
 There has 
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been a call to expand access to naloxone through clinical care settings, including primary 
care and pain management centers where patients receive routine care and may be 
prescribed opioids.
33,37,39–44
 While EDs have been identified as an important venue for 
naloxone provision, 
119,135
 they provide episodic and urgent care, not the longer-term care 
offered in primary care clinical care settings.  
There are a few clinic-based opioid overdose and naloxone prescribing programs 
that offer instructive programmatic experience, such as Project Lazarus aimed at reaching 
both medical and non-medical prescription opioid users; the Prevention Point Project in 
Pittsburgh, Pennsylvania using a pharmacy collaboration; and co-prescribing initiatives in 
San Francisco and New Mexico for patients receiving chronic opioid therapy in 
ambulatory care settings.
25,41,224,225
 Primary care clinics in other states, including 
Massachusetts, New York, and Washington, plus large federal healthcare systems such as 
the Veteran’s Administration, have also implemented opioid naloxone prescribing 
initiatives.
41,226,227
  
The traditional model of naloxone access in a clinical setting involves a prescriber 
writing a prescription for the patient to fill at a pharmacy. Naloxone is not a controlled 
substance, so the prescription can be written by any licensed prescriber (i.e., physician, 
physician assistant, nurse practitioner). The patient pays out-of-pocket or a co-payment 
determined by the health insurance company.
171
 To address pharmacy access and cost 
issues for patients, naloxone rescue kit distribution through clinical settings has been 
supported by state grants in some states.
186,228
 Recommended educational messaging is 
summarized in Table 5,
49
 which can be delivered in-person or through web-based videos 
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along with brochures.
229,230
 
Table 5: Opioid Overdose Prevention Education Messages Clinicians Can Convey to 
Patients 
 Only take prescription opioids prescribed to you and as directed 
 If you have an opioid problem, there are treatment options 
 Make sure your medical providers and pharmacists know your different medications 
 Do not mix opioids with other drugs or alcohol 
 Store medications in a safe, secure place; dispose of unused medication 
 Breaks in opioid use can affect tolerance, necessitating a lower dose if restarting 
 Teach friends and family how to respond to an overdose and use naloxone 
 
It is important to note the increasing role that pharmacists have played in 
expanding naloxone access in outpatient settings. Over an 18-month period spanning 
2013 to 2015, there was an increase of 1,170% in naloxone dispensing through retail 
pharmacies across the U.S. Interestingly, primary care physicians prescribed 35% of the 
these prescriptions.
223
 Table 6 outlines the roles that a pharmacist can play in assessing a 
patient’s risk of opioid overdose.49 In addition, pharmacists can directly distribute 
naloxone and offer overdose education to persons prescribed opioids or at risk of an 
overdose through collaborative practice agreements (CPAs), standing orders,
231
 and 
prescriptive authority.
232
  
Table 6: Pharmacist Role in Assessing Patient Opioid Overdose Risk 
 Review list of current prescriptions in the PMP 
 Check to see if patient takes concomitant psychoactive or sedating medications 
 Alert prescribers of multiple prescriptions 
 Ask patient about knowledge of overdose risks 
 
The CPA defines the prescriber and pharmacist roles in naloxone 
distribution.
41,161
 For example, pharmacists at the Prevention Point Project alert a 
prescriber that a patient needs a naloxone prescription, after which they receive a faxed 
prescription to fill.
41,233
 New Mexico passed legislation that grants pharmacists naloxone 
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prescribing authority if they deem patients to be in need.
232
 Other states, such as Rhode 
Island and Washington, have CPAs by which approved pharmacists can dispense 
naloxone to pharmacy clients without a prescription.
161,234
 As explained above, standing 
orders between an authorized prescriber and designated pharmacies or pharmacists allow 
people to access naloxone directly from the pharmacy without a prescription.
49,207,231
 As 
of July 2016, 40 jurisdictions in the U.S., including Massachusetts,
231
 have authorized 
naloxone prescription by standing order.
235
  
While pharmacies have been utilized to expand access to naloxone, barriers to 
implementation have been documented. These include limited pharmacist time, the need 
for pharmacist training, negative attitudes toward PWID, lack of a private space to 
conduct naloxone education, concerns about legal issues, and cost and reimbursement 
issues.
236,237
   
Table 7. Opioid Overdose Risk Assessment Steps for Clinicians 
 Review medications 
 Assess substance use history 
 Check PMP 
 Take an overdose history (experienced and witnessed) 
 Enquire about past overdose education and naloxone receipt/use  
 
Training tools for clinical providers have been developed over the past few years 
through national,
30,49
 state, and city initiatives. To begin with, providers are encouraged 
to conduct an opioid overdose risk assessment (Table 7),
30,49
 taking into account the 
multiple factors that increase patients’ risks of overdose. A list of these available opioid 
safety resources is summarized in Table 8 below. For example, the SAMHSA Opioid 
Overdose Toolkit, the online training module Prescribe to Prevent, and mytopcare.org 
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provide guidance on the steps prescribers can take to reduce opioid overdoses and 
fatalities among their patients.
30,49,238
  
Table 8. Opioid Overdose Training Resources for Clinical Settings 
Online Training Videos and Webcasts for Providers and Staff 
 Prescribe to Prevent. Overdose Prevention and Naloxone Rescue Kits for Prescribers and 
Pharmacists (prescribetoprevent.org) 
 California Society for Addiction Medicine. Talking About Naloxone in a Primary Care of 
Pain Management Setting (www.csam-asm.org/naloxone-resources) 
 California Society of Addiction Medicine. Opioid Safety with Naloxone: A Life-saving 
Tool for California Physicians (www.csam-asm.org/naloxone-resources) 
 Prevention Point Pittsburgh. Overdose Prevention and Response Training (wpic.pitt.edu) 
 Harm Reduction Coalition. Training Curricula for Providers 
(http://harmreduction.org/issues/overdose-prevention/tools-best-practices/training-
materials/curricula-for-providers/) 
 Reach For Me. Video and individual interviews with OEND program leaders 
(reach4me.org) 
 Portsmouth Department of Health, Ohio. Project DAWN. Training Video-Part 1 
(http://www.ncbi.nlm.nih.gov/pubmed/26507172) 
 My Top Care. Prescriber, pharmacist, and patient education on chronic opioid therapy 
(www.mytopcare.org) 
Toolkits 
 SAMSHA. Opioid Overdose Toolkit: Part IV. Information for Prescribers (samhsa.gov) 
 Project Lazarus, North Carolina. Community Toolkit (projectlazarus.org) 
 San Francisco Department of Public Health. Naloxone for Opioid Safety 
(prescribetoprevent.org) 
 Harm Reduction Coalition. Guide to Developing and Managing Overdose Prevention 
and Take-Home Naloxone Projects. Includes case studies and worksheets for training 
activities (harmreduction.org) 
 University of Washington Drug and Alcohol Abuse Institute. Guidance on Setting up 
Prescriber and Pharmacy Agreements (stopoverdose.org/pharmacy.htm) 
Job Aids 
 Prescribe to Prevent. Various job aids to guide risk assessment prescribing, coding, and 
reimbursement of opioid safety and naloxone prescribing (prescribetoprevent.org) 
Patient Education Materials  
 University of Washington Drug and Alcohol Abuse Institute. Patient videos and 
brochures (stopoverdose.org) 
 Boston Public Health Commission. Patient video 
(http://www.bphc.org/whatwedo/Addiction-Services/prevention/Pages/Narcan-
Program.aspx) 
 Prescribe to Prevent. Multiple patient videos about naloxone and overdose response 
(prescribetoprevent.org/videos) 
 Harm Reduction Coalition. Patient videos about naloxone and overdose response and 
patient education brochure (harmreductioncoallition.org) 
 San Francisco Department of Public Health. Patient education brochure 
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(http://www.csam-asam.org/sites/default/files/pdf/detailing_patient_final.pdf) 
 Stop Overdose.org. Patient education brochure 
(http://stopoverdose.org/docs/OpioidOverdose.pdf) 
 Massachusetts public awareness campaign posters and brochures 
(http://massclearinghouse.ehs.state.ma.us/category/ALCH.html) 
 Alleghany County Health Department, Pennsylvania 
(http://www.achd.net/overdoseprevention/#access) 
Naloxone Access Laws 
 The Network for Public Health Law. Naloxone access and Good Samaritan laws in the 
U.S. (lawatlas.org) 
 
Lessons Learned from Community-based OEND Programs Extrapolated to  
Clinical Settings 
Several studies highlighted below have identified barriers to overdose education 
and naloxone prescribing in clinical settings, categorized into provider, clinic or 
administrative, and system barriers (Table 9). A 2015 literature review summarized what 
has been learned from the operation of community-based OEND programs, with the goal 
of offering guidance to opioid safety initiatives in clinical settings.
37
 It is important to 
note that the community-based OEND programs that were studied have primarily 
targeted PWID. More recent studies have assessed naloxone access initiatives for patients 
who have been prescribed opioids for pain management. This section summarizes OEND 
program experience to date in addressing identified barriers to clinical implementation.  
Table 9: Potential Barriers to Opioid to Naloxone Prescribing in Clinical Settings  
Provider Level Barriers 
 Lack of provider knowledge about naloxone  
 Low provider confidence in discussing overdose risk and naloxone with patients 
 Negative attitudes and stigma towards PWID 
 Concern about offending patients 
 Belief that naloxone sanctions drug use and enables high-risk opioid use 
 Belief that naloxone does not address patient treatment needs 
 Belief that laypersons cannot identify and respond correctly to an overdose 
Clinic or Administrative Level Barriers 
  
47 
 Lack of consensus regarding who should receive overdose education and naloxone 
 Minimal provider training in chronic opioid therapy prescribing 
 Appropriate family member or peer unavailable to receive overdose education 
 Limited provider time with patient and high patient caseloads 
System or Policy Level Barriers 
 Fear that naloxone prescribing could result in criminal or civil liability 
 Challenges related to naloxone stocking, price, and insurance reimbursement 
 
Lack of provider knowledge about naloxone. A 2004 national survey assessed 
563 physicians’ willingness to consider prescribing naloxone and talking to patients who 
inject drugs about its use. Only 23% “had heard” of naloxone as a tool for preventing 
overdose among their patients who inject drugs. Over half (54%) indicated that they 
would never “consider prescribing naloxone and explaining its use to an IDU [injection 
drug user] patient.”51 A 2003 survey of New York City healthcare providers found that 
only 33% were willing to prescribe naloxone to their patients, while 29% were unsure 
what they would do.
52
 Two more recent qualitative studies, one among primary care 
providers in a Colorado healthcare system (2015) and one among academic physicians 
and medical students at a large urban hospital (2016), also found a low level of provider 
knowledge about bystander administration of naloxone.
40,54
  
Studies have suggested that medical providers who are knowledgeable about the 
benefits of naloxone are more likely to support its use among PWID.
51,52,239,240
 The two 
early studies described above were conducted prior to heightened national policy and 
media attention focused on opioid addiction, which most likely increased clinical 
providers’ awareness of naloxone and its effectiveness. A qualitative study conducted in 
Rhode Island and Connecticut in 2011— with a sample of 24 of general medical 
providers and specialists in emergency medicine, addiction, and pain management—  
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found overall support for prescribing naloxone to patients who use drugs and pain 
patients.
39
  
Still, implementation of clinic-based overdose education and naloxone prescribing 
remains a challenge. A study of an ED naloxone prescribing initiative found that barriers 
to education and prescribing were posed by a lack of staff knowledge about the policy 
and their role in prescribing.
209
 Two recent studies (2016), one with internal medicine 
residents and another with ED physicians, found that knowledge about naloxone and its 
benefits was high, but that having that knowledge did not correlate with actual 
prescribing practices.
53,55
  
Low provider confidence in discussing opioid overdose risk and naloxone 
with patients. Medical providers may not feel comfortable or prepared to talk with their 
patients about overdose.
240
 A study of Scottish general practitioners found low self-
confidence in their ability to educate patients about overdose and naloxone, and a lack of 
clarity in what their role should be related to overdose education and naloxone 
prescribing.
241
 Other recent U.S.-based studies identified low provider self-efficacy in 
performing overdose education and prescribing naloxone among internal medicine 
residents
53
 and ED physicians.
55
 In Massachusetts, a survey found that only 36% of 
respondents who were prescribed opioids in the prior two years had a discussion with 
their provider about any associated risks, compared to 61% nationally (see Figure 5).
178
 
In this context, it can be noted that there is a more general lack of provider self-
confidence in recognizing and responding to substance use disorders.
242
 In a national 
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survey of PLWH, of the 71% who reported substance use, only 24% received treatment 
and less than half discussed substance use with their HIV providers.
243
  
Figure 5. Percentage of Adults Prescribed Strong Opioids Who Had a Conversation with  
Their Doctor about the Risks of Addiction— Massachusetts and U.S., 2015 
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Source: Boston Globe and T.H. Chan Harvard School of Public Health. Survey: Prescription  
Painkiller Abuse: Attitudes Among Adults in Massachusetts and the United States, 2015. 
 
Negative attitudes and stigma toward PWID. Three studies assessing 
perceptions of naloxone use among medical providers and EMS personnel found negative 
attitudes toward PWID.
51,239,241
 Negative attitudes of physicians toward PWID have been 
shown to impede provision of other harm reduction interventions in clinical 
settings.
51,244,245
 Similarly, pharmacists’ negative attitudes toward PWID has been found 
to impede their participation in a non-prescription syringe pharmacy access program for 
PWID in San Francisco.
236
 Given the stigma around substance use, patients may also be 
concerned about having naloxone listed on their medication list or in health insurance 
records.
246
 A meta-analysis of studies about healthcare professionals’ attitudes toward 
persons with substance use disorder found that negative attitudes perpetuated stigma and 
negatively impacted healthcare professional and patient engagement in care. Further-
more, negative attitudes resulted in lower treatment outcomes.
247
  In an effort to stem 
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stigma in clinical settings, the ASAM and federal agencies have advocated for changing 
the language used to describe substance use.
248
   
Concern about offending patients. A survey of academic physicians and 
medical school students at a large U.S. urban hospital identified fear of offending patients 
as a barrier to overdose and naloxone discussions.
54
 Care providers’ unease about 
insulting patients may be particularly heightened when patients are using prescription 
opioids. One qualitative study noted that providers especially expressed concern about 
notifying their pain patients without any overdose history.
39
 Providers may also be 
concerned that patients will think they are being accused of drug abuse.
40,249
 All of this 
points to providers having differing perceptions of overdose risk when patients use illicit 
opioids as opposed to prescription opioids.
39
  
To combat stigma, primary care providers in a qualitative study suggested 
creating clinic-wide protocols that would call for offering overdose education and 
naloxone prescribing to all patients being given an opioid prescription.
209
 Clinical 
programs implementing opioid safety initiatives have presented similar recommenda-
tions.
107
 Importantly, interviews conducted with patients and providers at safety net 
clinics in San Francisco following a co-prescribing initiative for patients on chronic 
opioid therapy, found that opioid safety discussions enhanced open communication and 
trust between providers and patients.
221,226
 This was substantiated by another study in 
which patients receiving substance use disorder treatment reported that a naloxone 
prescription from their hospital-based provider would strengthen their patient-provider 
relationship.
250
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Belief that naloxone sanctions drug use and enables high-risk opioid use. 
Studies have documented that some medical providers and EMS responders expressed 
concern that naloxone could potentially increase risky opioid use by offering a “safety 
net.”25,39,40,54,209,239,250,251 Fear of being perceived as enabling drug use also emerged in a 
survey of academic physicians and medical school students at a large urban hospital.
54
 
Research has not substantiated this concern. A study of a pilot OEND intervention among 
PWID in San Francisco found that the provision of naloxone did not increase drug use or 
heroin overdose.
252
 A review of the Massachusetts OEND program found similar 
results.
253
 These findings were substantiated by a systematic literature review of 18 
additional studies of community-based OEND programs.
210
  
In contrast to this concern, two observational studies of OEND programs found 
that PWID who received OEND were more likely to enroll in substance use treatment 
programs compared to those who did not receive OEND.
24,253
 Another study evaluating 
an OEND program in Los Angeles, California found a reported decrease in drug use and 
an increase in treatment enrollment among PWID.
214
 In addition, a recent qualitative 
study assessing the experience of patients on chronic opioid therapy found that several 
patients reported beneficial therapeutic behaviors, such as taking their prescribed dose at 
the right time, after having received a naloxone prescription.
221
 Furthermore, because of 
the uncomfortable withdrawal-like symptoms that can occur after naloxone is 
administered, it is likely to be used only for necessary, life-saving measures.
254
 
Belief that naloxone does not address patient treatment needs. Some medical 
providers have stated that naloxone prescribing by itself does not properly address 
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addiction.
39,54,239
 Rather, these providers state that  overdose education and naloxone 
prescribing should instead focus on patients needing comprehensive pain management 
services (e.g., risk assessment, prescription monitoring program, pain treatment contracts, 
and dosage monitoring). This point of view is not uncommon. A U.S. study of medical 
doctors’ attitudes about naloxone use among PWID, plus a qualitative study assessing 
naloxone prescribing by primary care staff, reported that many providers are concerned 
about peer or patient disapproval.
40,51
 In contrast, advocates of naloxone distribution 
recognize that addiction is a powerful, complex disease that can take multiple recovery 
attempts, and that providing access to naloxone enhances the likelihood that a person will 
live to seek drug treatment and recovery.
39,255
  
Belief that laypersons cannot identify and respond correctly to an overdose. 
Healthcare providers and emergency medical personnel have expressed concerns about a 
layperson’s ability to properly identify an overdose, remember to have naloxone on-hand 
and administer it, perform rescue breathing, and monitor a victim for possible adverse 
reactions to naloxone or repeat overdose.
39,40,239
  
Countering these concerns, studies of OEND programs have consistently found 
that equipping non-medical health care providers and family, friends, and neighbors of 
persons at risk with the knowledge and skills needed to recognize and respond to an 
overdose is a feasible, life-saving harm reduction strategy.
252,256,257,27
 Several studies of 
OEND training for PWID and their peers and family members reported improved 
knowledge about overdose and naloxone use after the training,
213,219,252,258,259
 Laypersons 
were able to understand the signs of an overdose and to feel confident in administering 
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naloxone during an overdose,
213,260
 even up to a year later in one study.
261
 In turn, 
administration of naloxone by laypersons has been shown to be an effective means of 
reversing opioid overdoses, 
20,262
 with few adverse effects.
218,263
  
An important step in addressing the overdose crisis is activation of the local EMS. 
Recognizing the importance of clinical monitoring following an overdose, many 
providers have expressed concern about bystanders not calling 911.
39,40
 This concern is 
grounded in research 
findings; studies have 
shown that deaths from 
overdose occurred when 
witnesses did not call for 
medical help for fear of 
arrest and prosecution 
for drug use or possession.
23,56,85,252,264
 Studies assessing 911 calls following naloxone 
administration by PWID found a wide range of contact rates across cities, with calls 
made 74%,
213
 40%,
85
 23%,
264
 and 10%
56
 of the time. These findings heighten the 
importance of OEND programs emphasizing the message to call 911.  
To alleviate bystanders’ concerns about criminal repercussions, as of July 2016, 
nearly all jurisdictions in the U.S. have passed Good Samaritan laws that protect 
laypersons who use naloxone and call 911 from criminal (n=32) and/or civil (n= 40) 
liability.
235
 Despite the presence of these laws, there is still a need to educate providers, 
bystanders, and law enforcement about the protections that this law offers. A 
Image 2. Massachusetts “Make the Right Call” Poster 
 
 
 
 
 
 
Source: Massachusetts Health Promotion Clearinghouse, 2016. 
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Massachusetts campaign in 2016 illustrates the importance of conveying this information 
in simple, understandable terms (see Image 2).
265
 As of yet, the impact of the Good 
Samaritan law on the opioid overdose response has not been evaluated, but is identified 
as an important step for addressing the crisis.  
Lack of consensus regarding who should receive overdose education and 
naloxone. Absent a clear protocol, providers’ beliefs about which patients should receive 
overdose education and naloxone prescribing may vary, as demonstrated in an assessment 
of a naloxone rescue kit dissemination project in an urban ED
266
 and a qualitative study 
among primary care providers.
40
 In the context of these differing opinions, another study 
found that internal medicine residents had low levels of confidence in their ability to 
assess overdose risk and identify patients in need of naloxone.
53
  
Risk-based approaches for identifying patients in need of naloxone may miss 
patients whom providers or patients do not perceive to be “at-risk.”120,249 Furthermore, 
given the proportion of prescription opioids used for non-medical purposes that are 
obtained from friends or family members,
5
 prescribing naloxone alongside an opioid 
prescription could be a lifesaver for non-medical users or for children who inadvertently 
ingest them.
39,40,120,226
 In order to reach everyone at potential opioid overdose risk, 
SAMHSA has recommended co-prescribing naloxone with opioids.
30
 Dr. Phillip Coffin, 
Director of Substance Use Research at the San Francisco DPH, urges clinicians to adopt 
an “opioid safety” or “medication safety” plan for all patients prescribed opioids for pain 
management.
50
 With this arrangement, naloxone is explained to be an antidote to opioids, 
equivalent to an epinephrine pen for reversing a potentially fatal allergic response.
50
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Another concern expressed by primary care and ED providers is that a patient at-
risk of an overdose is unable to self-administer naloxone during an overdose, and 
providing education to that patient’s family member or friend is often not feasible in a 
clinical context.
40,209
 Therefore, the effectiveness of the intervention relies on the patient 
training others on how to respond or the patient using naloxone as a bystander.  
Minimal provider training in chronic opioid therapy prescribing. Overall, 
primary care providers receive minimal training on opioid prescribing, pain management, 
and addiction screening and treatment,
267–269
 and therefore they do not feel confident 
prescribing opioids to their patients.
270,271
 A study of a national sample of HIV care 
providers revealed that most do not feel prepared to manage chronic pain. 
242
 CDC’s 
recently released chronic opioid therapy prescribing guidelines recommend screening for 
overdose risk and co-prescribing of naloxone. Online training programs have been made 
to provide training to prescribers.
49
  
Fear that naloxone prescribing could result in criminal or civil liability. Fear 
of liability resulting from naloxone prescribing can also impede wider prescribing and 
distribution. Even though there are minimal legal risks to a medical provider for 
prescribing naloxone, as of July 2016, 33 states have acted to grant immunity from 
criminal prosecution (n=33) and civil liability (n=37) for prescribing, dispensing, or 
distributing naloxone to laypersons.
235
 Of course, when prescribers offer patient 
education on overdose prevention, this further minimizes their risk.
49
 
Third-party prescribing laws further protect prescribers. Given that naloxone is 
administered by a bystander, the person at risk of overdose may not be the best person to 
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receive the prescription, but instead a family member, friend, or peer. As of July 2016, 41 
states have laws that authorize third-party naloxone prescribing.
235
 These laws are seen as 
a low-cost strategy for creating a supportive regulatory environment in response to the 
opioid overdose crisis.
272
 
Challenges related to naloxone stocking, insurance reimbursement, and 
price. Prescription-based naloxone is a relatively recent initiative, and with increased 
demand, pharmacies do not always have sufficient stock of naloxone or the mucosal 
atomizer device used for intranasal administration. Research has documented that 
naloxone’s limited availability at pharmacies is a barrier to prescribing by primary care 
providers.
40
 Because of this, providers must take the time needed to verify the availability 
at each patient’s pharmacy.49 The single-step intranasal device approved by the FDA in 
2015
199
 should eliminate the additional barrier due to having to order mucosal atomizer 
devices and then assembling the kits prior to dispensing.  
The cost of naloxone has also posed a barrier to the implementation and 
expansion of community programs.
160
 Increased demand has led to increased prices for 
naloxone, which particularly affects budgets for state and local health departments and 
first responders.
273,274
 One survey found that nearly 30% of 136 OEND programs in the 
U.S. reported limits on their program activities resulting from increased cost of 
maintaining a naloxone supply.
26
 Amphastar, the only pharmaceutical company 
manufacturing naloxone for nasal administration before 2016, increased the price of the 
medication in Massachusetts from $42 per kit in late 2014 to approximately $75 per kit in 
early 2015.
186
 Of course, such sudden and drastic price increases limit the purchasing 
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power of grant-funded state and municipal programs. The Massachusetts Attorney 
General led an investigation into the state’s soaring naloxone prices,274 which resulted in 
discounted bulk purchased naloxone pricing for municipalities and towns.
275
  
In some states, restrictions on Medicaid reimbursement for naloxone also impede 
OEND programs’ ability to distribute the medication.161,229 Increasingly, private and 
public insurers are covering naloxone prescriptions, though billing and reimbursement 
policies do vary by payer and state. For example, there are variations in insurance policy 
coverage of the mucosal atomizer device for intranasal naloxone, the number of vials 
included in the kit, the number of refills, and the co-payment amount for the different 
naloxone formulations.
161
 Providers’ uncertainty regarding how to bill for the education 
session and naloxone rescue kit is also a concern.
40
  SAMHSA recommends billing 
opioid safety activities under the Screening, Brief Intervention, and Referral to Treatment 
(SBIRT) code.
30
 Likewise, pharmacists’ lack of certainty regarding insurance coverage 
for naloxone if the medication is for someone other than the insured individual can also 
impede access.
246
  
Limited provider time and high patient caseloads. Five studies assessing 
naloxone prescribing by medical providers working in various settings in the U.S., 
Scotland, and the United Kingdom (U.K.), found that limited provider time, competing 
priorities, and high patient caseloads were barriers to providing overdose education and 
prescribing naloxone.
40,54,55,240,241
 The U.K. study found that these barriers persisted 
despite provider training.
240
 Time concerns are very real, particularly given the potential 
need to coordinate pain medication management across multiple clinical providers
39
 for 
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patients with comorbidities.
40
 ED providers have recommended integrating overdose 
education and naloxone prescribing into the hospital electronic medical record (EMR) as 
one strategy for prompting busy clinicians.
266
 
Summary of OEND Program Lessons for Clinic Implementation 
Despite the many identified barriers to OENA through clinical care, several 
lessons from community-based OEND programs can be applied in those settings (Table 
10). In summary, naloxone is safe, does not increase risky opioid use, and is cost- 
effective. Effective partnerships among multiple OEND stakeholders serve to support 
broader dissemination. Staff other than prescribers can provide overdose and naloxone 
education. Therefore, in routine clinical care settings where clinicians have multiple 
priorities, staff including nurses, in-house pharmacists, case managers, and health 
educators can conduct overdose education. OEND programs have shown that laypersons 
can identify an opioid overdose and respond using naloxone, pointing to the additional 
need to equip patients who may be in a position to help others by using naloxone. Finally, 
a facilitating policy environment can support engagement of both prescribers and 
bystanders in implementing the intervention.  
Table 10. Summary Lessons Learned from Community-based OEND Programs 
 OEND programs have reduced community opioid overdose death rates 
 OEND programs are cost-effective 
 Multiple stakeholders can be engaged in naloxone access initiatives (e.g., community-
based organizations, medical providers, pharmacists, law enforcement leadership) 
 OEND training can be conducted by non-medical staff and peers 
 Overdose education can be conducted in a brief amount of time 
 Provision of naloxone does not increase risky drug use behavior 
 Laypersons can be trained to identify and respond to an overdose, including 
administration of intranasal naloxone 
 Good Samaritan laws, and increased awareness of those laws, may decrease overdose 
witnesses’ fear of calling 911 
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 Third-party naloxone laws offer civil and criminal liability protection to prescribers and 
bystanders, and can support clinic and pharmacy staff participation in prescribing and 
dispensing 
 
There are multiple opportunities for expanding naloxone program beyond 
community settings to reach people through primary care settings. In Massachusetts, a 
standing order to allow pharmacists to dispense naloxone without a prescription expands 
naloxone access for both patients and other community members. There are several 
additional issues to be addressed when seeking to increase naloxone access through 
community-based clinical care settings. 
First, there is a need to determine who will be responsible for conducting 
overdose education and prescribing or distributing naloxone in the context of a busy 
primary care clinic. Second, it is important to identify and communicate which patients 
should receive overdose education and naloxone and in what healthcare delivery context. 
Third, networks within the CHC and partnerships with pharmacy(ies) are needed to 
sustain the clinic’s OENA-related activities. Fourth, training and skill development for 
staff assigned to conduct overdose education and naloxone prescribing will be important, 
alongside leadership and organizational supports. Finally, determining the role of external 
partnerships in bolstering CHC overdose response is also important.  
Chapter Summary 
Drug overdose deaths, having risen at alarming rates over the past decade, are 
now responsible for the highest number of unintentional injury fatalities in the U.S., with 
opioids, primarily prescription opioids, being responsible for the majority of those deaths. 
PLWH are a group at significant risk of death from an opioid overdose. Naloxone, an 
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opioid antagonist, can quickly reverse an opioid overdose with minimal adverse 
reactions. Past community OEND programs have demonstrated their feasibility and 
effectiveness in reversing overdoses, primarily among PWID. 
Because naloxone has emerged to be the standard of care for opioid overdose 
treatment, national health organizations strongly endorse its expanded use. Extending 
opioid safety activities into primary care offers an opportunity to broaden naloxone 
access to patients who may be at risk of overdose due to either medical or non-medical 
opioid use. Such programs can build upon lessons learned from extensive community-
based OEND program experience and emerging clinical experience to develop effective 
interventions. 
An assessment of implementation strategies applied by CHC teams that provide 
primary care is needed to guide future program development. In meeting this need, this 
research study will help unravel the complex factors challenging CHC primary care 
OENA for patients, many of whom may never otherwise know about or access naloxone 
for themselves or people in their lives who may be at risk of an overdose. While this 
study was conducted through the lens of HIV care teams due to their past efforts to 
address the needs of PWID and their documented increased risk of opioid overdose 
fatalities, what is learned from this study will be transferable to other primary care teams 
and patient groups. The primary care setting is particularly important given the 
disproportionate role that prescription opioids play in overdose fatalities, and the 
enhanced opioid treatment services available in CHCs.  
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This dissertation is intended to fill the current research gap by assessing real-
world clinic implementation experiences in Massachusetts, from which useful guidance 
to the development and implementation of future programs within and outside the 
Commonwealth can be developed. The state is a prime location for this research given its 
new policies to address the opioid crisis, including expansion of naloxone access. OENA 
in primary care settings is not the sole solution, but it is an essential component of a 
comprehensive response to address the opioid crisis, and an urgent need to curb the rising 
overdose fatalities.  
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CHAPTER 3: RESEARCH DESIGN AND METHODS  
This chapter begins with an overview of the study and a description of the 
conceptual framework selected to guide the research design and analysis. This is 
followed by an explanation of the rationale for the selected methods, the study site and 
participant sampling plan, the data collection tools, and methods used for analyzing and 
interpreting the data. With the protection of study participants being the highest priority, 
the chapter also outlines the steps taken to ensure the ethical conduct of this research.  
Summary of Main Study and Methods 
This section documents the research aims and provides an overview of the 
methods used and types of data collected for the study, followed by the rationale for the 
selected research methods.  
Three research aims guided this study:  
1. To document how opioid OENA strategies are delivered within community health 
center primary care settings; 
2. To identify factors that influence implementation of OENA in this setting, 
examining the intervention, individual, outer setting, inner setting, and process 
domains; and 
3. To determine which strategies are likely to enhance the implementation of OENA 
in community health center primary care settings. 
The six major research activities and related methods conducted during this study are 
described below. 
  
63 
I. Preliminary research 
a. An initial review of the literature was conducted to provide an overview of the 
programmatic issues related to OENA programs, with a focus on their 
relevance to clinic-based settings.  
b. Based on key concepts from the literature, qualitative and survey data 
collection instruments were developed for the preliminary pilot study. 
c. An application to BUMC’s IRB for the preliminary study to obtain feedback 
from physicians at one of the study sites was submitted in November 2014. 
The IRB designated the research as exempt.  
d. A pilot study was conducted through interviews and a focus group with 
physicians at a large, urban HIV clinic in Massachusetts to test the data 
collection tools and explore implementation barriers and facilitators to 
overdose education and naloxone prescribing among HIV providers. 
II. Literature review 
a. A comprehensive review of the literature was undertaken to understand the 
background, context, and past research related to OENA initiatives. Existing 
training materials and educational resources used for community and 
prescriber trainings were identified. A review of opioid overdose prevention 
activities in Massachusetts set the policy and programmatic context. An 
implementation science framework was selected to guide the research process. 
Updates were made to the literature review during the study. 
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III. Research protocol development 
a. Data collection tools were developed based on the literature review, the 
research questions, and the implementation science framework. 
b. After the pilot, an amended IRB application was submitted in December 2015 
to BUMC’s IRB for approval to conduct the main study. After expedited 
review, the study was deemed exempt.  
IV. Site selection 
a. Selection criteria for site selection were developed.  
b. A structured matrix was used to describe potential CHC study sites in order to 
identify a diverse set of CHCs. 
c. Experts were consulted to gather background information on the study sites 
and to obtain recommendations for site selection. 
d. Eight Massachusetts CHCs that provide primary care to PLWH and had 
OENA efforts in place were selected to participate in the study.   
V. Data collection 
a. Interviews and/or focus groups were conducted with at least two providers 
and/or staff at each of the eight participating CHCs. Surveys were completed 
to characterize the clinics and participants.  
b. Interview and focus group recordings were transcribed. Clinic and participant 
survey data were entered into an online survey software program. 
VI. Data analysis, synthesis, and interpretation 
a. A qualitative, content analysis of the data was conducted in NVivo 11.0 using 
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codes from an implementation science framework.  
b. Descriptive clinic and participant data from the surveys were aggregated.  
c. Key findings were described using constructs from the framework. 
Implications of the findings and their relevance to the research literature were 
discussed.  
Summary and Rationale for the Selected Methods 
A study of CHC-based OENA implementation was performed employing primarily 
qualitative research methods to document the factors that facilitate or hinder overdose 
education and naloxone prescribing initiatives in primary care CHC settings which 
provide routine care to PLWH. Table 11 below summarizes the data collection methods 
for each study aim. Several types of data were needed for the study: 
 Contextual information required to understand each clinic’s organizational 
structure and opioid OENA activities were obtained through a clinic 
characteristics survey, collection of relevant clinic documents, and observations at 
a subset of the clinics. 
 Descriptive information to characterize the interview and focus group participants 
was gathered through participant surveys.  
 Implementation experience related to each clinic OENA program was gathered 
through individual and group interviews with clinic staff.  
These methods and related data sources are described in more detail later in the chapter. 
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Table 11. Overview of Research Aims by Purpose and Data Collection Method 
Aim Purpose Method 
1: To document how opioid OENA is 
delivered within community health 
center primary care settings  
Understand 
commonalities and 
variation in 
implementation 
approaches 
 Interviews and focus 
groups 
 Clinic surveys  
 Observation  
 Document review  
2: To identify factors that influence 
implementation of OENA in this 
setting, examining the intervention, 
individual, outer setting, inner 
setting, and process domains 
Assess factors that impede 
or support implementation 
from the perspective of 
clinic staff members 
 Interviews and focus 
groups  
 Provider 
questionnaires 
 Clinic surveys  
 Document review 
3: To determine which strategies are 
likely to enhance the implementation 
of OENA in community health center 
primary care settings 
Identify promising 
practices that could be 
adopted by other primary 
care CHC settings  
 Document review 
 Interviews with key 
stakeholders  
 
Because this study did not rely on a single method, the findings developed 
through any particular method could be corroborated, thereby building confidence in the 
study’s conclusions.276 Because qualitative individual and group interviews served as the 
study’s primary data source— with the other methods providing additional context— the 
rationale for the selection of this methodology warrants discussion.  
Individual interviews made it possible to learn each individual’s perspective 
regarding OENA at their CHC. Issues could be explored in-depth with multiple clinic 
staff members, each playing a different role in the clinic’s opioid safety activities, such as 
a clinic manager, a physician who champions naloxone prescribing, a nurse providing 
buprenorphine treatment services, or a pharmacist who dispenses naloxone through a 
standing order at the CHC’s in-house pharmacy. Across the CHCs, these interviews 
resulted in a respectable sample size adequate for generating key themes and achieving 
data saturation.
277
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Focus group and small group interviews were used to elicit a range of opinions 
and perspectives. This format made it possible to hear from clinical teams that work 
together and learn about their varying roles, perspectives, and experiences. This format 
also generated new ideas to explore in later individual interviews.
276
 As an example, one 
group consisted of a physician, nurse, and health educator, all of whom play different 
roles related to OENA. In another clinic, a nurse and pharmacist who serve 
complementary roles in their clinic’s naloxone access model were interviewed together.  
The semi-structured nature of the interview guide meant that the interviews could 
easily include themes and specific issues that emerged from one session to the next and to 
ask clarifying questions to develop the richest data possible.
276
 Probes were added across 
the interviews and focus groups within and across clinics based on reviews of the data 
during the collection process.
77
 This proved to be a critical requirement for understanding 
the implementation process across multiple sites. For example, after participants at one 
site mentioned a specific patient-level barrier to naloxone acquisition, later interviews 
included questions to determine if this was a barrier in other CHCs.  
Several measures were taken to help ensure the credibility, relevance, and 
transferability of the qualitative research findings. First, the study’s credibility was 
enhanced by using multiple sources of data to validate the findings.
78
 Second, a codebook 
of constructs from the CFIR implementation science framework was used to organize the 
analysis. An external reviewer coded three transcripts to validate the use and 
interpretation of the analysis coding schemes. Third, summary memos after each 
interview provided background information about the session, including notes regarding 
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interpersonal dynamics during group interviews that may have affected the findings. 
Finally, the data collection, coding, analysis, and synthesis process was documented 
along the way, including the rationale for mid-course decisions made during the study.
276
 
 The methods chosen also helped ensure the relevance and transferability— as 
opposed to the generalizability— of the research findings to other settings.77,78 The data 
collection methods took into account the context of the clinic and the study participants. 
Descriptive information presented with the findings can help guide other practitioners’ 
understanding of how the findings might apply to their setting.
77
 A review of clinic 
documents helped identify relevant examples for other settings. Finally, ongoing informal 
consultations with state overdose education and naloxone experts during the data 
synthesis and interpretation phase helped evaluate the relevance of the study findings to 
other clinical settings. A presentation of findings to a group of clinical providers in 
another state was an opportunity to determine the degree to which the study findings 
resonated with their practice settings.  
Research Conceptual Framework 
Implementation science has established that effective innovations, combined with 
high-fidelity implementation and an enabling context, results in successful change.
278
 
This study sought to learn how the innovation of overdose education and naloxone 
distribution— shown to be effective in community-based settings— has been translated 
into primary care settings. It set out to understand what implementation looks like in 
these settings— the what, how, and who— and the context that supported or hampered 
OENA. To understand that context, the study design and analysis was guided by the 
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Consolidated Framework for Implementation Research (CFIR). 
Since its development in 2009,
75
 CFIR has been used to assess several clinic-
based interventions, including weight management,
279
 opioid treatment,
280
 mental health 
services,
281
 and blood pressure control.
282
 CFIR has been especially useful in 
understanding barriers and facilitators that affect intervention implementation and the 
mechanisms that support or inhibit success in differing health service delivery 
settings.
76,283
 CFIR was selected because of its comprehensive and flexible design. 
Another strength is that it takes into account the multiple levels and complex factors that 
influence the implementation and maintenance of evidence-based healthcare delivery 
practices.
75
 CFIR consolidates 18 theory-driven health services implementation models 
plus theoretical concepts from the fields of organizational behavior, sociology, and 
psychology, such as Diffusion of Innovation theory.
75,284,285
  
The framework translates these into 41 constructs across five domains.
75
 Table 12 
depicts the CFIR framework and briefly defines each construct.
286
 The CFIR constructs 
served as an analytical lens for designing the data collection tools and then coding, 
organizing, and comparing the data.
283
 The nimble nature of the CFIR framework 
allowed for the addition and removal of constructs as needed during the data collection 
and analysis process.
286
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Table 12: Conceptual Framework (CFIR) Construct Definitions by Domain 
Domain and Constructs Brief Definition  
I. I. Innovation Characteristics 
A. Innovation Source 
B. Evidence Strength and 
Quality 
C. Relative Advantage 
D. Adaptability 
E. Trialability 
F. Complexity 
G. Design Quality and Packaging 
H. Cost 
 
Understanding of innovation source (internally or externally)  
Perceptions regarding the evidence, benefits, and quality of 
research related to the innovation 
Beliefs about the advantage of implementing the innovation 
Adaptability of the innovation  
Ability to pilot the innovation and alter its implementation 
Perceived difficulty of implementing the innovation 
Perceived quality of innovation materials and their assembly 
Costs of developing and implementing the innovation  
II. II. Outer Setting 
A. Needs and Resources of 
Patients 
B. Cosmopolitanism 
C. Peer Pressure 
D. External Policies and 
Incentives 
 
Degree to which the organization understands and prioritizes 
patient needs 
Extent to which organization is connected to other agencies  
Pressure to adopt the innovation from other organizations 
Policies and guidelines to support dissemination of the 
innovation  
III. Inner Setting 
A. Structural Characteristics 
B. Networks and 
Communications 
C. Culture 
D. Implementation Climate 
E. Tension for Change 
1. Compatibility 
2. Relative Priority 
3. Organization Incentives & 
Rewards 
4. Goals and Feedback 
5. Learning Climate 
F. Readiness for Implementation 
1. Leadership Engagement 
2. Available Resources 
G. Access to Knowledge and 
Information 
 
Characteristics of the organization (i.e., type, size) 
Communication networks within the organization  
 
Shared values and norms related to the innovation 
Expected practice and support of innovation  
Stakeholders’ perception that a response is needed 
Innovation’s fit with individual values and clinic systems 
Beliefs about the importance of implementing the innovation 
Existence of awards for staff engaging in the intervention 
 
Mechanisms for sharing innovation goals with staff 
Strategies that support leadership and staff implementation 
Visible indicators of organization’s commitment to change 
Degree of leadership engagement with the innovation 
Resources that support implementation (i.e., time, space) 
Ease of getting information about the innovation to support 
integration into clinic activities  
IV. Characteristics of 
Individuals 
A. Knowledge and Beliefs  
B. Self-efficacy 
C. Individual Stage of Change 
D. Individual Identification with 
Organization 
E. Other Personal Attributes 
 
 
Implementers’ awareness and attitudes about the innovation 
Implementers’ belief that they can implement the innovation 
Clinic staff members’ stages in implementing the innovation 
Individuals’ commitment to the organization 
 
Individual personal attributes that influence implementation 
V. Process 
A. Planning 
B. Engaging  
 
Extent to which innovation process is determined in advance 
Strategies for reaching implementers and patients  
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1. Opinion Leaders 
2. Formally Appointed 
Internal Leaders 
3. Champions 
4. External Change Agents 
5. Key Stakeholders 
6. Innovation Participants 
C. Executing 
D. Reflecting and Evaluating 
Individuals in organization who influence implementation 
Individuals designated with innovation oversight   
 
Individuals dedicated to promoting implementation 
Individuals with influence external to the organization  
Individuals in organization impacted by the innovation  
Individuals prioritized to receive the innovation 
Conducting implementation activities as planned 
Ongoing team sharing of data, staff experience. and feedback 
 
Study Sample 
This section describes the study site sampling plan, including study site and 
participant selection criteria and areas of expected variation across the clinic sites. It then 
describes the characteristics of the study sites and the participants who took part in the 
interviews. 
Sampling Plan 
The unit of analysis for this study is the CHC. This term is used to include both 
neighborhood/community-based health centers affiliated with larger medical institutions 
and federally qualified community health centers (FQHCs). CHCs have created systems 
of care to respond to the clinical and social needs of some of the most vulnerable 
residents in the local community. Furthermore, they have and will continue to play a 
major role in the response to the opioid crisis through increased provision of primary 
care-based opioid treatment.
63
  
HIV care teams were the focus of the research because they have been on the 
forefront of responding to the multiple needs of PLWH, including the integration of harm 
reduction services for PWID. Persons with HIV who inject drugs have been shown to be 
at increased risk of opioid overdose mortality.
57
 In addition, several CHCs received 
  
72 
overdose education and naloxone training sponsored by the New England AIDS 
Education and Training Center
287
 in the year prior to the study, and some CHCs were 
selected as an OEND pilot grant site through HIV, hepatitis, and STD testing 
programs.
288
 These settings should be able to provide detailed implementation experience 
in patient populations at high risk of an opioid overdose.  
Sampling criteria. The goal of the study site selection process was not to obtain a 
representative sample that can then provide generalizable findings, but instead to identify 
sites that offer information into the range of clinic implementation experience with 
overdose education and naloxone prescribing.
77,276
 With that in mind, the following 
criteria guided the selection of study sites: 
1. CHC located in a Massachusetts county or town with an overdose fatality 
rate higher than the state rate. CHCs located in counties that had experienced 
overdose rates close to or higher than the state rate of 17.7 deaths/100,000 
(January 2013–December 2015)289 were selected to ensure the need and urgency 
for a response.  
2. CHC that initiated opioid OENA activities at least three months before the 
start of the data collection phase. The study sites represent early adopters as 
clinic-based OENA activities were not yet widespread. “Initiation” was defined as 
implementation of clinic-based OENA for patients, so that healthcare prescribers 
and other clinic staff could speak to the actual implementation experience. Level 
of implementation (measured through naloxone prescription, dispensing, or 
distribution data) was not considered in the selection process.  
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3. CHCs providing routine primary care to PLWH. Clinic teams providing 
primary care to PLWH, along with patients without HIV, were the focus and entry 
point for the study given their past role in harm reduction services. In the interest 
of assessing clinic practice and policy, the selected clinics needed to have two or 
more prescribers on the HIV clinic team in order to assess implementation beyond 
a single prescriber.  
Variation was expected and sought in several areas including clinic size, patient 
population, means of naloxone access [i.e., in-house, on-site pharmacy (with and without 
standing order), and external referral], geographic location in the state, and 
implementation duration. 
Sample size. Eight CHCs were selected in order to produce findings both unique 
and shared across the study sites.
276
 It should be noted that this sample size did result in 
data saturation, where additional data gathering and analysis did not offer additional 
concepts or other information related to the research aims.
77
  
Study Site Recruitment 
With the three selection criteria in view, a purposive, criterion sampling 
approach
276
 was employed to select eight CHCs in Massachusetts. The following key 
stakeholders in the Commonwealth were consulted to understand the state context and 
identify an initial list of potential sites: 
 Sarah Ruiz, Massachusetts DPH, Bureau of Substance Abuse Services 
 Dr. Alexander Walley, Massachusetts Opioid Overdose Prevention Program 
Medical Director, Massachusetts DPH 
  
74 
 Dawn Fakuda, ScM, Director, Office of HIV/AIDS, Massachusetts DPH 
 Barry Callis, Director of Behavioral Health and Infectious Disease Prevention, 
Office of HIV/AIDS, Massachusetts DPH 
 Brianne Fitzgerald, RN, New England AIDS Education Training Center 
To prioritize sites, a Study Site Selection Matrix was created to describe the 
clinics in terms of the factors anticipated to affect implementation, including clinic size 
(staff and patients), patient characteristics, naloxone access model, geographic location, 
implementation duration, and other relevant information such as presence of an on-site 
champion or completed staff naloxone training. Working from a draft list of sites, a letter 
(Appendix A) was emailed to the HIV medical director or clinic director at each site to 
invite the clinic’s participation in the study and explain the study protocol. If there was no 
response, three additional emails were sent before a site was removed from the list.  
In several cases, follow-up emails and/or telephone calls with the medical director 
helped to clarify the purpose of the study and review the staff proposed to participate in 
interviews. Twelve sites were initially contacted; of these, eight agreed to participate in 
the study, two did not respond, and two did not meet eligibility criteria (one site 
explained that they were not implementing OENA, and one was a provider practice and 
not a CHC).  
Study site sample. The study site characteristics are described in Tables 13 and 
14. A snapshot of each study site is presented in Table 15 to illustrate the degree of 
variation across the sites. All of the study sites were CHCs, located in cities or towns in 
five Massachusetts counties with high opioid overdose fatality rates. Each site had a 
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different catchment area. Six were FQHCs; the other two health centers were affiliated 
with different hospital healthcare systems. All of the sites offered routine care to PLWH 
in the context of a primary care clinic that also provided care to persons without HIV. 
Nearly all of the CHCs received Ryan White HIV/AIDS Program funding. The number 
of PLWH seen for primary care ranged from 40 to 1,300 (average 374; median 282). 
Table 13. Study Site Characteristics (N=8) 
Characteristic Average (Range) Number (%) 
Clinic Type  
FQHC 
CHC 
 
-- 
-- 
 
6 (75) 
2 (25) 
Affiliated pharmacy 
Yes 
No 
 
-- 
-- 
 
6 (75) 
2 (25) 
HIV Clinic Size 
Small (< 500 patients) 
Medium (501 – 1,500 patients) 
 
241 (40–380) 
1,300 
 
7 (88) 
1 (12) 
Funding for HIV services  
Ryan White (state or federal) 
Other state, non-Ryan White 
Other federal, non-Ryan White 
No external funding  
 
-- 
-- 
-- 
-- 
 
7 (88) 
4 (50) 
2 (25) 
1 (12) 
HIV Staffing: Full-time Equivalent 
Physician 
Nurse 
Case manager 
Nurse practitioner 
Social worker 
Patient/peer educator 
Community education /outreach worker 
Physician assistant 
Pharmacist 
Patient navigator 
 
1.3 (.10–6) 
3.0 (2–5) 
3.8 (2–6.3) 
1.8 (.2 – 3) 
2.2 (.8 – 6) 
.94 (.75–1) 
2.6 (.5 – 5) 
.45 (.15–1) 
.47 (.16–1) 
1 (.2–2) 
 
8 (100) 
8 (100) 
8 (100) 
4 (50) 
4 (50) 
4 (50) 
4 (50) 
3(38) 
3(38) 
2 (25) 
County  
Bristol   
Essex  
Hampden  
Middlesex  
Suffolk 
 
-- 
-- 
-- 
-- 
-- 
 
1 (12.5) 
2 (25) 
2 (25) 
1 (12.5) 
2 (25) 
Number of towns primarily served 
One 
Two  
 
-- 
-- 
 
4 (50) 
1 (12) 
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Three -- 3 (38) 
Began offering naloxone  
Past 13–18 months 
Past 19–24 months 
More than 24 months 
 
-- 
-- 
-- 
 
2 (25) 
2 (25) 
4 (50) 
State-funded OEND pilot program 
Yes 
No 
 
-- 
-- 
 
3 (38) 
5 (62) 
 
Half of the CHCs had “in-house” pharmacies, and two utilized a nearby pharmacy 
that served the CHC patients. All but one of the pharmacies had a pharmacy standing 
order. signed by the CHC’s medical director, for pharmacy dispensing without a 
prescription, though one of the CHCs had not yet begun referring patients to the 
pharmacy for naloxone. Three of the CHC-based HIV programs had a DPH-funded 
OEND pilot grant to distribute naloxone rescue kits to clients seen for HIV, hepatitis, and 
STD testing and through community outreach efforts. 
Staffing models for the HIV clinics varied, based on clinic size and available 
funding for staffing (e.g., grants to support case managers). HIV clinical teams were 
comprised of a physician, nurse, and case manager. Physician assistants, pharmacists, 
social workers, health educators, and outreach workers were part of the HIV care teams at 
about half of the sites. Compared to physicians, nurses, case managers, social workers, 
health educators/outreach workers, and nurse practitioners had more full-time equivalent 
(FTE) time dedicated to HIV patient care.  
The characteristics of patients living with HIV also varied across the sites. At the 
time of the study, more than half of the patients were male, had MassHealth (i.e., 
Medicaid) insurance coverage, and were 45–64 years of age. Slightly over half of the 
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patients living with HIV were Hispanic/Latino. The percentage of white (7 % to 68%) 
and African American (7% to 36%) patients also varied greatly across the study sites.  
The average estimated percentage of patients living with HIV with injection drug 
use as a risk factor for HIV infection was 32%, though the range across the sites was 
extremely wide: one CHC estimated 9% and another 80%. It is important to note that in 
one of the CHCs with a small number of patients living with HIV, there was still a high 
number of patients at risk of overdose, and many living with chronic hepatitis C virus. An 
average of 10% of PLWH were estimated to be receiving prescription opioids for chronic 
pain management, and 20% of PLWH were estimated to be misusing or abusing opioids.  
Table 14: Percentage Estimates of HIV Patient Characteristics at Study Sites 
Patient Characteristics Average Estimated Percentage of HIV 
Patients (Percentage Range) 
Insurance coverage 
MassHealth 
Medicare 
Dually eligible Medicare/MassHealth 
Commercial insured 
None/uninsured 
 
66% (40–80%) 
14% (10–23%) 
14% (9–20%) 
10% (1–30%) 
3% (3–7%) 
Age (years) 
18–24 
25–44 
45–64 
65 and older 
 
3% (2–7%) 
28% (10–50%) 
62% (33–85%) 
9% (3–19%) 
Race/Ethnicity 
Hispanic/Latino 
White (not Hispanic or Latino) 
Black/African American (not Hispanic or Latino) 
Multi-racial (not Hispanic or Latino) 
Asian (not Hispanic or Latino) 
 
53% (10–85%) 
34% (7–68%) 
17% (7–36%) 
12% (1–28%) 
5% (1–10%) 
Gender 
Male 
Female 
Transgender 
 
61% (48–68%) 
38% (30–52%) 
4% (2–10%) 
Injection Drug Use HIV Risk Factor 32% (9–80%) 
Currently Prescribed Opioids for Pain 
Management (N=6) 
 
10% (1–25%) 
Currently Misusing or Abusing Opioids (N=5)         20% (10–50%) 
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Table 15. Clinic Characteristics by Study Site 
Site 
Location in 
state 
Type 
PLWH 
seen (#) 
OENA start 
Affiliated 
pharmacy 
Pilot 
OEND 
grant 
Percentage 
of patients 
with IDU 
risk factor 
1 Eastern 
Hospital-
affiliated 
CHC 
40 
+ 2 years 
ago 
No No 20% 
2 Western FQHC 160 
Past 13 to 18 
months 
Yes Yes 9% 
3 Western 
Hospital 
affiliated 
CHC 
1,300 
+ 2 years 
ago 
Yes No 80% 
4 Northeastern FQHC 325 
Past 19 to 24 
months 
Yes Yes 25% 
5 Northeastern FQHC 279 
+ 2 years 
ago 
Yes No 19% 
6 Eastern FQHC 285 
+ 2 years 
ago 
Yes No 40% 
7 Northeastern FQHC 380 
Past 13 to 18 
months 
Yes Yes 32% 
8 Southeastern FQHC 220 
Past 19 to 24 
months 
No No 34% 
 
Research Design: Data Collection Tools and Protocol 
Table 16 below lists the data collection methods and tools used during the study 
for both the pilot study and the main study. The IRB granted a waiver for both studies. 
Interview participants reviewed a written one-page summary (Appendix B) of the study 
and verbally consented to participate.  
Table 16. Data Collection Methods and Tools by Study Type 
Study Phase Methods Tools 
Pilot study  Focus group 
 Interviews 
 Questionnaire 
 Interview and Focus Group Guide 
 Participant Characteristics Survey 
 Interview Summary Memo 
Study of 
Implementation 
Experience 
 Interviews 
 Focus groups 
 Questionnaire 
 Document review 
 Observation 
 Interview Guide 
 Clinic Characteristics Survey 
 Participant Information Questionnaire  
 Document Summary Form 
 Interview Summary Memo 
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Pilot Study Data Collection Process 
To inform the main study methods and tools, preliminary interviews and a focus 
group were conducted at a large, urban HIV clinic (estimated 1,653 patients seen in 2015 
by 13 physicians) in Boston, Massachusetts. This work was completed over a 3-month 
period (November 2014 – January 2015) when the clinic was planning a clinic-wide 
opioid overdose education and naloxone prescribing initiative to begin in January 2015. 
The intent of the sessions was to learn about anticipated barriers and facilitators to 
naloxone prescribing from the perspective of the clinic’s physicians. 
Data collection tools for the pilot study included a participant characteristics 
questionnaire and an interview/focus group guide (Appendix C). Three interviews (30 to 
60-minutes each) were conducted with the following medical providers, each of whom 
provided a unique perspective as a result of their clinic role: 1) HIV medical director; 2) a 
physician currently prescribing naloxone to patients; and 3) a physician prescribing 
buprenorphine treatment to patients. One 50-minute focus group, scheduled in 
consultation with the medical director and held during the monthly clinic physician 
meeting, was conducted with 10 physicians practicing at the clinic.  
The interviews and focus group were digitally audio-recorded with the 
participants’ verbal informed consent at the start of each session. All data recording and 
storage procedures outlined in the IRB application were followed to ensure participant 
confidentiality. Participants were not compensated for their participation. 
The initial physician interviews and focus group served two purposes. First, they 
provided the opportunity to pilot test the data collection instruments. Second, the findings 
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provided a snapshot of provider perceptions about opioid overdose education and 
naloxone prescribing prior to clinic-wide implementation. These findings informed the 
development of the final interview guide.  A summary of the pilot study participants’ 
characteristics and the findings is included in Appendix D.  
Main Study Data Collection Protocol 
For the main study, focus groups and interviews were conducted with various 
clinic providers and staff members from the eight participating clinic study sites over a 
three-month period (January – March 2016). Table 17 below offers a summary of the 
number and type of sessions held across the eight study sites. 
Table 17. Summary of Study Data Collection Sessions across Eight CHCs 
 Number (Percentage or Range) 
Total Number of Study Participants 29 (1–7 per session) 
Interview Type (N=17) 
Individual  
2–3 participants 
Focus group  
 
12 (70.5) 
4 (23.5) 
1 (6.0) 
Average Number of Interview 
Sessions/CHC 
2.1 (1–3) 
Interview Format (N=17) 
In-person 
Telephone 
 
10 (59) 
7 (41) 
Average Duration 38.3 minutes (10–55 minutes) 
 
A total of seventeen interview sessions, composed of twelve individual 
interviews, four discussions with two or three participants, and one focus group, made it 
possible to collect data from twenty-nine clinic staff across the eight sites. Scheduling 
was done through a clinic point-of-contact or with the study participants directly. Clinic 
size, number of relevant staff, availability of staff, and the preference of clinic 
director/manager determined whether it was more appropriate to conduct an individual or 
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group interview.  
Clinic staff to be interviewed were selected in consultation with the clinic 
director/manager, while ensuring that at least one clinic manager was included from each 
site. A description of the study sent by email to the clinic medical director or HIV 
manager was emailed to all interviewees. Participants were sent a confirmation email two 
days before the interview. Stipends were not provided for participation. There was a 
100% participation rate for the scheduled interviews.   
More than half of the sessions were conducted in-person. In some cases, snowball 
recruitment methods resulted in the identification of additional persons to be interviewed 
either through impromptu in-person interviews or through telephone follow-up. There 
was an average of 2.1 interview sessions per site. As can be seen in Table 13, the roles of 
the participants varied across sites, in part due to the particular implementation strategy 
being employed.  
Interview sessions lasted an average of 38.3 minutes (range 10 – 55 minutes), a 
length feasible for busy clinic providers and staff. All interviews and focus groups were 
digitally audio-recorded. Telephone-administered interviews were audio-recorded using 
an application on a password-protected iPhone. Participant consent to audio-record the 
interviews was obtained verbally prior to recording. 
Data Collection Tools 
The following four data collection tools were used: 
1) Clinic Characteristics Survey. This tool captured key descriptive characteristics 
about the clinic. This 17 item close-ended survey (Appendix E) included several 
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descriptive items, some of which were linked with specific CFIR constructs, 
including: 
 Structural Characteristics: Organization type, affiliation, services 
provided, funding, staffing, patient load 
 Cosmopolitanism: Degree of external organizational networks to support 
OENA and related services 
 Readiness to Implement: Training, policies, pharmacy partnership 
 Implementation Climate: Policies and EMR supports 
 Patient Needs and Resources: Patient demographic data 
 Reflecting and Evaluating: Collection and review of naloxone data 
The survey was completed by the clinic director or manager prior to, during, or 
after the interview. Most of the study sites completed a hard copy survey in-
person, through the mail, or at the end of the interview. For others, the same 
survey in online format was sent to participants. 
2)  Participant Survey. This tool gathered descriptive information about the study 
participants. This 14-item close-ended survey queried about demographics, role, 
duration of time practicing at the clinic, perceived overdose risk of patients with 
HIV, and stage of readiness for overdose education and/or naloxone prescribing. 
Participants completed the questionnaire (Appendix F) in about three minutes 
prior to their interview or focus group.  
3)  Interview and Focus Group Guide. A semi-structured interview and focus 
group discussion guide created for the pilot study was modified for the main study 
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to reflect a) barriers and facilitators identified from the literature; b) findings from 
the pilot interviews and focus group; and c) conceptual framework constructs of 
interest. The same guide was used for both individual and group interviews. The 
interview/focus group guide (Appendix G) covered the following areas related to 
CFIR constructs:
286
 
 Available Resources: Funding, staff time, physical space, and training to 
implement the intervention  
 Champions: Presence and identification of a champion in the clinic 
 Complexity: The steps and time involved in conducting overdose 
education and naloxone prescribing 
 Cosmopolitanism: External organizations involved in the intervention 
 Cost: Supplies and costs associated with the intervention 
 Key Stakeholders: Which staff in the organization are directly impacted by 
delivery of the intervention 
 Intervention Participants: Who is prioritized for intervention; strategies 
used to engage patients in the intervention and inclusion of patient 
feedback in the design and ongoing implementation 
 External Policies and Incentives: The role of policies external to the 
agency in supporting the intervention 
 Leadership Engagement: Degree of support from clinic leadership in 
support of the intervention 
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 Patient Needs and Resources: Extent to which patient needs and 
preferences are known and considered  
 Readiness for Implementation: Tangible steps the clinic has taken to 
commit and prepare for implementation 
 Reflecting and Evaluating: Mechanisms in place to discuss 
implementation experiences; use of data to assess progress and inform 
future implementation 
4) Document Summary Form. Copies of documents referenced by participants that 
were related to their OENA activities were requested. In other cases, photos were 
taken (with permission). Each document was summarized using a form (Appendix 
H) to record its context or use.
290
 These documents included the following: 
 Patient education materials 
 Signs in the clinic or pharmacy 
 EMR templates 
 Written policies 
Clinic documents, obtained from six of the study sites, provided additional 
insights into clinic processes and offered information about the decisions and 
steps taken during planning and implementation stages.
276
 Finally, in many cases, 
these documents provided important background information that was useful 
during the provider and patient discussions.  
5) Interview and Focus Group Summary Memo. Immediately after each interview 
and focus group, a summary memo was written using a standardized format 
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(Appendix I),
290
 to immediately capture key findings by CFIR constructs which 
emerged from the interviews as well as areas for future inquiry. Additionally, the 
memo documented contextual information specific to the setting or group 
dynamics that would not be apparent from the transcript.
276
 This memo was 
reviewed during the data coding and analysis process to lend additional context to 
the data. 
Study Participant Characteristics 
As can be seen from Table 18, over half of the study participants were female, 
and most were between 36 and 45 years of age. Half of the participants had worked at 
their clinic for more than fifteen years. The participants’ role at the clinics varied, with 
program directors or managers represented at each site, followed by a mix of physicians, 
nurses, nurse practitioners, physician assistants, case managers, health educators, and 
pharmacists. Across the participants, the average caseload of HIV patients was fourteen 
patients per week, but most of the prescribers, representing about one-third of the 
participants, were seeing about 50 patients a week.  
Table 18. Study Participant Characteristics (N=29) 
Study Participant Characteristic Number (Percentage) 
Gender 
Male 
Female 
 
11 (37.9) 
18 (62.1) 
Age (years) 
26–35 
36–45 
46–55 
56–64 
More than 65 
 
5 (17.2) 
11 (37.9) 
8 (27.6) 
4 (13.8) 
1 (3.5) 
Role 
Physician 
Physician Assistant 
Nurse Practitioner 
 
7 (24.1) 
1 (3.5) 
1 (3.5) 
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Registered Nurse 
Case Manager 
Program Director or Manager 
Pharmacist 
Health Educator 
5 (17.2) 
3 (10.3) 
9 (31.0) 
2 (7.0) 
1 (3.4) 
Prescriber 
Yes 
 
9 (31.0) 
Years worked at clinic 
Less than 2 
3–5 
6–10 
More than 10 
 
6 (20.7) 
7 (24.1) 
1 (3.5) 
15 (51.7) 
Average weekly caseload of 
patients living with HIV* 
   
14.6 (range: 1–50) 
*Includes both clinical and non-clinical staff. 
Data Analysis and Synthesis 
This section describes the process undertaken for organizing, managing, 
categorizing, analyzing, and synthesizing the data. As previously explained, the CFIR 
served as the conceptual lens for the study, leading to a comprehensive set of codes 
applied to the data. An iterative, continuous review of the study data yielded a final set of 
constructs that frequently occurred within and across the transcripts. Patterns and themes 
emerged from the data through this coding process. Comparisons across the sites, plus 
other program experience described in the literature, supported the interpretation and 
transferability of the findings.  
Data management. All surveys were entered into Survey Monkey online survey 
software to house the data. All audio recordings were transcribed verbatim into a 
Microsoft Word file using an online transcription application on a password protected 
computer, and then reviewed for completeness. Each interview and focus group transcript 
was classified with a de-identified code, tracked in a separate, secure file in order to 
protect the confidentiality of the study site and the participants. Descriptive information 
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about the clinic site from the clinic survey and the clinic summary memo was linked with 
the transcript.  
For the pilot study, a rapid analysis of the transcripts was performed to identify 
key themes and issues to help inform the main study design. For the main study, the 
Microsoft Word files of the transcripts, interview summary memos, and copies of 
documents obtained from the sites were uploaded into QSR International’s NVivo 11.0 
qualitative data analysis software. This software was selected for its ease of access, 
training resources, and key features, including the ability to cross-code and visualize 
patterns that emerge from the coded data. Furthermore, NVivo was able to connect coded 
text to participants’ demographic information, clinic characteristics, and the memo 
insights documented after each interview or focus group.
291
 Table 19 summarizes the 
steps taken to work with the data.
291
  
Table 19. Process of Data Coding, Analysis, Synthesis, and Interpretation  
1. Identify “nodes” (e.g., codes) to extract from the data sources (e.g., transcripts, documents) 
2. Interact with the data through coding and memo writing 
3. Explore and query the data and examine data visualizations  
4. Organize results by research aim and significant conceptual constructs 
5. Determine the implications of the findings  
 
Data coding. An existing CFIR codebook, populated with definitions and coding 
criteria,
286
 was used to ensure a clear understanding of each construct (Appendix J) and 
served as the coding legend.
77,276
 The post-interview summary memos highlighted 
prominent CFIR constructs that emerged from the interviews. The transcribing process 
resulted in still other constructs being identified, which were documented in an additional 
memo. 
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All of the CFIR constructs were drawn upon during the data collection process 
and initial round coding in order to be as comprehensive as possible in the identification 
of key themes that emerged from the data. While some constructs emerged as more 
significant than others during the data interpretation phase, and some were not used at all, 
this open approach facilitated a thoughtful coding process that resulted in the 
identification of several constructs not hypothesized to be relevant.  
To support the validity of the coding process, two coders each coded a small 
sample of transcripts and met after each one to discuss the codes. This process stopped 
after three transcripts when agreement was reached on the coding rubric to be used. Any 
revised understanding of the constructs was then applied to remaining transcripts.
77
  
All of the transcripts and documents were coded within NVivo 11.0 over a five-
week period to help ensure continuity of the coding process across the transcripts. In 
many cases, multiple codes were applied to the same text, thereby recognizing the 
complex interplay between the constructs. Meetings with content experts prior to and 
after the coding process allowed for discussion of the process and the resolution of any 
questions. Given the data-driven nature of qualitative analysis, the codes selected were 
sometimes revised.  
The flexible nature of the CFIR framework allowed for codes to be collapsed, 
removed, or added as needed throughout the data collection and analysis process.
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When a new code was identified in a transcript, past transcripts were then reviewed again 
to see if that code applied. Coded data were housed within NVivo’s “nodes.” As needed, 
sub-codes (“child nodes” in NVivo parlance) were created to further classify the data 
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within the “parent nodes.”  
Data analysis. Key themes were identified by reviewing the data within each 
node. NVivo was also used to create visualizations of the patterns that emerged from the 
coded data, including word clouds and inter-code relationships. Such visualizations were 
especially useful when thinking through the data at the earlier stages of the analysis.
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Data from the online survey program were downloaded into Excel files for ease of 
analysis. Basic descriptive analyses were performed (e.g., sums, percentages, averages, 
ranges). Descriptive information related to the participants and clinic sites were also 
linked to the qualitative data, which allowed for the contextualization and comparison of 
the findings. The post-interview and focus group summary memo was also useful in 
providing context to the data. 
In addition to using NVivo software, the data were organized through the use of 
flipcharts, index cards, matrices, and tables to facilitate interpretation of the data. This 
was particularly helpful in documenting the clinical pathways for patient access to 
overdose education and naloxone. Through an iterative data review process, the observed 
codes, themes, and relationships were continually validated against the incoming data and 
modified throughout the analysis process.
77
 Overlap across the CFIR constructs was 
continually examined to determine which construct was the best fit for categorizing each 
key finding. Frequent references to the coded data and transcripts occurred during the 
analysis process to cross-check findings and to incorporate important information related 
to the clinic and participant context. Select quotes were identified to illuminate key 
findings. 
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Data synthesis and interpretation. Findings from the analysis were written with 
the three research aims in mind, and structured by domains and relevant constructs from 
the CFIR conceptual model. As noted above, illustrative quotes and examples from the 
coded transcripts bolstered the findings. Variations related to particular clinic 
characteristics were explained. 
Frequency tables were created during the data analysis to describe particular 
clinic characteristics, such as the number of sites which utilized particular clinic staff to 
conduct overdose education or that disseminated naloxone through a particular channel. 
Because quantifying frequency of responses is not the goal of qualitative research,
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these tables are not presented in the findings. Instead, the analysis focused on finding 
meaning in the data. While the number of study sites with a particular characteristic was 
referenced, this is not meant to signify increased strength to the findings, but to 
contextualize them. 
Conclusions from the findings were identified, along with similarities to and 
differences from what was expected and what was found in the literature. Suggestions for 
future CHC-based OENA activities were based on specific strategies identified at the 
different study sites. Broader recommendations for future practice and research were also 
articulated (see Chapter 5, Discussion).   
Human Subjects Research Considerations 
All study participants were aged 18 and older. Recruitment methods were based 
on participant selection criteria outlined in the sampling plan, which included women and 
minorities. Participation in the study was completely voluntary.  
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An application to conduct this research was submitted to BUMC’s IRB in 
November 2014 (Reference Number 491076), and the study was determined to be 
exempt in accordance with 45 CFR 46.101. This study was also deemed exempt from 
authorization under provisions of the Health Insurance Portability and Accountability Act 
(HIPAA). An amendment was submitted in December and was also deemed exempt 
(Reference Number H-33572). This research qualified as exempt because information 
obtained from participants was collected, recorded, and managed in a manner that did not 
allow for the identification of individuals participating in the study, thus preventing any 
risks related to confidentiality.  
The IRB determined that written consent was not needed, and a waiver of 
documentation was granted. All participants provided verbal consent at the start of the 
study after reviewing a one-page consent form describing the study’s purpose, the types 
of questions to be asked, the length of interview, data confidentiality, the voluntary nature 
of their participation, and contact information if participants had questions (Appendix B).  
For two of the CHC study sites, additional documentation was prepared to support 
internal clinic research ethics review protocols; both CHCs approved the study. 
Chapter Summary 
This research, organized through the lens of the CFIR, identified strategies for 
expanding naloxone access in CHC primary care settings for patients who may be at risk 
of experiencing or witnessing an overdose. This chapter described the study’s 
methodology, which relies upon interview methods to identify factors that influenced 
OENA activities in CHC primary care clinics. Additional data collection methods, 
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including clinic and participant surveys and document review, helped contextualize that 
qualitative data. Review of the literature and pilot study data collection guided the 
selection of constructs from the CFIR, which was used to develop the data collection 
instruments and structure the analysis.    
The study sample is comprised of eight CHCs providing routine care to PLWH in 
Massachusetts, purposefully selected using predetermined eligibility criteria. In an effort 
to focus this study, clinic teams providing primary care to persons living with HIV were 
targeted for interviews, though the activities that were reported reflected OENA activities 
occurring within the primary care clinic. Within each clinic, interviews were conducted 
with clinic staff involved in the delivery of OENA activities.  
A continuous, iterative review of the transcripts, initiated at the start of the data 
collection process, supported the coding process. CFIR constructs were used as the 
primary codes. Chapter 4 presents a comprehensive overview of the study findings based 
on the research aims— starting with a summary of which patients are reached, by whom, 
and with what means of naloxone access, and followed by a description of CFIR 
constructs found to influence implementation. This is followed by Chapter 5 which 
highlights conclusions from the study and discusses implications for practice, future 
research ideas, and limitations to the study design.  
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CHAPTER 4: FINDINGS  
This chapter reports the study findings in two sections, each focused on one of the 
primary research aims. Based on these findings, the chapter also lists strategies that could 
be considered and ultimately transferred to other primary care settings interested in 
implementing or scaling up OENA. Findings from the pilot study can be found in 
Appendix D. 
The first section documents different opioid OENA activities implemented by the 
CHCs. Implementation science emphasizes the importance of describing the intervention 
and implementation process,
278
 in this case who receives overdose education and 
naloxone, who implements it, and how naloxone is accessed. Variation and commonalties 
across the study sites are explained. 
The second section identifies the CFIR constructs that facilitated implementation 
of opioid OENA at the intervention, individual, organizational, external, and process 
domains. These findings are described by the constructs that emerged from the qualitative 
data analysis. Strategies employed by the CHCs related to CFIR domains are included, as 
well. These findings can help explain what will support the adoption and implementation 
of OENA activities in other settings.
278
  
Steps and Strategies for OENA 
 
The goal of this first section is to describe variation and commonalities in OENA 
activities across the eight CHCs that participated in this study. An understanding of what 
activities took place is an important starting point for investigating the contextual factors 
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that influence program implementation. The following four questions related to the first 
research aim are examined below:  
A. Which patients were identified for overdose education and naloxone receipt? 
B. What were the components of the provided overdose education? 
C. Who conducted the overdose education session? 
D. How was naloxone provided to the patients?  
 While the study’s focus was on the HIV team’s activities, the findings apply to 
the broader primary care clinic. All of the CHCs in this study provide both HIV and 
primary care to patients and are set up to provide integrated primary care. There are no 
physically separate or distinct HIV clinics.  
 Within four of the CHCs, the naloxone access program was managed out of the 
clinic’s HIV program. Staff overseeing the naloxone access programs at two of the CHCs 
also managed the clinic’s buprenorphine program. One CHC with a broadly disseminated 
overdose education and naloxone program noted that while it originated in the HIV 
program because of the high number of HIV patients with injection drug use as a risk 
factor, “Now we have made such a big emphasis about this in the clinic. All of the teams 
are really focused on it and all of the case managers and nurses in the entire clinic are 
really up to speed.”  
 In sum, the approaches reported below reflect activities throughout the primary 
care clinic and therefore have relevance beyond patients with HIV who are seen at the 
CHC. The extent to which these activities apply to the patients with HIV depends in large 
part on the number of patients with HIV who have an opioid use disorder or are on 
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chronic pain medication— risks that can be found with patients seen in the primary care 
clinic for other reasons.  
A. Which patients were identified for overdose education and naloxone receipt? 
 The following three groups of patients were prioritized to receive overdose 
education and naloxone: 1) patients with an opioid use disorder, with a focus on those 
accessing medication-assisted treatment; 2) family members and friends of those with an 
opioid use disorder; and 3) patients prescribed chronic opioid therapy. Each of these 
groups is described below. A summary of risk factors used to identify patients in need of 
overdose education and naloxone is included in Table 20.   
 Patients with an opioid use disorder. All of the study participants identified 
patients with an opioid use disorder to be in need of overdose education and naloxone. In 
fact, patients receiving MAT— meaning methadone, buprenorphine, or naltrexone— are 
at risk of overdose or relapse while in a treatment program. One pharmacist stated, “I 
think that anybody who is using opioids, who are on either Suboxone or methadone, 
or…if somebody is friends or family of someone also using opioids or methadone, they 
should be trained.” One nurse practitioner actively involved in OENA activities in her 
clinic explained: 
 It’s part of my repertoire when I speak to any patient. They say, ‘I've been 
clean for three weeks.’ I'm like, ‘Do you need assistance, methadone, 
Suboxone, have you been on Vivitrol?…Do you have a Narcan kit?’…It’s 
just part of what I say. 
 
 Another participant explained how overdose education and naloxone is 
incorporated into the buprenorphine program assessment and induction process at her 
CHC, “Any patient that comes in that's requesting addiction medicine treatment is 
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automatically referred over to our addictions nurse or myself and is screened as 
appropriate for our program. Part of that initial screening is their risk for overdose and 
naloxone.”  
 Specifically, patients transitioning in or out of medication-assisted treatment were 
considered at risk, as explained by one physician: “I will prescribe naloxone to my 
patients that I think are at risk because they are transitioning from one stage to another 
whether that’s going into or coming out of maintenance therapy.” History of overdose 
was also listed as a risk factor necessitating OENA activities, though past overdose 
assessment was performed inconsistently across the study sites, and CHC physicians 
rarely received reports about patient overdoses from EDs unless the physician was 
affiliated with the hospital. 
 
 Family members and friends of those with an opioid use disorder. Study 
participants were keenly aware that patients who receive naloxone cannot administer it to 
themselves. One CHC clinic manager voiced this as a barrier: “Yeah, but then if you give 
it to the patient and the patient gets trained but the patient is who it would actually get 
used on, then you have a disconnect as well.” However, there was widespread 
recognition that patients with an opioid use disorder are likely to witness an overdose and 
Table 20. Patient Factors Prioritized for OENA  
1) Opioid use disorder 
 Receipt of medication-assisted treatment, including 
buprenorphine, methadone, and naltrexone 
 Transitioning in or out of medication-assisted treatment program 
 History of overdose 
2) Family member or friend of person with opioid use disorder 
3) Receipt of chronic opioid therapy 
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therefore have high priority for naloxone receipt. One participant explained, “Anybody 
who has a history of addiction or has been struggling with it in the past, we know that 
they are still associated with persons and places that could put them in a situation where 
they might be rescuing somebody else.”  
 With this in mind, participants expressed the idea of  “blanketing” communities at 
high risk by reaching patients likely to witness an overdose. One physician at a CHC with 
a high percentage of patients with opioid use disorder reflected on this approach: 
Initially, we were thinking what the criteria are for this and we basically 
said everyone should be prescribed naloxone. So everyone over 18 should 
be prescribed naloxone here. Anyone who is coming to this practice has 
the chance of encountering someone who is overdosing and could 
administer it. So it is really much more universal precautions. Everyone 
should have this. We are now following it as a performance measure for 
the program. 
 
This community health focus was also voiced by a nurse program manager at another 
CHC who said, “Everyone who was already enrolled in the [Suboxone] program got 
Narcan also. So for us, it is getting more of it out there in the community, even if the 
patients are not actively using, often times they know someone who is.” 
 Study participants acknowledged that it is not often feasible or realistic to educate 
a family member or friend of an at-risk patient about overdose prevention and response. 
One participant explained,  
It’s not as easy. What we do encourage when a patient is treated in the 
clinic…I make sure they know that when they go home, to share the 
information packet and the naloxone with the family members because 
they are not going to be able to help themselves. We emphasize that as 
part of the teaching-- is this is for you to help others or to teach your 
family members to help you? If we aren't teaching them that, then we 
aren't doing our job. 
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The majority of study participants spoke about the toll of opioid addiction in their 
communities, and often saw patients who are not personally at risk of an 
overdose, but had a family member or friend struggling with opioid addiction. 
Two participants spoke about the role naloxone plays in reassuring family 
members— by equipping them with a tool to prevent an overdose death. One 
physician shared an experience with one of his patients who had a family member 
struggling with addition, and how his clinic team was able to respond and provide 
naloxone to the patient:   
One of my patients saw the naloxone sign [hanging in the clinic], 
and so asked our nurse and said, ‘It’s been really sad, one of my 
grandchildren is into this [heroin].’ And so the nurse knew how to 
educate about Narcan. She took the patient to the room, educated 
her about Narcan. And she walked out of here with two doses of 
Narcan, an atomizer, and training on how to use it. 
  
 Patients prescribed chronic opioid therapy. Only half of the eight CHCs 
assigned priority to patients being prescribed chronic opioid therapy for pain 
management as candidates for overdose education and naloxone. Two other CHCs 
identified these patients as a future priority. Two of the CHCs addressing this group 
reported that it was more feasible to start with this group because, as one CHC’s nurse 
practitioner explained, it was easier to engage providers by appealing to prescriber 
concern about overdose risk for their patients on prescription opioids.  
 This CHC implemented a pilot in the primary care clinic by targeting patients on 
chronic opioid therapy, as explained by the nurse practitioner championing the initiative: 
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I think a lot of the docs who had patients on chronic pain meds or who 
were worried completely jumped right on….We tried to lessen the stigma 
by saying, “Let’s just start with all of the chronic pain patients because 
this is a life-saving medicine for them.” 
 
A physician at another CHC explained how her CHC co-prescribes naloxone for every 
patient on chronic opioid therapy. She talked about framing the conversation with 
patients in terms of opioid safety, making it is a non-judgmental and therefore easier 
conversation to have: 
For me it’s like I offer this to every patient who is prescribed opioids. So 
for my chronic pain patients, in some ways it’s an easier sell because it’s 
“I'm not worried about you necessarily but what if this gets in the hands of 
somebody else? A child for example. You want to be able to reverse an 
accidental overdose.” So it’s not threatening. I'm not saying, “I think you 
are overusing your medicine or you are abusing it.” It’s like, “If there was 
an accident, wouldn't you want to have a tool in your hand to reverse an 
overdose? And that is an opportunity to talk about locking up medications. 
It’s also a no-brainer. 
 
 Staff at the CHCs not yet addressing this group identified several barriers. One 
participant explained that patients and providers thinking there was a little if any risk of 
overdose posed a barrier to discussing the need for naloxone: 
It isn't an easy conversation to have because the folks who have been on 
the chronic opioids for pain don't really see themselves at high risk. And, 
compared to many folks, and heroin use, they aren't, of course. I can't say 
that many of the folks actually particularly wanted to have naloxone at 
home available for themselves, those who are on chronic opioids, if they 
didn't have some other reason with kids in the house, or a child, typically 
a grown child who has an addiction problem.  
 
Two physicians from separate CHCs reflected on how rarely they discuss overdose 
education or offer naloxone to patients being prescribed chronic opioid therapy for pain 
management. One of the physicians explained, “If I have a 20- to 30-year history of them 
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taking their medicine responsibly and not overdosing I probably don't think about it. I 
haven't even done it.” The other physician noted, “I've never actually prescribed 
naloxone for patients on chronic opioids. I do have a number of them on chronic opioids 
for pain management.” A clinic manager at another CHC explained one prescriber’s 
reaction to co-prescribing naloxone with chronic opioid therapy— realizing the potential 
risk to an opioid prescription, “They thought it was interesting that they are prescribing 
something and then saying ‘But if you overdose on something I prescribe you, here is 
something that might help.’ They were struggling with that concept.”  
B. What were the components of the 
provided overdose education? 
Overdose education included overdose risk 
factors and signs and how to respond to an 
overdose, including the mechanics of using a 
naloxone rescue kit (Table 21). Participants described overdose education sessions lasting 
between five and 20 minutes, depending on the degree of “buy in” from the patient and 
the number of questions asked. Most participants highlighted the importance of having 
patients handle and practice using a naloxone rescue kit during the education session. 
One nurse explained her CHC’s process: 
So we give it [naloxone] to the patients or family member right on site, 
and do training and open up a demonstration kit and actually show step-
by-step how to use it and educate the patient or family member when to 
use it, what are the signs and symptoms of someone who is overdosing, 
when they should give it, the importance of calling 911 and all of the 
instructions that go along with it. 
 
Table 21. Content of Opioid 
Overdose Education Session 
 Overdose risk factors 
 Overdose signs 
 Overdose response, including 
calling 911 
 Naloxone rescue kit assembly 
and use demonstration 
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Most CHCs provided written education materials to patients receiving naloxone 
education. As required, pharmacies dispensing naloxone through a standing order also 
provided educational materials, such as the Massachusetts DPH-provided “Naloxone 
Pamphlet” for pharmacy use  (Image 3).230  One nurse commented on the need for patient 
education materials: 
We have them coupled with the prescription. I think the written materials 
are important. My impression is that folks do not remember months later. I 
don't expect people to remember how to do things. So having the written 
information with the naloxone makes sense. From the folks who I've talked 
to who have used it, they did not feel confident putting it together at the 
time. 
 
Important elements of patient education materials included use of pictures for 
low-literacy audiences and availability in Spanish. 
 
Image 3. Naloxone Education Pamphlet  
 
Source: Massachusetts DPH, 2015.   
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 Follow-up with patients who received overdose education and naloxone was 
reported to occur regularly. This follow-up step provided the opportunity for prescribers 
and nurses to assess naloxone use, provide refills, and answer questions. One nurse 
practitioner spoke about her clinic’s approach: “Every visit we ask if they have naloxone, 
do you need it, and I always educate them to watch expiration dates— how long have you 
had it for— it is time to get you a new kit.” Another CHC conducted follow-up every six 
months with patients in the Suboxone program to ensure they had naloxone on-hand.  
C. Who conducted the overdose education session? 
Overdose education and naloxone provision were often done by the same 
individual, but they are described in separate sections since that is not always the case. 
Overdose education was performed by various clinic staff members or pharmacists, 
depending upon the study site. As can be seen in Table 22, the actual clinic staff involved 
in the provision of overdose education varied. 
 Nurses. Across the study sites, nurses 
were the staff most frequently responsible for 
providing overdose education. Education often 
occurred in the context of an HIV case manage-
ment session or buprenorphine assessment.  
 Prescribers. While they supported the intervention, prescribers played a less 
direct role due to barriers explained later. Mostly, prescribers referred a patient to other 
staff for overdose education or wrote a prescription when requested by another clinic 
team member who was seeing a patient. Some prescribers did have discussions about 
Table 22. Clinic Team Members 
Conducting Overdose Education   
 Nurses 
 Prescribers (physicians, nurse 
practitioners, physician 
assistants) 
 HIV counselors 
 HIV case managers 
 Health educators 
 Pharmacists 
 Behavioral health providers 
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overdose and naloxone during patient visits.  
 Pharmacists. Pharmacists played a key part in providing overdose education, 
especially when their role in dispensing naloxone was formalized through an agreement 
or standing order with the CHC. One nurse explained the primary role that pharmacists 
play in overdose education: “I'm not a certified [overdose education and naloxone] 
trainer. But I can certainly go through the steps for them of how to use it, and I have a kit 
at my desk, but the pharmacy does most of the training at this point.” A couple of CHCs 
called upon the pharmacists to identify and educate patients in need of naloxone, as 
explained by one study participant:  
Anybody who is receiving a chronic opioid prescription is also offered 
Narcan through the pharmacy. The pharmacy knows who they are and 
that's also a part of the agreement or discussed in the nurse and physician 
agreement, and patients are encouraged to ask the pharmacist and the 
pharmacist is also offering them Narcan when they pick up the script. 
 
 Case managers and health educators. Case managers and health educators 
provided naloxone education in some of the CHCs. Typically this was conducted during a 
“warm hand-off” from the prescriber to the case manager or health educator.   
 Behavioral health providers. In some CHCs, the behavioral health providers 
identified the need for and provided overdose education, but several study participants 
spoke about the expanded role that behavioral health team members could play. One 
nurse practitioner explained: 
“They [behavioral health providers] have 45 minutes with a patient. A lot 
of them are dealing with family issues, and a lot more of them would [be 
able to say] more about it than a 15-minute visit with a primary care 
provider… It is everyone's duty or responsibility to bring this up. Because 
as a therapist if you are sitting in and discussing that a client's loved one 
is using then you can do a reverse warm-hand off to the nurses and say 
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this person needs a kit. 
 
 Team-wide responsibility. While particular team members were identified as 
playing a greater role than others in OENA activities, many participants believed that 
OENA should be provided by anyone who interacts with clients at risk of overdose. One 
nurse shared his perspective: 
I think everybody should be doing it. Any of those people, wherever the 
patient is at. If they are just coming to their case manager and they are 
actively using, then that is the person that, if they have the Narcan and can 
do the training, then that is where the patient is going to get it. That 
person might not go to the pharmacy if you tell them to. So I think as many 
people that are trained and able to provide it, the better. 
 
A pharmacist participating in the interview added, “It doesn't make one person 
more qualified than someone else to be involved in this. It is a simple process to 
explain— just [need] everyone being on board.” A physician at another site 
agreed:  
I would say anyone who is seeing patients, just ask the question. It’s a lot of just 
asking, are you using substances, does your family member-- it is asking the 
question and giving them the referral and places they can get help or Narcan kits. 
Everyone is touched by it at some point. 
 
D. How was naloxone provided to the patients?  
 CHCs have implemented a variety of strategies to provide patients with naloxone, 
as they recognized that expanded access would require additional avenues beyond 
prescribing. While the initial research 
questions focused on naloxone 
prescribing, the focus of inquiry quickly 
turned to naloxone access more 
Table 23. Points of Naloxone Access  
 Internal clinic distribution 
 Pharmacy partnership via prescription or 
standing order- patient request or 
pharmacist initiated 
 External referral to community OEND 
program 
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generally, as prescribing was rarely utilized by the CHCs in this study sample.    
 Points of naloxone access varied across the CHCs (see Table 23), including  
1) internal clinic distribution, 2) pharmacy dispensing, and 3) external referral to an 
OEND program. The avenue that is utilized also determines how naloxone is paid for or 
reimbursed. Each of these options is described below.  
Internal clinic distribution. Two of the CHCs stocked naloxone for direct 
distribution to patients, typically in an exam or counseling room, during the patient visit. 
(This is to be distinguished from naloxone stocked as part of clinic emergency response 
kits.) With this in-house distribution model, both prescribers and nurses identified 
patients who needed a naloxone rescue kit and made a “warm hand-off” to a trained 
clinic nurse, health educator, or case manager, who in turn provided OEND. One nurse 
explained her CHC’s rationale for choosing this avenue: 
You hand a patient a prescription and it’s like with anything— do they 
choose to pick it up? The thing I love about having naloxone here, you 
actually hand it to the patient. There’s not going to be any question if they 
went and got it or not. 
 
One hospital-affiliated CHC received funding for naloxone as part of the 
hospital’s substance use response initiative. Another center purchased naloxone rescue 
kits as part of a clinic pilot program with the expectation of future pharmacy 
reimbursement, which turned out not to be feasible. As a result, the clinic eventually 
maintained a small number of naloxone rescue kits for direct distribution to patients 
deemed to be unlikely to access kits under the established standing order at the pharmacy 
across the street.  
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Three of the CHCs received Massachusetts DPH-funded OEND pilot grant 
funding which paid for naloxone rescue kits, though the kits were earmarked for non-
patient populations. Nonetheless, some of these OEND programs were utilized as an in-
house source for patients in immediate need of a naloxone rescue kit. Recognizing the 
merit in this approach, one physician working at a CHC with a different model reflected, 
It would be easier and more effective if we could give it out in-clinic. Not 
everybody goes down and picks up that prescription. And people who get 
their medicines normally at other pharmacies don't want to wait here 
because there is a wait time. That is a barrier for patients. So that would 
definitely improve things if there was a way to dispense it out of the clinic. 
  
Pharmacy dispensing.i Six of the CHCs used a pharmacy, either co-located 
within the CHC or a nearby CHC-affiliated pharmacy vendor, to provide naloxone, with 
patients using their health insurance or paying out-of-pocket. There was variation across 
the study sites in how this method was implemented.  
The most common method, used by five of the study sites, was having a standing 
order with the CHC-affiliated pharmacy, by which the CHC’s medical director authorized 
naloxone dispensing for patients or community members who request naloxone without a 
prescription. As part of the standing order, pharmacists are required to provide overdose 
education. A CHC pharmacist outlined this approach:  
We have a standing order where anyone can come off the street and buy 
naloxone. Because of the standing order you can actually use your insurance. So 
we have the kits already set up. We have all the pharmacists trained. We met with 
DPH to get approval for this. The prescription is “pre-filled” out. We do our best 
to get the patient in and out. 
 
                                                     
i
 While naloxone rescue kits were available through a DPH standing order with select commercial 
pharmacies in the state without a prescription (i.e., Walgreens), partnerships with or referrals to 
commercial pharmacies were not in place among the eight study sites. 
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Existence of a standing order did not preclude prescription writing. In fact, one 
CHC continued to write prescriptions to ensure that patients would receive naloxone at 
the pharmacy and to support documentation in the EMR. Naloxone prescribing was 
reported to be relatively infrequent, however, in part due to time barriers and competing 
priorities faced by prescribers, and possibly because of the standing order itself being in 
place.  
One CHC used a pharmacy to dispense naloxone without a standing order by 
establishing an agreement with the pharmacy. Patients received overdose education from 
the nurse at the CHC, a prescriber wrote the naloxone prescription, and the patient picked 
up the prescription at the pharmacy after confirming that education had occurred.  
External referral to community-based OEND program. One of the CHCs 
referred patients to a Massachusetts DPH-funded OEND pilot grant program operated by 
a nearby behavioral health agency. Staff from the agency also came to the CHC agency’s 
opioid treatment program once a month to offer OEND directly to patients.“[Overdose 
and naloxone] is more of an everyday conversation and referral,” stated the clinic 
manager. “We have [an organization] a couple of miles down the road that is funded to 
distribute naloxone.” Reflecting on this, he said, “Of course, once someone leaves the 
clinic, the likelihood that they will go to another place goes down.” 
 Summary of naloxone access approaches. These naloxone distribution methods 
were not mutually exclusive; three of the CHCs implemented two or more approaches at 
the same time. One nurse program manager explained her CHC’s rationale for having 
multiple pathways for naloxone access: 
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For our clinic, you need to have it in both places [pharmacy and clinic] because 
there are people who won't walk into the pharmacy and wait. So if you have 
someone who is agitated and not willing to wait in the pharmacy, you know, 
stand in the line, wait for the pharmacist, they have to fill it, and then you have to 
get educated. People aren't going to be willing to sit there and do that; you have 
to meet them where they are at. And that is why being able to provide it in our 
model works really well. But also giving people the freedom to walk into the 
pharmacy and request it works really well. So you have to have both. [I] think 
that what makes our program so great [is] that we are all integrated and 
working together and have these different options. 
 
The advantages and disadvantages of the different means of accessing naloxone should 
be considered to determine which approach— or approaches— might work better in a 
given organizational context at a particular point in time based on patient needs. The 
benefits and challenges of the different approaches identified in the study are summarized 
in Table 24.  
Table 24. Advantages and Disadvantages of Naloxone Access Points 
Naloxone 
Access Point 
Advantages Disadvantages 
Internal clinic 
distribution 
(by clinic 
staff during 
patient visit) 
 Integrated into patient visit 
 Provides patient with naloxone 
directly to ensure access 
 Offers private space to conduct 
training.  
 Minimizes pharmacy access 
barriers that may occur outside 
the clinic (i.e., travel, long 
wait, lack of privacy) 
 No patient cost for naloxone  
 Obtaining funding for clinic-purchased 
naloxone kits 
 Sustaining funding for kits 
 Need to ensure providers and clinic 
staff are trained 
 Need to ensure naloxone distribution is 
built into clinic flow and appropriate 
staff are available 
 Need system to track naloxone 
distribution 
Pharmacy 
dispensing 
(by CHC-
affiliated 
pharmacy 
through 
prescriptions 
or a standing 
order) 
 Naloxone cost covered by 
patient health insurance 
 Naloxone prescribing or 
referral integrated into clinical 
care (i.e., Suboxone induction 
or chronic opioid therapy) 
 Pharmacist can support 
protocols to offer naloxone as 
part of co-prescribing 
initiatives for buprenorphine 
and chronic opioid therapy 
 Prescription access: Ensures 
 Cost of naloxone if insurance does not 
fully cover the prescription 
 Need to ensure pharmacists are trained 
and comfortable providing overdose 
education 
 Stigma can impede patient request for 
naloxone 
 Lines, waiting time, and space 
constraints in the pharmacy limit the 
opportunity for private overdose 
education sessions 
 Concern that patient will have naloxone 
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prescription will be prepared 
for patient pick-up at 
pharmacy 
 Standing order: Allows 
patients and other persons to 
request naloxone without 
prescription 
on health insurance record  
 Naloxone receipt tracking hindered by 
different CHC and pharmacy systems  
 Prescription access: Getting a prescrip-
tion from prescribers with competing 
priorities and limited time can be a 
barrier 
 Standing order: Unless a prescription or 
other supportive measure is in place, 
the onus of requesting naloxone is 
placed on patients 
External 
referral (to a 
community 
organization 
funded to 
provided 
OEND) 
 Collaboration with a local 
organization providing OEND 
services 
 Links patient to an organiza-
tion that could offer other 
supportive services 
 No patient cost for naloxone  
 Requires patient to access another 
service in a different location, with a 
risk of referral drop-off 
 OENA is not built into CHC clinical 
care systems 
 No follow-up information  on referral 
uptake 
 
 
CFIR Constructs Influencing Implementation 
 
This section describes the 20 constructs from the five CFIR domains that were found to 
support or inhibit implementation success (Table 25). The constructs are stated in 
positive terms as facilitators, but their absence could pose a serious barrier and be just a 
neutral factor. For example, the presence of a champion at the CHC who drives 
implementation forward would facilitate implementation. The reverse, however, is also 
true— the absence of a champion would impede implementation. Each of the constructs 
is described by domain. Table 12 in the Methods chapter provides a brief glossary of 
construct definitions for reference. 
  
110 
Table 25. CFIR Constructs Identified During Analysis by Domain 
Domain Constructs Found to Facilitate OENA Activities 
Innovation 
Characteris-
tics 
 
Adaptability: OENA can be tailored to the needs and resource of the CHC and 
revised in an ongoing manner as program needs evolve. 
Trialability: OENA activities can start as a pilot initiative with a particular group 
of patients or clinic and then be changed or expanded based on experience. 
Complexity: Integrating OENA activities into clinical care provision by clinic 
team members who are non-prescribers (i.e., nurses) supports implementation. 
Cost: OENA activities involve minimal costs, depending on the means of 
naloxone access by the CHC. 
Outer Setting  Needs & Resource of Patients: Clinic staff’s understanding of addiction theory, 
a harm reduction approach, and non-judgmental communication supports patient 
engagement.  
Cosmopolitanism: Partnerships can be put in place to help initiate and expand 
the clinic’s naloxone access activities. 
External Policies: Governmental policies offer opportunities for enhancing 
naloxone access in clinic settings. 
Inner Setting Networks & Communications: Partnerships with pharmacies support the 
provision of naloxone to patients and the community. 
Culture: The CHC culture and mission supports patient-centered health services 
and is open to innovations that could better meet patients’ needs  
Implementation Climate: Team-based provision of OENA supports clinic staff 
participation and implementation of OENA. 
Tension for Change: An expressed sense of urgency to address the local opioid 
epidemic serves as a catalyst for CHC response. 
Readiness for Implementation: Clinic-wide training on a clinic’s overdose 
response and leadership support are among two key initial steps for OENA 
adoption. 
Leadership Engagement: Ongoing clinic and pharmacy leadership supports 
program initiation, adaptation, and long-term maintenance of OENA activities. 
Available Resources: ongoing training, educational materials, physical space in 
the pharmacy and clinic, and identified staff roles are important components to 
OENA implementation. 
Characteris-
tics of 
Individuals 
Knowledge & Beliefs about the Intervention: Clinic staff understanding of 
how naloxone benefits different patient groups at risk of experiencing or 
witnessing an overdose supports engagement. 
Individual Stage of Change: Implementers with differing levels of comfort and 
skill development need different supports depending on their stage. 
Process Engaging: Training, peer guidance, inclusion of OENA in regular meetings, and 
decision tools help engage clinic staff. Outreach efforts, signage, and models of 
delivery that address patient barriers support patient engagement. 
Champions: The presence of a passionate champion who leads the clinic team’s 
implementation effort can keep the OENA intervention on track.  
External Change Agents: Reputable experts and advocates help get CHC staff 
on board during the initial OENA implementation phase. 
Reflecting & Evaluating: Staff sharing of implementation experience and 
ongoing data reviews provide feedback to staff and guide quality improvement 
efforts related to CHC-based OENA activities. 
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Domain 1: Intervention Characteristics 
Four characteristics of the intervention were found to affect the adoption and 
implementation of OENA activities: adaptability, trialability, complexity, and cost. 
Findings related to each construct are described below.  
Adaptability 
The first finding from this study was that CHCs have implemented a variety of 
strategies in addition to traditional prescribing to equip patients with naloxone. The study 
therefore focused on implementation of naloxone access activities, as opposed to 
naloxone prescribing alone. The variety of strategies used at each of the sites, combined 
with differences in who conducts the activities, demonstrate that OENA activities can 
easily be adapted to meet the needs of a specific CHC. Where policies were in place, 
they were developed after implementation started and offered guidance rather than a rigid 
protocol.  The flexible nature of the intervention activities meant that they could be 
revised as needed. Likewise, implementers were able to try out new strategies. For 
example, one CHC with a pharmacy standing order recently piloted a primary care-based 
OEND initiative with pre-purchased naloxone rescue kits and posted local overdose data 
to engage clinic staff. Upon implementation, the team realized that the naloxone kits 
could not be reimbursed and discontinued the purchases. Likewise, the introduction of 
pharmacy standing orders also offered new access strategies for some CHCs that had 
already implemented other distribution strategies.  
 The “adaptable” nature of OENA activities enabled CHCs to respond to changes 
in either the inner or outer settings. For example, the availability of a pharmacy standing 
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order in Massachusetts in March 2014, plus CDC’s release of chronic opioid prescribing 
guidelines in March 2016, offered new opportunities to introduce novel program options.  
During all of the interviews, participants reflected on planned future enhancements and 
ways to streamline their programs, including whom they wanted to reach, additional 
outreach strategies, clinic staff engagement activities, and ways to decrease stigma 
related to requesting or receiving naloxone (Table 26).  
 
Trialability  
The degree to which a health services intervention can be piloted first 
(“trialability”) has been shown to support implementation.75 OENA activities typically 
started on a small-scale in a particular program within the CHC and were then 
modified or expanded over time. The CHCs’ OENA activities operated in the HIV 
programs, a primary care clinic, the buprenorphine program, or across the whole CHC. 
One nurse practitioner commented on the transformation of her clinic’s pilot OENA 
initiative, “So it’s not so much a pilot anymore. It’s supposed to be like a process that we 
are doing and are going to continue to do.”  
 Starting OENA activities on a small scale aided the early adoption phase. An 
intervention pilot within a particular care team or targeted to specific patients allowed 
Table 26. Examples of CHC OENA Program Adaptations  
 Obtaining a standing order for nurses to order naloxone 
 Utilizing the behavioral health team to conduct OEND  
 Expanding the program to serve patients on chronic opioid therapy 
 Working with senior administration to create a standing order with CHC pharmacy 
 Making preparations to utilize the CHC pharmacy standing order if needed 
 Adding signage at the clinic to increase overdose and naloxone awareness 
 Designing request cards so patients can easily ask for naloxone at the pharmacy 
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CHCs to figure out what worked, demonstrate success, and identify program elements 
needing improvement before moving toward broader implementation. Demonstrated 
success was then used to galvanize leadership and colleagues in expanding the reach of 
the CHCs’ naloxone access activities.  
Costs 
 Overall, the investment and supply costs related to OENA activities were 
minimal, though cost does become a major consideration if naloxone is distributed in-
house. A summary of cost consideration appears in Table 27. Note that these costs do not 
include staff time, training, or clinic space, which are discussed later the “Available 
Resources” construct in the “Inner Setting” domain.  
 In terms of supplies, educational materials and signage were mostly available for 
free through the websites for the Massachusetts DPH and Prescribe to Prevent. Several of 
the participants spoke about the importance of having a naloxone rescue training kit on-
hand for patients to practice assembly.  
Table 27. Cost Considerations for CHC OENA Initiatives 
 Printing of patient-friendly, linguistically appropriate education materials 
 Posters and signage for the clinic 
 Naloxone rescue kit supply, if the CHC is using in-clinic distribution 
 Co-payment or full cost of the kit at the pharmacy, depending on patients’ health 
insurance coverage 
 
For the majority of the CHCs using a pharmacy to dispense naloxone, the cost of 
the naloxone rescue kits was covered by patients’ health insurance. In-house naloxone 
rescue kit distribution required long-term institutional or grant resources. External 
referrals to OEND programs relied on naloxone rescue kits paid for and made available 
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by the Massachusetts DPH.    
Five of the sites with a pharmacy partnership indicated that cost for naloxone 
was not a barrier for the patients. A pharmacy director at one of the study sites 
explained: 
I can't even remember a time when it wasn't completely covered. And if 
it’s not, it’s usually a co-pay of $3.65 or something minimal. And if they 
can't afford it then we put it on the pharmacy account and write it off. 
Because we would rather have the patient leave with Narcan versus lose a 
co-pay. Because we are a FQHC, we are able to get great benefits in the 
pharmacy where we are able to do special things like that. 
 
Even so, a program manager at a CHC with an OEND pilot program and a pharmacy 
standing order, which had not yet been utilized, expressed concern about the potential 
costs to patients of providing naloxone through a pharmacy standing order if insurance 
were not to cover it fully. “It’s the cost barrier for those people who have anything but 
Mass Health…the cost that is incurred. Our clinical manager has been in communication 
with the pharmacist to try and figure out how we can encourage pharmacy distribution.”  
Complexity 
Overall, participants who regularly conducted overdose education and 
distributed naloxone to patients did not find it to be complicated, and reported that 
OEND was typically integrated into existing assessment and follow-up appointments, 
such as HIV or buprenorphine visits with a nurse.   
For prescribers, integrating OENA activities into patient visits was more 
difficult. Participants continually spoke about the challenge of covering multiple clinical 
issues during a short visit. One physician’s description of the problem was echoed by 
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others:  
Time and multiple competing demands: patients have ten different things 
that they want to talk about. And I have so much time, and so I probably 
under-prescribe naloxone simply because I'm not always thinking about 
[it]. There are other things I am thinking about. 
 
Time constraints were often exacerbated by the need to address both primary care and 
HIV-specific care during the same visit. Training other staff members who had more time 
with patients to provide education was a common strategy for addressing this issue.  
 Yet for some prescribers, a busy clinic flow impaired their ability to utilize other 
team members’ expertise. One physician who was a naloxone champion in her clinic 
shared her experience, “I hardly ever do it [refer to a case manager], I have to say. It’s 
one more thing, and it ends up making my visit longer in reality. I have to find that case 
manager. I have to page them. There is a back and forth. So often times I'm doing it 
myself.” The utilization of other team members worked best when it was built into the 
existing workflow. For example, if a nurse already saw patients as part of her regular 
buprenorphine treatment assessment, and overdose education was conducted as part of 
that visit, then that would be a natural fit. 
Summary: Intervention Characteristics Domain 
 Regarding intervention characteristics (Table 28), CHCs identified different 
strategies based on the clinic’s structure and existing programs, staff roles, and internal 
and external partnerships. Starting small, such as with a particular group of patients, 
allowed staff to see what works and what changes are needed. Finding ways to make the 
intervention as simple as possible also seemed to support implementation. Examples 
included utilizing staff that could spend more time with patients, building overdose 
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education into regular visits, and adding prompts to the EMR system. Most 
implementation-related costs seemed to be low, but the cost of naloxone rescue kits mean 
that it is not sustainable for a clinic to distribute naloxone in-house in the absence of 
patient insurance coverage. Accordingly, it is important for clinics exploring OENA 
options to investigate the extent to which different insurers cover the cost of naloxone.  
Table 28. Summary of Strategies Related to CFIR Constructs within Intervention 
Characteristics Domain 
Construct Implementation Strategies 
Adaptability  Adapt model based on patient needs, interest of implementation team, 
staffing model, clinic structure, and internal and external partnerships  
 Modify the program as needed based on experience, including who 
conducts the education, which patients are reached, and ways of engaging 
clinic staff and patients 
 Adapt approaches, practices, and policies from other programs 
Trialability  Start with a pilot project within a particular program or department and 
scale back or expand the program based on experience 
 Start where it makes the most sense, based on the clinic staff and patient 
needs 
Complexity  Utilize non-provider staff to implement the intervention 
 Minimize steps for implementers and patients by integrating OENA 
activities into regular visits 
 Ensure availability of staff for a “warm hand-off” to ease provider burden 
and patient waiting time 
 Build overdose risk assessment, education, and naloxone into the EMR 
Cost  Create a partnership with a pharmacy to minimize cost barriers 
 Use or adapt free, readily available patient education materials 
 Determine the financial costs incurred by patients with various health 
insurance plans and ways to remove costs barriers 
 
Domain 2: Outer Setting 
The following three constructs from the “Outer Setting” domain were found to 
influence implementation: needs and resources of patients, cosmopolitanism, and external 
policies. Each of these constructs is described below.  
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Needs and Resources of Patients 
 Individual patient assessment activities and community outreach helped clinic 
staff understand patients’ needs. One nurse talked about the patient assessment process in 
the buprenorphine program: “It is through our reassessment that we do every six months 
and also our base knowledge of patients. We typically know what’s going on with them, 
and their historical situation.” Participants from a few of the CHCs talked about the 
importance of having staff spend time in the community. One pharmacy director 
described her process: 
Our clinical pharmacists have gone out with the homeless providers. Once 
you see what is going on, you are like, “Wow, we need to do something.” 
Most pharmacy directors probably aren't there. They got to get in it. 
Whenever there is any kind of community outreach or program, the clinic 
continuity of care director will tell me about it, and I will have someone 
on my team go to it. Just get out there. 
 
For many participants, clinic staff’s personal experience heightened awareness about 
the opioid crisis. A nurse program manager spoke about her CHC being in a community 
experiencing high opioid overdoses as a factor in facilitating clinic staff sensitivity to 
opioid use disorder:   
Most people who live in this community are affected by opioid addiction, 
whether it is themselves or someone they know. I think we have less 
resistance than maybe there would be in other communities. And I think 
that makes the providers, staff, and pharmacists more on board because 
we see this, and we know it’s a problem, and it needs to be addressed. And 
this is one thing we can do to try to help. 
 
Another participant at a different CHC echoed this sentiment: 
 
You know, I don't know what the statistics are, but I can guarantee you 
that every patient who walks in this door has been affected by addiction in 
some way, shape, or form, and I'm sure a large number of them have been 
connected to somebody who has had an overdose or has lost somebody to 
an overdose. 
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 Just as awareness of the opioid crisis in the community facilitated responses, lack 
of awareness of patient needs outside the confines of the clinic setting was reported as 
a barrier to implementation. One participant expressed frustration: “It’s what we see in 
the community…When I came here I was surprised…What people were not realizing was 
the community perspective, and as a healthcare provider seeing what's going on outside 
the doors.”  
 Resistance to using a harm reduction model posed another barrier to addressing 
patients’ needs by inhibiting open discussions about overdose risk, naloxone use, and the 
potential for relapse while in recovery. Conversely, a harm reduction approach to 
substance use disorder treatment facilitated the integration of OENA activities into 
the clinic’s work. A nurse who underwent harm reduction training spoke about how this 
helps her support her patients:  
It’s about taking the stigma out of it. You know, I brought it up with a 
patient: talking about the risk of relapse, overdose, and the importance of 
naloxone. I was worried that she would not want to hear it from me. And 
the patient said to me, “I come here because I'm not judged.” So I was 
glad I brought it up. I just talk about it now, and let people know we are 
here for them no matter what and recognize that relapse may be a part of 
the recovery process, and there are some ways for them to stay safe. 
 
Some participants spoke about patients’ resistance to receiving naloxone based on 
their perception that they do not need it. This belief is common among patients who 
are in treatment for opioid use. One participant explained:  
A lot of them are very resistant. They are like “I'm not going to use that stuff, I 
don't need that stuff [naloxone].” So it is hard to convince them [they] should 
have this because they are in the mind frame of “I'm not going to do that 
anymore.” 
 
One participant shared how she addresses this barrier: 
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I've had a couple of patients say, “Why do I need this? I'm not using 
drugs. I'm not hanging around with people who use drugs anymore.” We 
kind of just say, “Oh we want to get more of this out there in the 
community. You never know where you might be when someone you know 
might need it.” I say, “Well, I have it. I carry it with me.” [I]try to kind of 
normalize it. 
 
Another CHC HIV program manager outlined his message: “I remind them that relapse 
is part of the disease— there is a 60% chance of relapse.”  
 Stigma was frequently reported as a barrier to OENA activities. Participants 
observed, for example, that it was difficult for patients to ask for naloxone at the 
pharmacy for this reason. Additionally, a few participants stated that patients are 
concerned about having naloxone listed on their health insurance or medical record. 
 Across all of the interviews, clinic staff expressed compassion towards patients 
with an opioid use disorder and spoke about ways to remove stigma. As demonstrated by 
some of the participant statements reported above, the clinic staff’s recognizing opioid 
use disorder as a brain disease and having knowledge of the recovery process 
seemed to enhance clinic staff members’ communication with patients about 
overdose. One physician identified this as a facilitator to OENA in his CHC; “It is 
recognition that this is a chronic disease of the brain, and it’s not a moral failing.” An 
HIV program director from another CHC noted the benefit to offering naloxone to 
persons struggling with an opioid use disorder: “There is the empathetic message— by 
offering someone Narcan, you are letting them know, and ‘You are worth it. You deserve 
to make it.’” 
Cosmopolitanism 
 A list of study site external partnerships can be found in Table 29. As Figure 6 
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shows, the CHCs established partnerships with multiple programs to ensure that patients 
had access to the continuum of opioid treatment services, including detoxification 
methadone treatment, and outpatient counseling. Some CHCs established formalized 
referral processes with these agencies.  
 Two of the CHCs partnered closely with the 
pharmacy vendor serving the CHC to stock and 
distribute naloxone through a standing order. 
Communication and partnerships with commercial 
pharmacies was limited. One nurse discussed the 
need for a commercial pharmacy partnership in 
order to expand OENA activities to a CHC without 
an in-house pharmacy:  
Once I roll out the addictions program up there and integrate it with the 
HIV program, the next step is to integrate the Narcan piece into it and 
figure out how we implement it without a pharmacy on-site….. If we are 
unable to keep Narcan in stock at the clinic to distribute and bill for, then 
patients would be given a script that is sent to that CVS, but then I would 
work to meet, along with the nurse and one of the physicians, along with 
the CVS pharmacist and make sure they are doing the teaching, and make 
sure we can have that streamlined referral process. We may teach the 
patient[s] how to do it and then have them go pick it up. That would be the 
next phase. 
 
 Three participants represented their health center on a local coalition established 
to respond to the opioid crisis, which played a role in information gathering and 
coordinating a multi-sector response. One coalition was described as follows: 
[It] brings together a variety of people— faith-based organizations, police 
departments, school representatives, treatment facilities, health centers. 
Table 29. CHC External 
Partners Supporting OENA 
 Detox programs 
 Methadone treatment 
programs 
 Outpatient counseling services 
 Residential programs 
 Behavioral health agencies 
 HIV service organizations 
 Harm reduction programs 
 Homeless service providers  
 Pharmacies 
 Hospitals and their EDs  
 EMS department 
 Police departments 
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These groups are useful in terms of disseminating information and pooling 
resources together…. They are trying to get more data from the 
ambulance service and hospital related to overdoses and track when 
naloxone is used. I am trying to get all of the outreach workers from the 
different agencies together so we can train them all in Narcan and make 
sure they know what resources each individual town has available. 
 
Another CHC physician who attends an opioid community coalition takes the 
information from these meetings directly back to his clinic:  
We talk about the overdoses and what we are seeing in the community, 
and the rates, and we discuss the police report. We get the data from the 
police. So that is what you saw on the board in the clinic. That just helps 
hit it home to the folks, to just say, “Hey, you know this is a patient of 
ours.” So everyone should be offering everyone a kit. 
 
 
  
CHC connections with EDs were limited to physicians who had hospital 
privileges at the ED’s hospital. Although hospitals were a part of the local opioid 
coalitions, formal strategies to coordinate overdose follow-up with patients were lacking. 
One physician shared his success with getting a local ED to distribute naloxone to 
persons who visited the ED because of an overdose. Another nurse practitioner talked 
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about her expectation for additional collaboration with the local ED: 
I would love to see more of the patients discharged from the hospital with 
Narcan. We are trying to work with the hospital on that because we will 
get the ER reports, and we can't find the patient. And everyone is like, 
“Can someone get a Narcan kit in that person's hands?” Well, if he is the 
one overdosing he’s not going to be able to use it on himself anyway. We 
need to find out where he's going or where he's hanging out.  
 
To address overdose response beyond the CHC, one CHC implemented an innovative 
pilot with the local EMS to identify patients who had an opioid-related ambulance 
transfer. Through this arrangement, primary care providers were made aware of patients 
who had overdosed.  
  Several of the CHC participants named specific harm reduction agencies and 
organizations serving the homeless population as being instrumental in helping initiate 
their clinic’s OEND activities or serving as a program model. For example, one of the 
physicians spoke about his CHC’s early partnership with a needle exchange van to 
distribute naloxone rescue kits to patients. Another CHC partnered with a local CBO to 
jointly conduct outreach activities, and used a naloxone policy from a healthcare 
organization serving homeless populations to draft the CHC’s policy.  
External Policies 
There were 
external policies, funding 
mechanisms, and 
recommendations or 
Table 30. External Policies Influencing CHC OENA  
 DPH-funded OEND pilot grants 
 Pharmacy standing order 
 MassHealth (Massachusetts’ Medicaid program) naloxone 
reimbursement 
 Chronic opioid prescribing guidelines 
 Opioid treatment funding in CHC primary care settings 
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guidelines that influenced the adoption of OENA activities by the CHCs, as listed in 
Table 30.  
The Massachusetts DPH-funded OEND pilot grants provided naloxone rescue 
kits to select HIV programs in the state, including some clinical sites (see Image 4). 
Three of the CHCs in this study had an OEND pilot program, and two partnered with a 
local community agency that had an OEND pilot grant. These programs, particularly 
when located at a CHC, facilitated the development of clinic-based OENA activities; all 
three of those CHCs implemented pharmacy standing orders to increase naloxone access 
for patients, though one CHC had not yet begun referring patients to the pharmacy. The 
OEND pilot program served a supportive function by making overdose prevention a 
priority during regular HIV team meetings. Concrete supports, such as training, 
educational materials, and referrals were also provided by these programs. One OEND 
program manager articulated the supportive role of the OEND pilot grant program: 
We have worked really hard…to remind all of the physicians, if they have 
someone with a substance use problem, they should be prescribing a 
naloxone kit because you can pick it up at any of our pharmacies. We have 
always had referrals, especially when the doctors have a patient with a 
substance use problem, they will send them over to us to find a detox spot. 
When they are over with us, we will always make sure they get naloxone if 
it is an opioid substance abuse program. The doctors will also prescribe 
naloxone and sometimes refer them to us for education. 
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In addition, the network of Massachusetts DPH-funded OEND grant programs 
played a role in disseminating best practices. One HIV and OEND grant manager 
explained: 
Getting involved in the [DPH OEND pilot] Narcan meetings and going to 
those meetings has really broadened my understanding of it. And a lot of 
the discussion and watching what was happening in [other parts of the 
state] with the overdoses was good for me to see, so I felt like we were 
prepared and had all of this information about the Narcan even though we 
weren't yet getting the issues… in terms of the overdoses. So when it hit us 
we had all of that available. I think we were definitely involved by the 
state OEND program and policies. It was also really great in encouraging 
our pharmacy to get Narcan….So the [CHC] administration was really 
supportive of that, and it was really easy for me to get the policies and 
procedures because I had access to all of these other programs that were 
doing this in the state. 
While the DPH OEND pilot programs may have facilitated clinic-based naloxone 
expansion in two of the CHCs, having an OEND pilot program at the clinic was not a 
necessity. In fact, four of the CHCs implemented activities without such a program. One 
Image 4. CHC Primary Care Waiting Room Screen Promoting 
Massachusetts DPH OEND Program 
 
Source: Author, 2016. 
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of these CHCs partnered with the 
community-based OEND pilot grant 
program to bring education and 
distribution in the clinic entrance area. 
One referred patients to the OEND 
program as the CHC itself did not 
implement OENA activities. It is 
important to note that for two of the CHCs 
without an OEND program, identifying 
training resources for the clinic staff posed 
an initial barrier, as the external OEND 
pilot programs were limited in their 
training capacity, and clinical sites were 
not a priority for them.  
For some of the CHCs, the Massachusetts pharmacy standing order, promoted 
on a pharmacy sign in Image 5, was vital to expanding access to naloxone. One physician 
credited this policy change as follows: “At the state level, having the ability to prescribe 
freely on demand... the standing order. When [Dr. Alexander Walley] pushed that 
through that was big— really critical to expanding access for people.” The pharmacist at 
this CHC explained how the standing order works in their clinic: 
We have a standing order [with the pharmacy at the CHC] where anyone 
can come off the street and buy naloxone. Because of the standing order 
you can actually use your insurance. So we have the kits already set up. 
We have all of the pharmacists trained. We met with DPH to get approval 
Image 5. CHC Pharmacy Sign Promoting 
Standing Order (Available in Spanish) 
 
Source: Author, 2016. 
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for this. We are on a website or database that we are one of the 
pharmacies that people can go to for Narcan. The prescription is pre-
filled out. We do our best to get the patient in and out. 
 
Further supporting pharmacy access by removing cost barriers, MassHealth 
(Massachusetts’ Medicaid program) provides full coverage of naloxone without requiring 
a co-payment.
292
  
 Despite their awareness of the state’s standing order that allows for distribution of 
naloxone by certain commercial pharmacies, CHCs did not refer patients to 
commercial pharmacies for naloxone. One participant expressed doubt about the 
degree to which clinic staff and colleagues promote this option: 
I don't know how much people are utilizing, “Go to Walgreens. Even if 
you don't have a prescription from the doc, you can just buy it and use 
your insurance.” I know that, but I don't know that message is going out to 
everybody. 
A few participants talked about negative experiences reported by patients, making the 
interaction with the pharmacist “difficult and humiliating for them.” One participant 
discussed his concerns regarding the retail pharmacies, including space constraints: 
I'm not sure what environment they are teaching them [in], if they are 
teaching them with that one-foot wall that kind of protects your 
conversation, but you are still showing somebody how to use Narcan. But 
here it isn't done in the pharmacy; it is done in a private consult room 
with the patient, and the patient is allowed to play with the equipment and 
get a feel for it. 
 
A participant from another CHC discussed the stigma that patients might experience if 
they sought naloxone from a retail pharmacy:  
I think we work really hard in our setting to remove barriers. We have 
certainly heard from people in other parts of the state [that] when they go 
to a commercial pharmacy they haven't been treated very well when 
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asking for Narcan. I think we try to have a different approach here so they 
don't feel like they are getting judged here or we are getting into their 
business. 
 
Finally, a pharmacist expressed her concern about the co-payment requirement at 
commercial pharmacies in contrast to CHC pharmacies, noting: 
If it is a co-pay issue, we are a CHC, we are a 340b pharmacy, so we get 
cheaper rates. It shouldn't be a reason to deny someone. I am adamant 
with pharmacy services that cost is not a reason to deny a patient 
medications or a life-saving drug like Narcan. Our pharmacy never has. 
Everybody in the pharmacy really gets it. We are fortunate. You may not 
be able to find someone who cares at CVS.  
 
 Several of the study participants spoke about the impact of their health center’s 
revised chronic opioid therapy prescribing guidelines in response to the recommended 
guidelines released by the state and then by CDC in the past year. One physician 
explained the positive impact of these guidelines on her CHC’s practice,  
The other big prong and big push in this program has been safer opioid 
prescribing. For every patient on chronic opiates, we have totally 
overhauled our clinical guidance around that. We have now templated 
[sic] into the EMR a risk tool before we prescribe…Based on the score, it 
guides us to more or less intensive monitoring. So that has been super 
helpful…..The other thing I would say related to that is we have also just 
increased requirements around monitoring in general. Even the patient 
who is a "good" candidate for opioid prescribing, we are reminded every 
three months [that], minimally, urine toxs have to be done. We have to 
check the PMP quarterly. But if they are high risk you have to do those 
things more frequently. So it will prompt you monthly-- you should do 
urine tox and [a] PMP check. 
 
Two of the CHCs prioritized naloxone access for patients on chronic opioid therapy, but 
at the other four study sites, naloxone co-prescribing was not uniformly done for these 
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patients. One barrier to this was the increased monitoring requirements and time demands 
imposed by the new guidelines: 
Well, the chronic opioids, there are a lot of things that kind of catch up 
and meet the current recommendations. Checking that— state pharmacy 
exchange, contracts, and urine testing. I think folks with patients on 
chronic opioids are struggling to kind of keep up with all the things that 
need to happen over the past couple of years. 
  
 While some of the CHCs did not prioritize patients on chronic opioid therapy as 
candidates for naloxone, two of the CHCs were in the process of expanding naloxone 
efforts to include these patients. One study participant outlined the benefit of co-
prescribing naloxone with opioids: “They are working on that in the chronic pain 
program to make it part of the program. Part of the agreement when the patient is being 
prescribed opioids chronically…is you need to have naloxone just in case of an 
emergency.” At another site, the nurse program manager highlighted his vision of the 
overdose education and naloxone program’s future direction:  
We also want to have a more centralized program for our patients on 
chronic opioid therapy, like our Suboxone program, with an addictions 
nurse, education, Narcan provision. So the whole clinic functions with this 
model. Champion providers came up with this idea— we want to hire 
another nurse who is part of the team. 
 
 Finally, the scale-up of opioid treatment programs— specifically, 
buprenorphine (Suboxone) programs— at the CHCs played a major role in the provision 
of OENA activities. Several of the sites received grants from the Massachusetts DPH to 
implement Office-Based Opioid Treatment Programs (OBOT)— a Massachusetts-
developed nurse case manager model for primary care-based MAT delivery. In addition, 
recommendations to integrate OENA into opioid treatment programs were issued by 
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SAMHSA, ASAM, and the Massachusetts DPH in spring 2015.
293
 One participant 
explained how the buprenorphine program served as the focal point for OENA activities 
within her CHC:  
Our Suboxone program really is the motivating factor of keeping this 
relevant. They are the ones that are seeing this on a regular basis and 
working with patients who are at highest risk, making sure that patients 
are getting access to Narcan, and making sure they are following up with 
them. That has been supportive— and keeping it going, rather than it 
being a hot topic and then going away. 
 
Implementation Strategies by Outer Setting Domain 
 Regarding the Outer Setting (Table 31), federal and state policies and funding 
streams for naloxone access, opioid prescribing, and medication-assisted treatment 
provision greatly influence the opportunities for program adoption, expansion, and 
maintenance. Providing CHC staff the opportunity to talk about the impact of the opioid 
crisis with other medical professionals and community leaders also served as an impetus 
for CHC response. As described above, connections with external agencies broadened 
naloxone access through outreach partnerships and patient referral mechanisms. CHC 
participation in community opioid coalitions played a key role in coordinating a 
comprehensive local response. 
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Table 31. Summary of Strategies Related to CFIR Constructs from Outer Setting Domain 
Construct Implementation Strategies 
Needs and 
Resources of 
Patients 
 Identify opportunities for the clinic staff to discuss the impact of the 
opioid crisis in the community 
 Partner with community-based organizations and conduct community 
outreach events to learn more about the community’s needs outside 
the clinic 
 Conduct training for providers and staff on addiction, treatment, and 
recovery science, and on the role of naloxone in the treatment and 
recovery process 
Cosmopolitanism 
 
 Join a community coalition to coordinate the local opioid response 
 Identify new partnership opportunities (e.g., ED) to expand naloxone 
access for patients. 
External Policies  Document and share naloxone access laws with clinic and pharmacy 
leadership and staff at the start of the initiative, and outline those laws 
in the clinic’s policy document 
 If needed, partner with community-based OEND programs to support 
naloxone access 
 Build a relationship with the clinic’s pharmacy to establish a standing 
order for increased naloxone access  
 Create new partnership with commercial pharmacies when the CHC 
does not have an affiliated pharmacy 
 Integrate naloxone co-prescribing into revised chronic opioid 
prescribing guidelines 
 Build OENA into buprenorphine treatment  
 
Domain 3: Inner Setting 
 
The following six constructs were found to influence implementation within this 
domain: networks and communications; implementation climate; tension for change; 
readiness for implementation; leadership engagement; and available resources.  
Networks and Communication  
 The team-based care model at the CHCs facilitated internal networks and 
OENA-related communication. Table 32 lists various internal stakeholders at the CHCs 
who were involved in implementation. One CHC nurse described her perception of the 
integrated, team-based environment and how that works to support the multiple needs of 
a patient or families who may be struggling with addiction:  
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I think that is part of the team model, too. A patient walks in here and gets 
all of the services they need in one building. This area in general is a 
resource-rich community, but what I have seen there is an integrated 
model approach where it’s about pulling in different skill sets so that a 
patient can really feel well supported. From our end, from a clinical 
standpoint, you know that a patient is going to be well cared for, that some 
of those barriers that could potentially prevent someone from actually 
taking that action, you are setting them up so they can be successful in 
whatever that next step is. 
 
 This team approach, in turn, was reported to support the provider, as explained by 
one physician: “It’s so great not carrying this by yourself, to have the addictions nurse, 
health educator, recovery coach, our social workers, our case managers.” While 
particular team members played a greater role than others, all team members shared a 
vision for the program and worked together to ensure that patients had this service. All of 
the participants talked about how the weekly and monthly HIV and Suboxone team 
meetings facilitated coordination and communication about patient cases and reinforced 
the need for supports including naloxone access.  
 
 Within the integrated care team model, several participants talked about the 
important role that the behavioral health team members play in terms of screening 
and counseling for mental health and substance use issues. One physician endorsed their 
involvement in overdose prevention initiatives:  
Table 32. OENA Implementation Team Members Identified at the CHCs 
 Prescribers, including physicians, physician assistants, and nurse 
practitioners providing HIV, primary care, and buprenorphine 
 Nurses providing HIV, buprenorphine, and primary care 
 Case managers and health educators 
 Behavioral health providers 
 Pharmacists 
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The behavioral health team and the role of behavioral health integration 
have been huge. Having that team be on board with all of these initiatives 
is really important.”  
 
A CHC director spoke about the role that the behavioral health team plays in the 
overdose education and referral process:  
We do two screenings in primary care for mental health and substance 
abuse…When the screening is positive, they should be making a referral to 
behavioral health staff who would handle the overdose education or 
referral. So the provider themselves probably doesn't do a lot of the 
overdose education... because of the 15-minute visit. 
 
Participants at other CHCs talked about the future promise of involving the behavioral 
health team in overdose education initiatives, given that they have more time and are 
already interacting with patients who may be at risk of an overdose.  
The HIV care teams’ OENA activities matched what was being done in primary 
care generally, and sometimes the HIV care team took the lead in implementation. In 
most cases, in fact, OENA activities originated and were often managed within the HIV 
departments. Given that all of the CHCs deliver HIV care in the context of a primary care 
clinic, participants explained that the activities they were describing pertained to the 
primary care clinic overall. In the majority of sites, the HIV programs were instrumental 
in the beginning stages of implementation, after which the CHCs focused their attention 
broadly on all of their patients at greatest risk. 
This resulted in varying organizational options. If a CHC saw a high number of 
PLWH who also had a substance use disorder or an overdose history, then the OENA 
activities would be tied to the HIV program. The CHCs that received Massachusetts DPH 
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OEND grants through the HIV programs primarily managed their OENA activities out of 
those programs. In two of the CHCs, OENA activities were managed by a HIV program 
manager who also managed the CHC’s opioid treatment (OBOT) program. In two other 
CHCs, OENA activities had diffused throughout the center, without a direct tie to the 
HIV program. In another CHC, however, OENA activities were piloted by a primary care 
team not focused on HIV care and were in the process of being brought to the CHC’s 
HIV team. Expansion of buprenorphine treatment programs and involvement of a CHC-
affiliated pharmacy further broadened naloxone access throughout the clinic for patients 
with and without HIV. 
 The buprenorphine programs reached patients across the HIV and primary 
care programs with overdose education and naloxone. A program manager overseeing 
both the HIV and buprenorphine treatment programs facilitated staff communication 
between the two programs. The buprenorphine treatment program reached patients from 
across the clinic, including primary care and HIV programs. One participant explained 
how his CHC identifies patients for overdose education and naloxone as follows:  
When it’s clear they have an addiction and it’s identified, or when the 
patient comes in and asks to be referred to the addictions program. That's 
mainly the primary care pool, but if we talk about the HIV care pool that 
we have here, our services are so integrated that the nurse practitioners 
that have been here— and they have been here for years and know the 
patients and know when they need to refer them over— they really work 
closely with our addictions team to make sure a patient is on our 
Suboxone program, and making sure they do the naloxone teaching, have 
a prescription for Narcan, or have Narcan on hand. 
 
 The CHC-affiliated pharmacies played a crucial role in expanding OENA. 
Well-defined and understood roles for the clinic and pharmacy staffs facilitated the 
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process. One example of this was described as follows by a nurse, “The pharmacy has a 
standing order for naloxone so it doesn't need to be prescribed here. I answer questions 
and talk about it… but the pharmacy does most of the training at this point.” Another 
CHC without a standing order employed a different model that required open and regular 
lines of communication between the pharmacy and CHC, as explained by the nurse 
program manager: 
So we have a process set up where the provider, we have general scripts 
in the system that are simplified to click and you can get a prescription for 
a naloxone kit from the pharmacy for any patient or family member that 
requires it. And we have an agreement with our pharmacy that they will 
not fill a script until the patient had had a demonstration from the 
addictions nurse or the nurse on our HIV team. So for any of our HIV 
patients, it functions the same way. It’s just the addictions nurse is part of 
the HIV team so it streamlines the process that the providers can call in. 
One of the nurse practitioners who does HIV primary care can actually 
get the patient in, get them the prescription, and have them talk to 
someone about how to use naloxone immediately. So once they get their 
teaching, the nurse then lets the pharmacist know that they can now pick 
up their naloxone prescription. 
 
A CHC nurse manager at a different CHC described how first-time Suboxone patients are 
reached: “So there is a standing order so it isn’t actually a prescription. We work closely 
with the pharmacy and they know the person is getting Suboxone for the first time and so 
the pharmacist would offer Narcan to the patient.” In this case, the role of the pharmacist 
was expanded to further extend access to patients and support the clinical team in the 
process.  
CHC Culture 
 Many of the participants recognized that the organizational culture at their 
CHC set the stage for initiating OENA activities. This culture was manifest in the staff 
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commitment to community health and patient-centered care, the team-based model of 
care, and having a mission-driven organization. Repeatedly, the sentiment expressed by 
one nurse was heard across the interviews:  
The biggest piece is the mission. It’s the administration and mission of the 
agency. It’s the recognition that this is a huge problem that we deal with, 
and we face not only in our professional lives but many of us in our 
personal lives. There’s a lot of conversation about it. That's a huge 
support. 
 
 Participants from one CHC that was affiliated with a large hospital noted that the 
hospital’s commitment to addressing the opioid crisis enabled them to purchase and stock 
naloxone rescue kits in their clinic’s medicine cart. A physician from another site 
indicated that integrating opioid overdose into clinical care is a natural part of working at 
a CHC located in a neighborhood with high opioid use:  
It’s been part of what the doctors do in their day-to-day practice, thinking 
about overdose risk and prevention, prescribing treatments for addiction, 
and making sure patients who are at risk and family members of patients 
at risk have naloxone in their household to prevent overdose… You 
wouldn't choose to work here or stay working here if you didn't have this a 
part of what you do... It’s just part of where we are and what we do. 
 
Implementation Climate 
 The degree to which OENA was expected and supported within the clinics varied. 
In some CHCs, OENA activities had diffused across the clinic and in one place was 
included as a quality of service measure. The degree of leadership engagement and the 
involvement of a champion also influenced the implementation climate. One of the CHC 
physicians with a supportive working environment reported the following:  
There are things that we are incorporating to make it better and better, 
but I think what we have is extremely useful. If people are willing to get 
everyone on board— that is the main goal, to have everyone feel 
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passionate about the same outcome….It’s not going to work unless 
everyone is on board. And that is the case here and that’s why it is so 
successful. 
 
A participant from another CHC reflected on the domino effect of leadership support and 
how this permeates the implementation climate: “It comes from the top down being 
supportive of the whole program. It starts with a pharmacist director being ultra-
supportive and a great resource. It works its way down to everyone else being 
supportive.”  
 The tone set from leadership was important in a CHC pharmacy. One pharmacist 
explained the expectation in her pharmacy as follows:  
We can fill up to 1,500 prescription in 10 hours, but even if one person 
comes in [for naloxone] and someone needs to step away to counsel them, 
the pharmacy director expects that comes first rather than filling the 
thousands of dollars that are coming in. She would rather the person step 
away and provide this to the patient and actually save someone's life. 
 
Within other CHCs where OENA activities were more sporadic or conducted on a case-
by-cases basis, study participants were not as effusive about the level of CHC-wide 
support. One champion leading an initiative within her primary care clinic lamented, “I'm 
honestly a little disappointed that it hasn't really caught on at the rest of the health 
center. I am hoping it will continue to grow and be offered.” 
Tension for Change 
 Study participants continually spoke about the need for an urgent response to 
the opioid crisis in their communities, and the visible impact of overdoses among their 
CHC’s patients as an impetus to OENA. One physician assistant at a CHC serving a 
population at high risk of overdose explained: 
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The providers— the openness of it all, it’s not a taboo to us — we are used 
to it. We unfortunately have several overdoses a month where we are 
administering Narcan here in the clinic— in the bathrooms, people are 
using in the bathrooms and overdosing in the bathrooms. Things I 
wouldn't necessarily do if I worked in a private practice. When I go to the 
waiting room to call someone, I scan, and if someone is slumped over, I'm 
going to walk over to them. People are watching how the bathrooms are 
used— who is in there, how long have they been in there? We have just 
incorporated it into every aspect of our daily lives here…You can see 
people overdosing on the street and that is at 7:00 in the morning when 
you are just coming into work. 
 
Several participants attributed the location of the CHC in a community with high 
overdose rates as a call-to-action for the health center. One physician noted: 
Most people who live in this community are affected by opioid addiction, 
whether it is themselves or someone they know…And I think that makes 
the providers, staff, and pharmacists more on board because we see this, 
and we know it’s a problem, and it needs to be addressed. And [overdose 
education and naloxone provision] is one thing we can do to try to help. 
 
Other participants spoke about the staggering opioid overdose data in their local city or 
town, and used this as a way of engaging their clinic colleagues in a response. One nurse 
practitioner charged with clinical outreach emphasized, “It's so prevalent in [name of 
city] and on the streets. From what we've seen in our program, I think trying to just drill 
that into the health center and say this is what’s happening outside our doors.” In 
addition, participants spoke about the personal toll of the opioid crisis on CHC staff:  
It's affected everyone in our clinic— all the providers and staff 
members and many of the, not only the doctors and nurses, but 
many of the front desk staff and medical assistants are from the 
town, and it’s affected their family members… [and] patient’s 
children or grandkids. 
 
 This articulated tension for change seemed to be the impetus for all of the CHCs 
to stock naloxone in clinic emergency carts and to train clinic staff— from the front desk 
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staff to the CHC leadership— on how to respond if an overdose occurred in the clinic. 
This often served as a first step in the CHCs recognizing that they needed to respond 
more broadly to the reality of the opioid crisis in their community.  
Readiness for Implementation 
 As illustrated in Figure 7, the study sites were at varying stages of implementation 
with regard to certain OENA activities. At the start of this study, the presence of these 
activities was thought to signal a CHC’s commitment to implement OENA activities. For 
example, all of the CHCs reported distributing patient education material about overdose 
and naloxone. Seven of the eight sites distribute education materials to clinic staff, hold 
regular discussions with clinic staff, and stock naloxone in the affiliated clinic pharmacy. 
Six of the CHCs have conducted staff training and established a partnership with the 
pharmacy. Five have established a clinic policy or protocol and track and monitor data on 
naloxone prescribing, dispensing, or distribution. Half of the CHCs record information 
about a patient’s receipt of naloxone in the EMR. 
These indicators, along with others identified during the course of the qualitative 
data collection, served as visible, concrete indicators of a CHCs decision to implement 
OENA activities. It is important to note that these indicators emerged from a review of 
eight CHC models. Not all of these activities were in place at each CHC, nor are they all 
necessary in order to begin OENA implementation.  
  Some of these activities were necessary initial steps, such as figuring out how 
patients would get naloxone. For example, if a CHC chose to use its affiliated pharmacy 
for naloxone access, the clinic would need to create a standing order or establish an 
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agreement with the pharmacy, and easy electronic prescribing would need to be set up to 
support prescriber implementation. Other activities, such as creation of a policy or 
protocol, were not required for implementation to begin, but their later development 
improves service quality and bolstered implementation rates.  
Leadership Engagement 
 Communication by the CHC’s leadership about the need to address the 
opioid crisis was reported to be vital in initiating and sustaining OENA 
implementation, including leadership at the senior administrative, medical, and 
pharmacy levels. One physician at a CHC that has been implementing OENA activities 
for several years stated: 
I think the key is having leadership being involved and taking their role very 
seriously. Our medical leadership took this on. We didn’t have a choice; it was 
the way to do it. We weren't seeing the overdoses when we first got this data. We 
got this going and then you start seeing it, and no one is questioning the value of 
it anymore…..The one thing I would say to other CHCs is you have to get your 
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medical leadership to take this on and take it seriously and then the rest of the 
staff follow. 
 
Though not engaged at the implementation level, CHC leadership played an important 
role in the initial program implementation activities, including the development of the 
standing order, naloxone stocking, and later, the approval of CHC-wide policies. 
Furthermore, they helped keep overdose prevention as a priority by raising the topic 
during management meetings.  
Available Resources  
 Resources include physical space, staff training, and staff time. All of the 
individuals who conducted overdose education with patients participated in training. As 
can be seen in Table 33, the majority of the study participants received OEND training, 
with most of them receiving it at the CHC. This was often a part of the health center 
training when naloxone was added to the emergency kits, but also may have been 
delivered by the in-house OEND pilot grants or an external expert.
294
 Other participants 
were trained at a community-based organization or through an online webinar.  
Table 33. Study Participant Receipt of OEND Training 
 Number 
(Percentage) 
Receipt of OEND training (N=29) 
Yes 
 
22 (76) 
Location of OEND training (N=22)* 
Current workplace (CHC) 
Community-based organization 
Previous employer 
Online webinar 
Other (e.g., DPH and community college) 
 
17 (77) 
  4 (18) 
2 (9) 
  3 (14) 
2 (9) 
                        *Multiple responses allowed. 
 For clinic staff training sessions, educational materials were often provided, 
including the Massachusetts DPH Naloxone Pamphlet, PowerPoint slides, and a CHC 
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naloxone distribution policy. One program manager talked about her CHC’s staff training 
activities: 
We have done in-services with groups at a few of the OBOT programs. We 
do it with the clients of the OBOT programs, and the nurses will sit in on it 
which is almost like an entire training on it. We've done that with the 
pharmacy staff especially at the beginning phases of when they were 
implementing pharmacy access. We did a lot of in-services with them to 
help them be comfortable if they were going to be explaining how to use 
Narcan to others. 
 
 Frequent, ongoing training sessions were reported to be beneficial, not only 
for the new staff, but to keep the issue salient and increase the comfort level of existing 
staff, particularly those who may have only attended one brief training when naloxone 
was added to the emergency kits. One pharmacist noted that the trainings do not need to 
be time intensive or burdensome, “I think especially with turn-over. For a pharmacy 
where we have new pharmacists coming in at a healthy rate, having more trainings for 
them— it is such an easy and fast training. It can be done super easily.”  
 Lack of dedicated, private space for patient education in the pharmacy was 
noted as a barrier by several of the participants with a pharmacy model. As noted 
earlier, most prescribers reported that not having time to provide overdose 
education was a barrier. For some nurse and case management staff, providing 
overdose education was often integrated into regular patient visits. Likewise, pharmacists 
conducting the education component did so as part of their patient education activities. 
Implementation Strategies by Inner Setting Domain 
 Regarding the Inner Setting (Table 34), recognizing that OENA requires a team 
approach supported implementation, as did including a pharmacy as part of the response 
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team. Ongoing articulation of overdose prevention as a priority by CHC and pharmacy 
leadership contributed to a facilitating implementation climate, and tangible, visible 
activities across the CHC demonstrated leadership’s commitment to respond. Ongoing 
training on how to conduct overdose education and provide naloxone to patients, plus the 
role that naloxone plays in the treatment process provided clinic staff with the knowledge 
and skills they needed to discuss naloxone with patients effectively. Identification of staff 
with available time and space to conduct education activities was also essential to 
successful implementation.  
Table 34. Summary of Strategies Related to CFIR Constructs from Inner Setting Domain 
Construct Implementation Strategies 
Networks and 
Communications 
 
 Set up weekly and monthly interdisciplinary team meetings where 
overdose risk is discussed 
 Establish clinic and pharmacist partnership with defined roles and 
responsibilities 
 Integrate program activities into the buprenorphine treatment program 
 Engage behavioral health team in overdose OENA activities 
Culture  Connect mission-driven focus of CHC with the CHC’s overdose 
prevention response 
Implementation 
Climate 
 
 Find opportunities for implementing teams to share their experiences 
with other clinic staff 
Tension for 
Change 
 
 Discuss the impact of overdose in the community with CHC staff 
 Train clinic staff on naloxone use and stock naloxone in clinic 
emergency kit 
Readiness for 
Implementation 
 Identify clinic team implementation roles 
 Set up a pharmacy standing order 
 Train staff and providers 
 Write overdose education and naloxone policy 
Leadership 
Engagement 
 Articulate leadership support and expectations in regard to naloxone 
access 
Available 
Resources 
 Create staff training plan, including provision of patient education 
materials and refresher training 
 Identify staff who can be available to provide real-time overdose 
education, including nurses, behavioral health providers, and other 
staff who can include this function in their sessions with patients 
 Determine what private space(s) will be used for education 
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Domain 4: Characteristics of Individuals 
The following individual-level constructs were found to influence OENA 
implementation: knowledge and beliefs about the intervention and the individual’s stage 
of change.  
Knowledge and Beliefs about Intervention 
 Study participants were knowledgeable and believed naloxone would be a 
beneficial intervention for patients at risk of overdose. One participant summarized this 
in the following way:  
As far as the pain management and drug use is concerned, I think most of 
the providers are aware of opioid addiction and long-term narcotic use, 
and the benefits of using Narcan, because of the patients we see on a daily 
basis— we have so many patients on narcotics, we have a Suboxone 
program here. People are well aware. 
 
Not every study participant agreed. Two prescribers questioned the utility of 
providing naloxone to patients at risk of an overdose since they cannot administer 
naloxone to themselves. Another clinic manager explained his clinic’s 
prescribers’ reaction to co-prescribing naloxone with chronic opioid therapy:  
…they thought it was interesting, then saying, “But if you overdose on 
something I prescribe you, here is something that might help.” They were 
struggling with that concept. But I like it as a harm reduction public 
health concept. But we don't do that here. 
 
Other CHC leaders were able to engage prescribers in reaching patients on chronic opioid 
therapy, as they were persuasive in stating that these patients could benefit from having a 
naloxone rescue kit.  
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 Clinic staff knowledge and believing in a harm reduction approach facilitated 
OENA activities. Participants across the clinics talked about the transformation in 
knowledge and beliefs that several staff had to go through as they changed their thinking 
about the role of naloxone for people in treatment. A program manager at another CHC 
commented on the change his program had gone through: 
Our program has really evolved from an abstinence model to more of a 
harm reduction model. We are not doing a lot of kicking people out for 
using. That will put them at a higher risk of overdose. You are still in our 
narcotics program; if you are using, you should have Narcan. And we 
refer them to other levels of care to help get them to recovery, but not 
everyone is going to get there immediately. 
 
Several participants talked about the need for staff training on this new treatment 
paradigm: 
It’s really about educating staff— some people may be set in their ways 
about the old models of behavioral health and substance use treatment 
care, but those are going away. I have seen the change in our behavioral 
health [group] in the past nearly 18 years, seeing the changes in people's 
attitudes. People had to change to a more harm reduction approach. 
People are accepting [this] as the right way to do it. 
 
Individual Stage of Readiness for Change 
 Study participants spanned the continuum of stages of readiness for change in 
regards to OENA activities. The participant survey asked study participants to self-
assess their stage of readiness for providing overdose education to participants, and if a 
prescriber, their stage of readiness for prescribing naloxone to patients. The findings are 
presented in Figures 8 and 9 below.  
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Given that anyone trained could provide overdose education, 26 of the 29 participants 
who had patient contact as part of their role answered this question. More than half of the 
participants reported that they conduct overdose education regularly, with about one-third 
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indicating that they have fully integrated overdose education into their practice. Less than 
a tenth of the participants reported having tried overdose education. One-third of 
participants had not conducted overdose education activities. An alternate view of this 
data can be seen in Figure 10 which categorizes participant responses to provision of 
overdose education into the Stages of Change Model’s readiness categories. 
 Similar to the survey findings, participants reported a range of comfort levels with 
OENA activities. Participants who regularly see patients with an opioid use disorder were 
reported to conduct overdose education more frequently and with greater comfort 
compared to those who rarely care for such patients. One participant explained: 
We have a lot of providers who are super-comfortable doing this, 
especially our Suboxone providers who are also primary care providers 
here. They are really great doing all of that and comfortable with the kits, 
they all carry kits. We have a bunch of providers here that are provider 
champions around things like this and are really comfortable talking with 
patients. And there are providers who maybe don't have a lot of 
experience doing it and maybe have to learn it on an annual basis. So not 
everybody is in that place; everybody is in a different place. 
 
Another CHC program manager talked about how some nurses in the buprenorphine 
clinic were uncomfortable in the beginning, “And there was discomfort [among the 
nurses] with doing the education at the beginning, and I think that is still the case for 
some providers.”  This same relationship between experience and increased confidence 
was heard during interviews with the pharmacists, as one explained:  
It varies. Some people are not as comfortable as others, especially those 
who are newer. The pharmacists who focus on clinical services are used 
to seeing patients and are offering education. So a lot of this is done by 
our clinical pharmacy team. 
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 The participant survey also asked prescribers to rate their stage of readiness for 
naloxone prescribing. This question did not take into consideration the fact that many of 
the CHCs had standing orders in place, thus limiting the necessity for a prescription. That 
being the case, four of the nine prescribers interviewed reported prescribing naloxone 
“regularly,” two have “tried it, but don’t do it regularly,” and two “plan to try it in the 
next three months.” Only one prescriber reported not having “thought much about it.” As 
described earlier, prescribers perceived this intervention to be complex due to a variety of 
barriers (i.e., limited time, competing priorities) so this range of stages is not unexpected.  
Implementation Strategies by Characteristics of Individuals Domain 
 With the Characteristics of Individuals domain (Table 35), it was clear that 
participants were aware of the benefits of naloxone, though some thought about overdose 
  
148 
risk differently for people receiving treatment for opioid use disorder compared with 
those on chronic opioid therapy. It is important to recognize that clinic staff are likely to 
be at different stages of readiness in implementing overdose education and naloxone 
prescribing or dispensing. Different strategies are needed to reach CHC based on the 
staff’s stage of readiness and on the role they play when the program is implemented.  
Table 35. Summary of Strategies Related to CFIR Constructs from Characteristics of 
Individuals Domain 
Construct Implementation Strategies 
Characteristics of Individuals 
Knowledge and Beliefs 
about Intervention 
 
 Integrate harm reduction principles into the CHC’s approach 
 Increase provider and staff perceptions of overdose risk for 
persons on chronic opioid therapy 
 Discuss risk of overdose among patients on chronic opioid 
therapy, particularly in the context of new guidelines issued by 
CDC 
Individual Stage of 
Readiness for Change 
 Find opportunities for implementers to regularly practice 
overdose education discussions with patients 
 Utilize in-house peer support 
 Conduct booster training sessions 
 Keep OENA activities on the agenda for team meetings 
 Build in a mechanism to give providers data reports on 
naloxone ordering/prescribing 
 
Domain 5: Process 
The following CFIR constructs were found to influence the implementation 
process domain: engaging, champions, external change agents, and reflecting and 
evaluating.  
Engaging  
 Different strategies were used across the study sites to engage clinic staff and 
patients in OEANA activities, depending on the program’s implementation stage. 
Strategies for reaching both of these groups are described below.  
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 Engaging clinic staff. Community overdose statistics were used as a call to 
action by some of the health centers. One CHC primary care clinic posted statistics on the 
number of overdoses in the city and the number of naloxone rescue kits provided to 
patients that week. A staff member reported “sending emails and reminding people how 
many overdoses we had in the city, how many deaths— these are our patients.” CHCs 
also found ways to begin implementation that resonated with clinic staff. For example, a 
nurse practitioner explained why they started with patients on chronic opioid therapy:   
 …a way to really get into the docs who aren't into this and aren't aware 
of it is to start with the pain management because everyone is embracing 
that. Say, “Okay, well someone is on chronic pain pills, let's make sure 
they have a Narcan kit.” Kind of introducing it that way. 
 
Integrating OENA activities into buprenorphine programs seemed to help engage nurses 
given the obvious connection between opioid use disorder and the potential for relapse 
and overdose.  
 Modeling how to use naloxone was reported to be an important component in 
helping nurses to feel comfortable. A pharmacist also used this technique to train her 
pharmacy staff: “As part of our trainings, we always do demos…Having the practical, 
hands-on [experience] and you trying it also helps you be able to train others. So this is 
what it’s going to feel like.”  Peer support was also noted as an important component to 
engaging clinic staff. One nurse practitioner champion at another CHC planned to have 
the nurses in her clinic who had successfully adopted OENA share their experiences with 
others who were less engaged. 
 In addition to basic overdose education and naloxone use training, two 
participants talked about the importance of conducting training on substance use 
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disorder, addiction, and the treatment process as a way to increase their comfort with 
participating in OENA activities. One participant explained her clinic’s process: 
We had to do a lot of education around feeling comfortable talking about 
abuse. I think it is a very uncomfortable topic to broach. I think given my 
background and the patient population I work with it is pretty normalized 
in a way, the discussion and talking and asking those questions. I think 
that has been challenging for some staff. So we did a lot of education 
around that. 
  
 Identifying strategies to support individuals along the continuum of 
readiness to change was found to be important. In particular, maintenance of OENA 
activities was reported to be a challenge for staff that had been doing it regularly, but not 
consistently. At one CHC, where the expectation is to provide naloxone to everyone over 
18 years of age, one physician acknowledged the following: 
Even though we have the leadership behind us, there are policies in place, 
there are helpful tools in the medical record, we are following this in 
terms of quality, I think I had the highest score for prescriptions and I am 
only at 53%. Even though I feel like I'm doing it for everybody, I'm only 
doing it for about half my patients. So it is taking a while to roll out.”  
 
Clinic staff engagement was not seen as a one-shot activity, but as an ongoing process. 
The physician continued to talk about the challenge of maintaining a sustained effort: 
Keeping the fire underneath it. There is often alert fatigue and we are onto 
the next big initiative. Just continuing to keep it a priority. Continuing to 
remind people it is our goal to have everyone have a naloxone 
prescription. We probably do need to put an emphasis on getting 
prescribing percentages higher. 
 
 Participants also spoke about the challenge of keeping opioid overdose a priority 
when there are so many competing priorities. One nurse manager commented, “That is 
one thing that I am contending with, getting our message out when there are a lot of 
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other different messages that everybody else wants to get out as well.”  Building 
discussions into team meetings and data sharing helped keep clinic staff engaged over 
time.  
 
 Engaging patients. Strategies to engage patients facilitated implementation 
success. Visual cues in the clinic or pharmacy in the form of posters and signage seemed 
to be effective strategies for engaging patients who might be at risk of overdose or who 
may be friends or family members of persons at risk. In several CHCs, posters about 
overdose and naloxone could be seen in the waiting room, exam rooms, clinic walls, and 
pharmacy walls, such as the ones depicted in Images 6 , 7, and 8. 
 A physician shared a recent experience with naloxone signs in the main area of 
the primary care clinic: “We had another patient who saw the sign out here by the desk. 
And it was the first time he informed his primary care provider that he was struggling 
with opioid dependence.” One pharmacist noted how the presence of signs in her 
Image 6. Sign on Exam Room 
Cabinet 
 
Source: Author, 2016.  
 
Image 7. Sign in Waiting Room 
 
Source: Author, 2016. 
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pharmacy heightened patient awareness about naloxone access via a standing order. 
These posters and signs let patients know that the CHC or pharmacy is a safe place to 
seek overdose prevention services.  
 
 In recognition of the challenge of requesting naloxone at the pharmacies, two of 
the CHCs had also discussed ideas for how to increase naloxone access for patients. One 
pharmacist explained what her CHC is considering:  
Sometimes the patients who come to the pharmacy, just telling someone 
they want Narcan can be difficult. So we are trying to come up with a 
voucher that just says, “Hand this to the pharmacist,” and it says, “Please 
give me Narcan per the standing order,” or something like that. They 
don't even need to discuss what they want, they can just hand it to 
someone which would be much more comfortable. We would put a stack of 
those vouchers in the clinic. Also sometimes people don't remember the 
name of it, so to describe it becomes more uncomfortable. 
 
A few of the health centers spoke about community outreach activities, such as health 
Image 8. Sign on Exam Room 
Bulletin Board 
 
Source: Author, 2016.  
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fairs, that clinic and pharmacy staff participated in. One CHC utilized a local cable 
network station to market the availability of naloxone at the CHC-affiliated pharmacy 
after a spike in opioid overdose deaths in the city: 
We recently had a rash of overdoses. We had eight deaths in [name of 
city]. Our pharmacy is really awesome. We have really great people 
dedicated to our patients and community. They called the local news and 
asked them to get the word out that people can get Narcan at the 
pharmacy [through a standing order]. They did a couple of news stories. 
There was a short uptake and then it leveled out again. 
 
Another CHC brought up the role of a health center consumer board as a key element in 
both engaging the patient population and informing OENA activities. A physician 
explained:  
The other important piece of this is the consumers. We have a Consumer 
Advisory Board (CAB). Both at the program level and an HIV CAB that is 
a sub-committee. They have been interested in [OENA]. They did a big 
event last summer for International Overdose Awareness Day. They had 
tables and were doing naloxone education, showed people how to put the 
kits together. 
 
Champion 
 As referenced throughout this chapter, the presence and ongoing, active 
involvement of a champion inside the CHC was instrumental to implementation 
success. These champions included nurse practitioners, nurses, program managers, and 
physicians. They were not formally appointed OENA champions, but assumed this role 
out of a desire to change the situation, and started with their own patients and then their 
own clinic teams. They were clearly recognized as a champion by others, and served as a 
resource for CHC staff that were at different levels of comfort with the intervention. 
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Given the multitude of clinical and public health priorities that CHC primary care 
settings face, and the need to assess clinical practice on a continuing basis, having a 
champion dedicated to overdose prevention activities was a major factor in clinics 
adopting and implementing OENA activities long-term. Having such a person in place 
was particularly beneficial during the early stages of adoption when the champion served 
as a point-of-contact for OENA activities. In this role, the champion facilitated training, 
internal and external partnerships, and data sharing. In addition, the champion helped 
overcome identified barriers, such as procuring naloxone rescue kits or suggesting that an 
experienced nurse help a more novice implementer. In many cases, the champion 
connected the CHC to external change agents, such as innovators in the field, and made 
staff aware of promising practices from other settings. Finally, the champion helped 
sustain activities by continuing to model sound OENA practice and advocating for the 
program to be an ongoing priority at the administrative and management levels of the 
CHC. 
External Change Agents 
 Participants spoke about the influence of external change agents in paving the 
way for their clinic’s OENA activities. These individuals were often leaders in the harm 
reduction response, such as a street outreach advocate or a physician overseeing the 
state’s OEND program. The external change agents were most instrumental during 
the early stages of OENA activities by increasing CHC clinic staff awareness of the 
needs of persons with substance use disorder, connecting CHC patients with harm 
reduction services, and explaining how a clinic-based OENA program might work. One 
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participant championing activities in her CHC explained, “That's how I kicked this all off. 
I had [name of a physician OEND leader] come out and give a talk….that was the kick-
off.”  
 As discussed previously, the presence and growth of buprenorphine programs was 
seen as contributing to the need for and expansion of OENA activities. The leader of the 
state’s nurse-led OBOT response was mentioned by a few of the clinics as an important 
influence.  
Reflecting and Evaluating  
 Quantitative and qualitative data documenting OENA activities varied across the 
CHCs. Four of the CHCs reported having an EMR field that collected data on overdose 
education and naloxone provision. At most CHCs, a referral for naloxone was 
documented in an open text field in the EMR. One CHC developed a comprehensive 
EMR system that systematically prompted and allowed for prescriber documentation 
regarding receipt of overdose education and a naloxone prescription (see Images 9 and 
10).  
 Naloxone prescribing was then included as a services quality measure. As one 
physician at the CHC stated, “Another big programmatic piece is actually making 
Narcan prescribing a quality measure, developing quality measures around substance 
use disorder— so, screening, treatment, and provision of naloxone.”  
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Image 9. EMR Template Prompt for Overdose Prevention Counseling 
 
Source: Boston Healthcare for the Homeless, 2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image 10. EMR Template for Naloxone Prescribing 
 
Source: Boston Healthcare for the Homeless, 2016. 
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 The other four CHCs indicated they had “no plans” to add such a field to the 
health center’s EMR in the next six months due to logistical constraints on modifying the 
EMR. Several CHC participants talked about the gaps in documenting OENA-related 
data. One participant described his CHC’s documentation needs as follows:  
There is not currently an overdose and naloxone field in the EMR. I'm not 
sure of the feasibility of getting a general primary care provider to have it 
too high on their radar. What I do think is any nurse, case manager, and 
behavioral health clinician within the medication-assisted treatment 
program certainly could, on their template, have a field, like we have a 
nursing Suboxone template. I honestly don't know if naloxone is on there, 
but it should be, at least to document that we discussed and offered a 
referral. 
 
 
 
 
 
 
 
 
 
 
 One of the challenges with relying on a pharmacy standing order or referral 
method was not knowing if the patient actually obtained naloxone. The pharmacy 
directors played an important role in sharing aggregate naloxone dispensing data, though 
Image 11. Primary Care Clinic Whiteboard Tallying Overdose 
Deaths in City and Naloxone Kits Distributed 
 
Source: Author, 2016.  
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there did not seem to be any relationship between this data and actual prescriptions or 
referrals from the CHC.  
Weekly and/or monthly HIV and Suboxone team meetings offered the 
opportunity for clinic teams to share updates and experiences related to OENA. One CHC 
pilot project had an interesting approach where a whiteboard in the primary care clinic 
kept track overdose deaths in the city (Image 11), the date of the last overdose, and the 
number of naloxone reversals, SBIRT “warm hand-offs” to nurses, and naloxone kits 
provided. This board was continually seen by all staff who worked in the clinic. 
 Stories from patients about how they used naloxone had a powerful effect on 
the participants. One physician explained how patients share their experience with 
naloxone: “We aren't doing any formal tracking now. We certainly have patients who 
share that they reversed overdoses, but I don't have a number.” A nurse added, “A lot of 
patients give feedback. They say they had to use it, ask for another one.” A nurse at 
another CHC shared a story based on feedback she received from a patient who had 
administered naloxone: 
A couple of times, we have had people come back and report the use of 
Narcan. And that is powerful. I had this one particular patient who…lives 
in a rooming house, and he had Narcan and used it on someone who 
overdosed in his apartment building. And he reversed the overdose. The 
man told me this story with tears in his eyes. And I was like, I have to hug 
you. Do you know what you did? You saved this person's life. That 
moment was so profound. I think for him, and for me— like, oh good, this 
really does work. We know the drugs work, and that people are actually 
using it. 
 
A nurse practitioner from another CHC talked about the role of patient feedback in 
helping sustain OENA activities among the primary care clinic team nurses:  
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They [the nurses] come to us, a patient is worried, “I don't know what to 
do for her, she is using, should we offer it to her?” That is how it was in 
the beginning….and the feedback that came back—“I helped her, I gave 
her something concrete that she could do. That is so powerful and life-
changing….I'm going to do this again.” 
 
Implementation Strategies by Process Domain 
 For the process domain (Table 36), strategies included engaging staff through 
ongoing training, technical assistance, providing job aides, and sharing data. A champion 
was important for organizing implementation activities, coaching staff, and overcoming 
hurdles. While tracking and monitoring of overdose education and naloxone provision 
was sporadic across the sites, building data updates from the EMR or pharmacy records 
into team meetings helped demonstrate the degree of OENA uptake across providers and 
patients. Alongside this, sharing of clinic staff experiences with OENA helped reinforce 
the impact of the intervention.   
Table 36. Summary of Strategies Related to CFIR Constructs with Process Domain 
Construct Implementation Strategies 
Engaging Engaging Clinic Staff 
 Increase awareness of providers and staff in the early stages 
 Build in ongoing supports for providers and staff, including an agenda 
item in regular meetings 
 Provide job aides for clinic staff including EMR templates, patient 
education materials, and a written policy 
 Have peers share their experiences with other clinic staff and model 
education sessions 
 Share data on naloxone access with clinic staff 
Engaging Patients 
 Conduct outreach events 
 Partner with community-based organizations 
 Utilize signage in the CHC and the affiliated pharmacy 
 Identify barriers and implement strategies to address patient-level 
barriers 
Champions  Draw on the passion of a provider or staff team member who is on the 
ground implementing and has emerged as a champion 
External Change 
Agents 
 Utilize the expertise, reputation, and influence of external change 
agents to bring senior leadership, providers, and staff on board or to 
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model program delivery policies and protocols 
Reflecting and 
Evaluating 
 Build in basic data collection systems and monthly reporting and data 
sharing  
 Offer the opportunity for implementing staff to share personal stories 
related to OENA implementation 
 Share success stories in meetings as a way to reinforce the benefits of 
OENA activities 
 
Chapter Summary 
Table 37 lists questions that CHCs can consider when planning or altering an OENA 
program, which are based on the CFIR’s implementation science constructs. Deliberation 
on these questions may help expedite the clinic’s implementation efforts. 
Table 37. Questions to Consider by CFIR Domain When Implementing CHC Primary 
Care OENA Activities 
CFIR Domain Questions to Consider 
Intervention 
Characteristics 
• What aspects of the different models resonate with our setting? 
• Where might we begin an initiative in the clinic?  
• How can activities be integrated into the existing workflow, thus 
minimizing implementation barriers?  
• What are the costs to the program, especially for naloxone?  
Outer Setting • What are the needs of our patients when it comes to opioid overdose?  
• What are the mechanisms in place for obtaining feedback from patients on 
the implementation strategy? 
• Whom should we partner with to initiate or expand our activities?  
• What pharmacy(ies) should we establish partnership(s) with in order to 
best support the needs of our patients?  
• How can we become engaged in community-wide overdose response 
activities?  
• What outreach opportunities are there for reaching patients in the 
community and giving the clinic and pharmacy staff an opportunity to see 
the patients’ needs first-hand? 
• What policies and guidelines exist— at a state or national level— that can 
support our efforts?  
Inner Setting • What is the sense of urgency around this issue for CHC providers and 
staff?  
• How can leadership get involved in communicating overdose as a priority 
issue?  
• What steps can we take as a clinic to demonstrate we are ready to begin 
activities?  
• What communication systems are in place to discuss activities on a regular 
basis? 
• What communication systems need to be established, particularly between 
the clinic and pharmacy? 
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• What resources do we need to have in place to begin the program, in terms 
of staffing, time, training, and space? 
Characteristics 
of Individuals 
• What are the training needs of providers and staff, both initially and over 
the first year of implementation, to support practice change?  
Process • Who will be the champion of these activities, leading implementation on 
the ground and resolving any staff resistance?  
• What can we do to engage patients in this process?  
• How can we continue to engage providers and staff long-term?  
• What external change agents can we involve to support provider and staff 
participation?  
• How can we continually use qualitative and quantitative data to reflect on 
our process? What program changes could be made as a result of our 
experiences?  
 
An understanding of the constructs and strategies found to support OENA 
implementation can be used to accelerate implementation in other settings. These 
constructs could be considered one by one, but it is the interplay of these factors that 
ultimately determines the implementation experience. For this reason, the next chapter 
provides an integrated presentation of the study’s conclusions and recommendations 
regarding the uptake and maintenance of OENA efforts.  
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CHAPTER 5: DISCUSSION 
The purpose of this study was to explore the overdose education and naloxone 
access (OENA) implementation experiences of CHCs in Massachusetts. This chapter 
discusses the major findings and conclusions drawn from this research. The degree to 
which the findings corroborate, differ from, or enhance relevant literature is also 
explained. This is followed by recommendations for practice and future research, and 
then a concluding section on the study’s limitations. 
This study is the first qualitative examination of OENA implementation in 
primary care settings that used an implementation science framework focused on multiple 
systems-level factors. In contrast, most past studies have focused on provider-level 
barriers and facilitators to naloxone prescribing.
51,39,40,55,53,54
 More recently, Drainoni et 
al. examined implementation barriers and facilitators in an ED setting
209
 and Coffin et al. 
assessed the feasibility of a standardized naloxone co-prescribing intervention for patients 
receiving chronic opioid therapy at primary care safety net clinics.
224
 The present 
investigation supplements this nascent literature by going beyond an analysis of 
individual-level factors to highlight system-level factors that support or hinder OENA 
implementation.   
This section brings together the significant findings across the five domains and 
20 constructs from the Consolidated Framework for Implementation Research (CFIR) 
that were found to influence implementation. Ideally, the study’s “take-away lessons” 
will guide other primary care settings as they grapple with how best to ensure naloxone 
access for their patients.  
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Conclusions 
 Table 38 provides a summary of the study’s eleven major conclusions, which are 
discussed in more detail below. 
Table 38. Summary of Study Conclusions   
1. A variety of OENA approaches are feasible in CHC primary care settings, with different 
approaches available to fit each clinic’s particular context.  
2. Effective OENA implementation requires a systems-level response that goes beyond 
addressing individual-level factors that inhibit adoption.  
3. Successful implementation relies on a team-based care model, with nursing playing a 
major role in OENA implementation. 
4. Pharmacy teams are vital partners for broadening and sustaining OENA activities. 
5. Determining the best means of providing naloxone to patients should center on a 
workable reimbursement mechanism to minimize cost barriers and ensure sustainability. 
6. A clinic culture that supports harm reduction approaches greatly facilitates 
implementation. 
7. Stigma needs to be acknowledged as a barrier to naloxone access and proactively 
addressed by both CHCs and pharmacies.  
8. CHCs play an important partnership role in the community’s response to a local opioid 
crisis. 
9. Integrating OENA activities into buprenorphine treatment and chronic opioid 
prescribing greatly expands the scope of OENA implementation.  
10. Differing clinic staff’s perceptions of patients’ overdose risk differed for patients with 
opioid use disorder and those being prescribed chronic opioids need to be considered in 
training and technical assistance response.  
11. Clinic training and technical assistance plans should be customized according to the 
staff members’ potential OENA roles and their stage of readiness. An OENA champion 
on-site who coaches and supports members can motivate staff to implement the 
intervention and address barriers.  
 
Conclusion 1: A variety of OENA approaches are feasible in CHC primary care 
settings, with different approaches available to fit each clinic’s particular context.  
Despite the many barriers to naloxone access in clinical settings that have been 
identified in the literature,
39,40,53–55,266
 this study demonstrated that a range of CHCs were 
in fact able to integrate OENA into primary care service delivery. In doing so, CHCs 
utilized different strategies based on patient needs, the CHC context, available resources, 
staffing, and overall readiness to adopt this innovation.  
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The adaptable nature of the OENA activities meant that CHCs could implement 
an approach that worked best for their setting, and then change or add to it based on 
experience. Starting on a small scale to determine what worked best also supported 
adoption. Several of the CHCs with established OENA activities were able to adjust to 
intervention-related changes with relative ease, such as the new chronic opioid 
prescribing policies or the integration of naloxone prescribing into the clinic’s EMR. 
Conclusion 2: Effective implementation requires a systems-level response that goes 
beyond addressing individual-level factors that inhibit adoption.  
 Studies have shown that greater knowledge, positive attitudes, and self-efficacy 
among physicians and residents regarding OENA correlate with a greater willingness to 
prescribe naloxone and conduct overdose education.
51,53–55
 In contrast to other studies, 
participants in the present study did not express concern about naloxone being a “safety 
net” drug or leading to high-risk substance use behavior.39,40,54,251 Rather, participants 
across nearly all of the study sites were well aware of naloxone’s benefits.  
 Nevertheless, a 2016 study of barriers to naloxone prescribing among internal 
medicine residents found that despite high awareness of naloxone, a willingness to 
prescribe, and a large number of patients at risk of overdose, only a small percentage of 
residents actually prescribed naloxone.
53
 Another 2016 study among ED physicians 
found a similar gulf between “willingness” and “action.”55 Clearly, system-level supports 
need to be in place to bring about change, including leadership engagement, an enabling 
implementation climate, partnerships, ongoing clinic-wide staff engagement, and staff 
education to reduce stigmatization of persons with opioid use disorder.  
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Conclusion 3: Successful implementation relies on a team-based care model, with 
nursing staff playing a major role in OENA implementation.  
The involvement of clinic staff in addition to the prescriber served to enhance 
OENA implementation. Physicians and other prescribers faced multiple challenges 
providing OENA to patients on their own, including limited time, competing clinical 
priorities, and the need to address patients’ additional clinical needs. Of course, 
physicians and other prescribers do play an important role: they identify patients in need 
and can begin a discussion about naloxone, after which they can conduct a “warm hand-
off” to other staff who have more time for patient education. A 2016 study of naloxone 
co-prescribing for patients on chronic opioid therapy also reported that intervention 
activities were shared across multiple healthcare team members, including the physician, 
pharmacist, nurse, and health educator.
225
 
The present study also identified the importance of creating a positive 
implementation climate with shared goals and expectations among team members. 
Equally important was the identification of specific roles and responsibilities for different 
team members. Related to this, a 2016 study found that in an ED setting, making 
naloxone distribution every team member’s responsibility resulted in confusion about 
who was actually accountable for making sure the protocol was implemented.
209
 Team-
based care is common practice within most CHC primary care settings.
295
 Employing this 
approach for naloxone access is a natural fit. 
In the context of a team-based care model, nurses emerged as vital OENA 
implementers. The expanded nursing role in opioid-related care is not new. Since 2007, 
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for example, the Massachusetts Office-based Opioid Treatment (OBOT) model 
successfully utilized nurses to assess and monitor patients receiving buprenorphine 
treatment in select CHCs.
64
 Building on this program’s success, a study is currently 
assessing the efficacy of having a nurse care manager in place to support CHC-based 
primary care prescribers in managing patients who are prescribed chronic opioid 
therapy.
296
 Likewise, the present study demonstrated that nurse involvement facilitated 
implementation, particularly when OENA activities were made part of their official 
duties during HIV case management visits or when working with patients being 
prescribed buprenorphine treatment or opioids for chronic pain management. 
Conclusion 4: Pharmacy teams are vital partners for broadening and sustaining 
OENA activities.  
This study found that pharmacists at the CHC-affiliated pharmacy also played a 
key role in supporting expanded naloxone access for CHC patients. At a national level, 
there was a 1,170% increase in naloxone dispensing from retail pharmacies over a 21-
month period of time between 2013 and 2015, with 35% of the prescriptions coming 
from primary care physicians.
223
 Further expansion is possible, as a review of 
international studies assessing pharmacists’ attitudes about participating in harm 
reduction interventions have generally found them to be supportive.
297
  
The study also identified additional types of working partnerships between the 
CHC clinical teams and pharmacy teams to support OENA implementation. Forming 
these partnerships allowed the CHC and pharmacy staff to collaborate in new ways to 
determine the most appropriate methods for reaching patients and addressing access 
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barriers. Examples include creating a standing order with the pharmacy and having the 
pharmacist offer naloxone to patients prescribed buprenorphine treatment.  
For CHCs without pharmacies, establishing a partnership with a commercial 
pharmacy would be an important step to expand naloxone access. Given the doubts 
expressed by the study participants regarding the ability of commercial pharmacies with 
standing orders to respond positively to patients requesting naloxone, innovative 
approaches for engaging patients in these settings are needed to enhance the viability of 
this naloxone access point. 
Conclusion 5: Determining the best means of providing naloxone to patients should 
center on a workable reimbursement mechanism to minimize cost barriers and ensure 
sustainability. 
Ensuring the financial sustainability of OENA activities is an important 
consideration for determining how patients will get naloxone. Only one of the CHCs 
referred patients to an external agency funded by the Massachusetts DPH to provide 
OEND. Relying on external referrals to a state grant-funded program for naloxone access 
does not guarantee long-term access, nor does it support the integration of naloxone 
access activities into clinical practice.  
Even so, for CHCs that prescribe naloxone or have a standing order in place, a 
partnership with a community-based OEND program can contribute further to expanded 
naloxone access for the clinic’s patients. This was demonstrated by one of the CHCs that 
partnered with a local OEND program to conduct naloxone distribution events both at the 
CHC and in the community. 
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Two of the CHCs in this study distributed naloxone rescue kits at the CHC in 
order to minimize patient access barriers. Finding funds to cover the cost of the kits is a 
major consideration in both the short- and long-term. To facilitate access, some state 
health departments have allocated funds to support community-based naloxone 
distribution, including at some CHC sites. It is unlikely, however, that state-level 
policymakers will be able to justify funding naloxone rescue kits for patients in clinical 
settings when there is pharmacy access with insurance reimbursement. Direct clinic 
distribution, however, may be the most effective means of naloxone access for some 
patients, particularly those without easy pharmacy access, who may never go the 
pharmacy, or who do not have health insurance coverage for naloxone.  
Future innovations could explore additional ways for clinic’s to acquire naloxone, 
such as through “buy and bill” where a clinic would buy naloxone directly from the 
manufacturer, a designated pharmacy, or specialty distributor and stock it on the clinic 
floor. The clinic would then bill the patient’s insurance company for the cost of the 
naloxone. While this study did not identify any instances where this option had been 
implemented, precedent for this approach has been established through the provision of 
other pharmaceuticals in outpatient primary care settings.
298
 Examples include in-clinic 
provision of  IUDs to allow for same-day insertion
299
 and antibiotics for chlamydia to 
prevent treatment delay and a greater risk of long-term complications.
300
 Other potential 
strategies can also be explored with a pharmacy partner to enhance real-time naloxone 
access at the clinic.  
Finally, insurance-related barriers should be anticipated and worked out in 
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advance of implementation to prevent cost from being a barrier to patient access. The 
cost of naloxone, if insurance does not fully cover it, was cited as a potential patient 
barrier in both this study and a qualitative study with primary health care providers.
40
 In 
Massachusetts, the Medicaid payer fully covers the cost of a naloxone rescue kit, and the 
state worked with the commercial insurers to include the kit in their drug reimbursement 
list. For the patient, however, an insurance co-payment could be a deterrent. Unlike 340B 
pharmacies located in safety-net CHCs that support drug access,
301
 commercial 
pharmacies do not have the same flexibility to waive receipt of co-payment.  
It is important for CHCs and pharmacies to be aware of various insurance 
limitations that could pose a barrier to patients receiving naloxone from commercial 
pharmacies so they can inform patients and customers. In addition, pharmacists 
themselves may need education related to third-party dispensing laws and reimbursement 
policies. For instance, third-party billing is not allowed if a person wants to get naloxone 
for a friend or family member.
302
 This could result in a prohibitively high out-of-pocket 
cost (e.g., $100 for the new single-step
ii
 naloxone device).
303
 
Conclusion 6: A clinic culture that supports harm reduction approaches greatly 
facilitates implementation. 
This study found that a harm reduction treatment model rather than an abstinence-
                                                     
ii
 After this study was conducted, mucosal atomizer devices for the naloxone rescue kits were 
recalled, and the single-step intranasal device was the formulation of choice in pharmacies.
303
 
While more expensive, this new device is likely to save staff time at both CHCs and pharmacies 
as it does not require the ordering of the MAD, compilation of the naloxone rescue kits, and staff 
and patient training on how to assemble before administration. At the same time, it comes at a 
higher cost, borne by the consumer, health insurance company, or CHC depending on how the 
naloxone is purchased or reimbursed. Therefore, while this change may decrease the 
“complexity” of the intervention, which could facilitate adoption, it could also increase the 
“cost,” which may discourage uptake.  
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based treatment model facilitated the integration of overdose and naloxone education into 
both opioid treatment services and co-prescribing initiatives involving chronic opioid 
therapy. Supporting this integration, clinic-wide staff training on addiction theory and 
brain science, along with modification of treatment program protocols, led over time to a 
paradigm shift within the CHCs. 
A clinic culture that embraced a harm reduction philosophy and approach helped 
engage both clinic staff and patients through non-judgmental discussions about the reality 
and risk of relapse, compassionate exchanges about the importance of having naloxone, 
and the need for opioid safety precautions when prescription opioids are in the house. In a 
study of naloxone co-prescribing with chronic opioids, the authors also noted that they 
recommended a “patient-centered approach that is empowering and non-judgemental.”304 
Inclusion of language that clinic staff can use for framing naloxone discussions, 
reinforced through role-play exercises, can further support clinic staff and patient 
engagement in OENA discussions. 
Conclusion 7: Stigma needs to be acknowledged as a barrier to naloxone access and 
proactively addressed by both CHCs and pharmacies.  
 Acknowledgement and proactive response to the stigma experienced by persons 
with a substance use disorder, which in many cases has been perpetuated by the 
healthcare system itself,
248
 is paramount to successful OENA efforts. Stigma has been 
shown to increase psychological distress and to impede PWID from seeking care.
305
 
Several study participants in both this and another inveestigation
54
 expressed concern 
about stigma as a barrier to naloxone access.  
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 Finding ways for CHCs and pharmacies to address stigma proactively are 
essential for creating a partnership with patients in overdose prevention. Strategies that 
helped open the lines of communication about overdose included clinic and pharmacy 
signage about naloxone, patient education posters and other materials, and use of 
vouchers to facilitate pharmacy requests. Of course, clinic staff training should include a 
focus on how to show empathy and respect when working with patients. Along these 
lines, ASAM has called for changing the language used in clinical settings to discuss 
substance use disorder.
248
  
 There are different views about the effect of overdose education on provider-
patient communication. The present study and past investigations have documented 
providers’ fear of offending patients by bringing up the subject of overdose, especially 
those receiving chronic opioid therapy.
40,51,54
 There is preliminary evidence that properly 
framed overdose education and naloxone prescribing can reduce patients’ concerns 
regarding stigmatization and enhance the patient-provider connection.
221,250
 Discussions 
about overdose and naloxone can communicate the following: the patient’s safety is the 
clinic’s top priority; the possibility of overdose is a major concern; and the patient has a 
role in preventing an overdose-related death. Through this discussion, patients can see the 
provider’s concern, making them more receptive to what the provider needs to say and to 
using naloxone should they or someone in their social network have the need for it.
306
 
Conclusion 8: CHCs play an important partnership role in the community’s response 
to the local opioid crisis. 
CHCs have played a critical role in improving population health,
307
 and this study 
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further demonstrated their commitment to that mission in their responses to the local 
opioid crisis. In addition to reaching patients likely to experience or witness an opioid 
overdose, CHCs have helped expand OENA in their communities by working in 
partnership with other local agencies and through community coalitions.  
Studies have depicted the geographic concentration (“hot spots”) of opioid 
overdose cases.
308,220,309
 The mapping of overdose deaths in Massachusetts has uncovered 
several cities and towns with disproportionately high rates compared to the state 
overall.
310
 Such data suggest that highly targeted, community-focused initiatives may be 
effective in curbing the overdose death rate. Recently released data from the city of Lynn, 
Massachusetts demonstrated the success of one such effort: while the number of opioid 
overdoses rose, the number of people who succumbed to an overdose significantly 
decreased due to increased naloxone administration. Lynn’s opioid overdose fatality rate 
was 35.6 per 100,000 residents in 2012 and then decreased to 15.7 in 2016.
311
  
 The present study found that CHC engagement in local coalitions supported the 
development and implementation of both new initiatives and more coordinated efforts. 
Specifically, two CHCs formed partnerships addressing the communication void between 
EDs and primary care providers found in this and other studies. A study among over 
2,000 patients within a U.S. healthcare system who had at least one opioid overdose 
showed that less than 10% of those patients had a subsequent naloxone order, indicating 
the need for enhanced communication between EDs and improved naloxone access 
within follow-up primary care.
80
 In addition, a national study of commercially insured 
patients found that nearly all patients prescribed opioids continued to receive them from 
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the same provider even after an overdose, suggesting the lack of communication between 
EDs and primary care providers about the overdose.
312
   
 Clearly, then, shoring up communication lines and response systems between 
CHCs and EDs is an important step for coordinating across local care systems to prevent 
overdose fatalities. Through community coalition participation, one CHC worked with 
the local ED to provide naloxone to patients seen there for opioid overdose. Another 
partnered with their local EMS, which resulted in primary health providers being alerted 
when patients had an opioid-related ambulance transfer. Such efforts are crucial in 
addressing the complex systemic barriers to a coordinated response.  
Conclusion 9: Integrating OENA activities into buprenorphine treatment and chronic 
opioid prescribing greatly expands the scope of OENA implementation.   
 The integration of naloxone access into CHC protocols for buprenorphine 
treatment and chronic opioid therapy prescribing came about because clinic staff saw the 
benefit to providing naloxone to these patients. In turn, making OENA a routine practice 
helped sustain naloxone as a CHC priority. These practices were also supported by state 
and national guidelines.  
 In 2015, the Massachusetts DPH issued practice guidance for integrating overdose 
education and naloxone into opioid treatment programs.
70
 Federal funding has expanded 
the role of CHCs in providing medication-assisted treatment nationally,
63
 thereby 
encouraging additional opportunities for future naloxone access. The Prescribe to 
Prevent website offers sample policies and guidance that could be useful to implementing 
agencies and other jurisdictions.
293
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Opioid prescribing guidelines issued by the CDC in March 2016 recommend the 
provision of naloxone for persons prescribed chronic opioid therapy for non-cancer pain 
management.
45
 This is an area of tremendous opportunity. Two 2016 studies 
demonstrated the feasibility of naloxone co-prescribing interventions, one in San 
Francisco primary care safety net clinics, the other in an Albuquerque ambulatory pain 
clinic.
224,225
  
Conclusion 10: Differing clinic staff’s perceptions of patients’ overdose risk differed 
for patients with opioid use disorder and those being prescribed chronic opioids need to 
be considered in training and technical assistance response.  
Clinic staff’s perceptions of patients’ overdose risk differed for patients with 
opioid use disorder and those being prescribed chronic opioids. Those patients perceived 
to be at low risk were less likely to receive OENA. A few of this study’s physicians noted 
that they do not consider their patients on long-term chronic opioids to be at risk for an 
overdose, and one participant noted that these patients likewise do not perceive 
themselves to be at risk. Consistent with that finding, a 2016 survey of patients on 
chronic opioid therapy for pain management found that, despite their high rate of 
overdose, these patients had low knowledge about their overdose risk and naloxone.
313
 
This finding underscores the need for clinic-based interventions, as many of these 
patients do not perceive themselves to be at risk if they are taking medication as 
prescribed. 
The different levels of risk appraisal may also contribute to provider fear of 
offending patients or being perceived of accusing them of substance abuse, which has 
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been identified in the literature.
39,40,54,249
 The different notions of risk for patients 
prescribed opioids compared to those with an opioid use disorder likely require different 
clinic staff training and patient communication strategies. For example, study participants 
spoke about the importance of discussing relapse as a potential part of the treatment 
process, and the likelihood of being a bystander around others who may overdose. For 
patients on chronic opioid therapy, a physician spoke to her patients about the importance 
of having naloxone on hand for the safety of other household members. Another study 
reported that several patients prescribed naloxone alongside chronic opioid therapy 
reported safer medication behaviors, such as taking their prescribed dose at the right time, 
suggesting the role of this intervention in heightening patient awareness of opioid use 
risk.
221
  
Framed as a universal clinic opioid safety measure for all patients receiving 
chronic opioid therapy— an approach that has been previously recommended226— was 
found to be acceptable to patients.
221,250
 Coffin, et al. also found that universal co-
prescribing ultimately reached patients at highest risk of overdose (i.e., past opioid-
related ED visit and higher doses of opioids).
224
 While it is not feasible or always 
appropriate to offer every patient naloxone, having a universal guideline in place may 
help remove the stigma associated with OENA and create an implementation climate 
where co-prescribing is expected.  
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Conclusion 11: Clinic training and technical assistance plans should be customized 
according to the staff members’ potential OENA roles and their stage of readiness. An 
OENA champion on-site who coaches and supports team members can motivate staff 
to implement the intervention and address barriers. 
 The present study revealed that staff members, often based on prior experience, 
were at different stages of readiness for implementing overdose education and naloxone 
prescribing, a finding that should be considered during a program’s early implementation 
phase. All team members need to be “on board”— that is, sharing supportive beliefs 
about the need for the intervention and being fully prepared to implement OENA 
according to their clinic role. Therefore, ongoing training and technical assistance that 
reaches all clinic staff is imperative. In fact, as a starting point, all of the CHCs in this 
study conducted clinic-wide training on how to respond if an overdose occurred at the 
CHC. Not surprisingly, participants reported the need for ongoing pharmacist training 
since they too have different comfort levels with overdose education and naloxone 
dispensing. Studies of pharmacist-based interventions for PWID have found that training 
can facilitate pharmacist engagement.
236,314
  
Some clinic staff and pharmacists who struggle with OENA delivery may need 
additional in-service trainings. Ongoing booster sessions can establish a foundational 
level of knowledge and greater comfort with the intervention regardless of staff 
members’ degree of involvement in day-to-day patient education and naloxone access. 
Finally, given prescribers’ focus on clinical priorities, electronic reminders and easy 
online naloxone prescribing were reported to facilitate involvement over the long-term.   
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The study showed that having an on-site OENA champion supported roll-out, a 
finding shared by studies assessing implementation of other interventions in primary care 
settings.
315,316
 A champion can help keep the staff motivated by modeling implementation 
and connecting staff with their more experienced peers. At the same time, they are 
available to field questions and trouble-shoot problems that arise.  
Coffin, et al. outlined a one-year implementation plan for the NOSE intervention, 
which featured the co-prescribing of naloxone with chronic opioid therapy in primary 
care settings. While rolled out in the context of a research study, their plan can serve as a 
helpful roadmap for other settings,
224
  and, in fact, similar steps were taken by some of 
the CHCs in the present study. The NOSE plan includes the following activities:
224
  
1) meeting to introduce the program to clinic leaders; 
2) clinic-wide staff training that introduces the program to all staff; 
3) distribution of materials including naloxone rescue kit components and patient 
education brochures;  
4) prescriber trainings to review the protocol and answer questions, which were 
often conducted in pre-clinic “huddles”;  
5) nurse and medical assistant trainings to review activities, conduct role plays, 
and answer questions; 
6) emails to remind staff to follow the OENA protocol; and  
7) ongoing technical support for staff. 
This plan reinforces the point that implementing the intervention requires the 
involvement of multiple staff, and that a one-shot training is inadequate to support staff 
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longer term.  
In addition to training and technical assistance, the present study highlighted the 
importance of building in opportunities for information sharing as a way to engage clinic 
staff. Information shared included both quantitative data (i.e., naloxone prescribing and 
standing order data) and clinic staff stories about patients’ reports of naloxone use. The 
practice-feedback loop is a fundamental component of implementation science, meaning 
that practice experience is documented, assessed, and then revised as needed.
317
 A study 
of the Australian naloxone pharmacy access program also found that ongoing use of data 
systems supported implementation over time.
318
 
Recommendations for Practice 
The study’s findings in Chapter 4 were organized according to the CFIR’s five 
domains: Intervention Characteristics, Outer Setting, Inner Setting, Characteristics of 
Individuals, and Process. The fact is, however, that these constructs are interrelated, and 
therefore focusing on any one of these domains on its own would accomplish relatively 
little to produce systemic change. The complex interplay of these domains must be 
addressed.  
Implementation science frameworks reinforce the point that implementation 
experience is highly dependent upon context. As outlined above, this study identified a 
large number of contextual factors across multiple domains that may support or impede 
the uptake and implementation of OENA activities. In consideration of this, nine broad 
practice recommendations are put forth in Table 39, organized according to what CHCs 
may want to consider at different stages of program implementation— specifically, 
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adoption, implementation, and maintenance, as per the RE-AIM Model.
319
 It is important 
to note that many of the listed activities can be engaged in across program phases.  
Table 39. Recommendations for Various Phases of OENA Program Implementation 
 
Adoption Phase 
• Ensure senior leadership support and have leadership communicate importance of 
overdose prevention activities to CHC staff 
• Document and disseminate naloxone access, prescribing, and Good Samaritan laws to 
all clinic and pharmacy staff 
• Identify a champion within both the clinic and pharmacy, if a pharmacy model is used 
• Identify clinic team members who will be involved in implementation 
• Adapt the OENA model to fit the clinic’s workflow and patients’ needs 
• Start small with one clinic team or with a particular patient group 
• Determine the best method for purchasing naloxone 
• Determine a mechanism for stocking naloxone in the pharmacy or clinic 
• Create a clinic emergency overdose response plan and clinic-wide staff training  
 
Implementation Phase 
• Establish formal partnerships with external organizations as needed 
• Recognize different stages of readiness among the implementing team and conduct 
ongoing trainings to support the staff 
• Conduct staff trainings on creating a stigma-free clinic environment 
• If using a prescription model, create an easy online prescribing process  
• Review data and implementer and patient feedback to determine any needed changes 
to program 
• Post signage in both the clinic and the pharmacy 
• Conduct outreach events in the community 
• Participate in a community coalition that addresses the opioid crisis in the community 
 
Maintenance Phase 
• Build in decision supports for providers and staff, and discuss the initiative in weekly 
and monthly team meetings 
• Consider the long-term cost implications for naloxone access and plan for any changes 
to ensure sustainability 
• Create a written policy and train new and existing staff on it 
• Support the efforts of the champion by acknowledging impact of OENA activities 
across the CHC 
• Continue to evaluate and reflect on progress as a team and make adjustments as needed 
 
Recommendations for the Adoption Phase 
 Determine what costs and resources are needed. While OENA is not a 
resource-intensive intervention for the CHC unless naloxone is purchased by the 
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CHC directly, certain resources need to be in place: physical space for patient 
education (at the clinic or pharmacy), training for staff, designated training time 
for staff, stocking of naloxone rescue kits, and patient education materials.  
 Identify how patients will access naloxone. It is important to determine how 
patients will access naloxone. Various strategies can be utilized and are not 
mutually exclusive. These approaches can also change over time based on the 
clinic, patients’ needs, and available resources. Table 24 summarizes the 
advantages and disadvantages of the various approaches.  
 Determine staffing capacity and workflow. Finding ways to build OENA into 
the existing workflow, such as during buprenorphine assessment visits, can 
support routine service provision. In recognition of prescribers’ competing 
clinical priorities and their limited time with patients, nurses and other staff such 
as health educators, case managers, and behavioral health providers can all play a 
role in the delivery of OENA. Standing orders can help remove the need for a 
prescription and create an opportunity to expand the role of the pharmacist as a 
key member of the OEND team. Clearly articulated staff roles in the OENA 
process helps ensure that the intervention actually occurs with fidelity.  
 To start, consider piloting OENA activities. Starting with where CHC clinic 
staff perceives the need to be the greatest, and working with the support of an 
enthusiastic champion, can support the intervention’s initial implementation. 
OENA activities can be modified or expanded over time as needed. 
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 Engage staff throughout the CHC in OENA training and technical assistance 
activities. There are several opportunities to engage clinic staff, including 
training, ongoing booster sessions, on-the-job peer support, and provision of job 
aides. The provision of training on addiction theory and science can also help 
equip clinic staff with knowledge and tools for they need to integrate discussions 
about naloxone into patient visits.  
Recommendations for the Implementation Phase 
 Build a relationship with the pharmacy used by most of the CHC patients. 
CHCs can forge new or expand relationships with pharmacies to provide 
coordinated care for persons in need of overdose education and naloxone. 
Together, the CHC champion and pharmacy director can create a strategy to 
increase naloxone access for CHC patients 
 Actively work to create a stigma-free environment at the clinic and 
pharmacy. Training on the science of addiction and evidence related to the 
treatment and recovery process can help engage both clinic staff and patients in a 
productive dialogue about naloxone’s role in the recovery process. Trainings on 
the best language to use when working with patients can further support a culture 
that helps destigmatize addiction. During these discussions, it is important to 
recognize that clinic staff and patients may perceive overdose risk differently for 
patients who are on opioid treatment and those who are prescribed opioids for 
chronic pain. After staff receive training, signage in the clinic and pharmacy can 
help communicate that those are safe spaces to discuss overdose prevention.   
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 Offer ongoing training and technical assistance activities to staff. A training 
plan that includes basic training for all staff, specific training for staff conducting 
patient education, and ongoing booster trainings can support implementation. 
Effective training and technical assistance plans should recognize that CHC and 
pharmacy staff— both veteran and new— will likely be at different levels of 
readiness for implementing OENA activities. A written policy developed at this 
point will be a useful tool for communicating expectations to staff and giving 
them increased guidance regarding their OENA responsibilities. Table 8 in 
Chapter 2 lists free online clinic staff, prescriber, pharmacist, and patient training 
and education resources.  
Recommendations for the Maintenance Phase 
 Gather and share data about the CHC’s opioid overdose activities. Data about 
OENA activities can be useful in measuring how frequently patients have 
received naloxone, documenting progress, and identifying barriers to improved 
implementation. Reviewing these data with the CHC staff, and with the pharmacy 
staff if that approach is used, provides the opportunity to provide feedback and to 
brainstorm solutions to enhance the program. 
 Leverage local partnerships in the opioid response. Local partners are vital to 
ensuring that patients have access to the full continuum of opioid treatment 
services, as well as to supportive social services. CHCs are key partners in the 
community response and can collaborate with community-based organizations to 
conduct outreach events, including naloxone distribution. Finding ways to 
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coordinate with local EDs, EMS, and police departments, such as through local 
opioid coalitions, are a great forum for bringing multiple stakeholders together for 
a coordinated response.  
Transferability of Findings 
 Qualitative research findings are rarely generalizable to other settings,
77
 but can 
provide important guidance to a broader range of practitioners when those findings are 
organized according to implementation science concepts. An implementation science 
perspective looks for common underlying themes and constructs that can guide the 
transfer of findings from one setting to another. The present study’s findings offer 
sufficient detail to inform OENA implementation in other settings. 
 At the same time, of course, context is also essential to identifying what might 
work most effectively in one setting and not in another. Important contextual elements 
identified in this study include whether there are facilitative state policies, and whether 
the CHC has a clinic culture that is mission-driven, patient-centered, team-focused, and 
open to innovative methods of healthcare delivery that might better address both patient 
and community needs.   
The findings from other CFIR domains— namely Characteristics of Individuals, 
Inner Setting, and Process— should also be considered by other settings as they create or 
expand a naloxone program. For example, when the findings were shared with an HIV 
physician at a large urban hospital, she reflected on aspects of the findings that applied to 
her setting, such as the need to train all clinic staff and increase patient awareness through 
signage.  
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Similarly, findings shared with attendees at a New Hampshire behavioral health 
conference led to one CHC nurse practitioner planning to find out which staff at her CHC 
are giving out naloxone, which patients are getting it, and how OENA could be integrated 
more formally into the clinic’s buprenorphine treatment program. Another conference 
participant who manages a network of treatment centers stated that he planned first to 
share the laws with his clinic leadership and then reach out to the health department to 
learn how to procure naloxone rescue kits. He spoke about his plans to start on a small 
scale at one center to see what works before expanding the program to all sites. A third 
participant reflected on ways to enhance her clinic’s partnership with the pharmacy that 
has a standing order. Based on these reactions, the hope is that these study findings will 
trigger new ways of thinking about naloxone access for patients in different primary care 
settings and help guide their adoption.  
Recommendations for Future Research 
Evaluate the intervention’s outcomes. Future studies can examine naloxone 
distribution, prescribing, and standing order data from the clinics. Such data could 
identify actual trends within CHCs, including prioritization of patient risk factors, extent 
of provider and staff involvement, and patterns of naloxone access. Furthermore, a 
comparison of the number of naloxone rescue kits prescribed or ordered and actually 
received by patients would be important, particularly given that the study identified this 
disconnect as a barrier to effective care. This type of analysis could help identify the 
effectiveness of different naloxone access models, as well as point to program areas in 
need of quality improvement. 
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Conduct a case study of exemplary programs. An in-depth examination of two 
CHCs could supplement the cross-site findings produced by this study by providing a 
greater level of implementation detail that could guide newly launched programs. Sites 
with exemplary practices can be selected based on the outcome measures described 
above, while ensuring that different settings and methods of delivery are represented. 
Such case studies could build upon case studies prepared by The Harm Reduction 
Coalition.
320
 When posted online, the case study description could include links to sample 
policies, EMR template screen shots, staff training curricula, and patient education 
materials.  
Explore further the role of the CHC-based pharmacy partner. Future studies 
can explore the efficacy of different pharmacy arrangements for increasing naloxone 
dispensing, including new innovative models such as including adding a pharmacist to 
the CHC clinic team. Subsequent investigations could examine the factors that increase 
naloxone dispensing rates from the pharmacy. Some of the factors identified in this study 
that could be explored include the relationship between the pharmacy staff and clinic 
champions; the clinic’s physical space; community outreach activities; and stigma 
reduction activities. Identifying specific implementation factors that facilitate pharmacy 
access models will be an important step in overcoming the barriers identified in this 
study.  
Obtain the patient perspective. The patient perspective has been largely absent 
from studies exploring clinic-based OENA activities. In future research, hearing directly 
from patients through a mix of qualitative and survey research can help inform new clinic 
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strategies and quality improvement efforts. Two studies in 2016 assessed chronic pain 
patients’ attitudes toward naloxone prescribing in primary care settings found that 
patients found it acceptable to be prescribed the medication,
221
 though barriers could arise 
if the discussion was not framed well.
304
 Another 2016 study among ED patients using 
opioids found a two-thirds acceptance rate for a naloxone kit.
321
  
Future studies should strive to sample a wider range of groups, including patients 
receiving buprenorphine treatment, patients prescribed opioids for chronic pain 
management, and patients who are family members or friends of persons at risk of 
overdose. The patient perspective, combined with the existing literature and these 
implementation findings, could be used to inform future education messages and methods 
of naloxone delivery. 
Limitations of the Study 
While the proposed methodology was well suited for addressing the study aims, 
there are inherent limitations to the research design that warrant attention. A brief 
explanation of these limitations and how they were addressed is presented below.  
Location of the study. This study was conducted with a sample of CHCs located 
in the Commonwealth of Massachusetts, a state with a highly facilitative political 
environment for OENA programs. While more and more states are moving in that 
direction, it is important to note that CHCs in other states may not be operating with fully 
supportive policies or may be at an earlier stage of policy implementation. Even so, this 
study’s documentation of the Massachusetts CHC’s implementation experience can 
inform practice in other states. 
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 Timing of the study. Focus groups and interviews were conducted over a four-
month period. It is important to note that the CHCs’ OENA activities may have evolved 
during and after the data collection process, and that the study’s findings represent only a 
snapshot in time of their implementation experience. The continued focus on national and 
state policies and the broader dissemination of promising clinic practices is likely to 
increase clinic-based implementation of OENA. Likewise, it would be important to 
assess the degree to which fatigue may be setting in as CHCs grapple with the opioid 
crisis in their communities.   
Absence of outcome evaluation. It is not possible to say which OENA approach 
is the most effective for increasing naloxone access since process and outcome data 
collection was not part of the research plan. As this is a relatively new intervention, 
conducting an outcome evaluation would be premature. All statements regarding the 
effectiveness of each approach, plus the identification of promising practices and key 
considerations for intervention planning, stem from the participants’ descriptions of their 
experience.  
Response bias. Findings from the clinic staff interviews are not representative of 
all providers at the clinics.
77
 Different clinic staff involved in oversight, management, and 
implementation roles were interviewed to get multiple perspectives regarding the 
implementation experience, including the challenges each CHC faced. In addition, data 
sources were triangulated for each study site to validate the interview data.     
Researcher bias. Several steps were taken to minimize the potential impact of 
researcher bias during this study. First, a series of meetings with experienced qualitative 
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researchers and a Massachusetts subject matter expert were held during development of 
the data collection tool, site selection, and outlining the data collection processes. Second, 
code definitions were discussed with an objective qualitative researcher, and the codes 
were applied to a subset of transcripts until consensus was established. Throughout the 
coding process, queries and uncertainties were documented in memoranda to refer to 
during the data interpretation phase. Patterns and key themes were discussed with the 
qualitative researcher and a state expert, resulting in continuous feedback throughout the 
study. In addition, the findings were shared with state experts and conference participants 
at a New Hampshire Behavioral Health Conference workshop in an effort to assess the 
broader relevance of the study’s findings.  
Chapter Summary 
The CHCs in this study played an important role in increasing access to naloxone, 
particularly given their role in providing primary care to PWID, providing opioid 
treatment to persons with substance use disorder, and in prescribing opioids for chronic 
pain management. The present study elucidated the variation in OENA activities 
implemented in these primary care settings. Beyond demonstrating the feasibility of 
OENA in these settings, the study highlighted important considerations to be taken into 
account when designing or modifying programs to suit a CHC’s particular context.  
Several activities were found to facilitate the implementation of OENA activities. 
Starting small and identifying an implementation team and key internal and external 
partners is essential. Providing ongoing training and technical assistance on naloxone-
related laws, harm reduction approaches, and OENA with all CHC staff can create a 
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supportive implementation climate. Identifying opportunities to integrate OENA 
activities into existing care delivery avoids unnecessary complexity and supports staff 
engagement. Working continuously to eliminate the stigmatization of persons with an 
opioid use disorder supports patients and the goal of getting naloxone into the hands of 
persons likely to experience or witness a future overdose.   
The study findings, combined with the existing literature, paint a comprehensive 
picture of what implementation entails, highlighting the fact that system-wide support is 
needed to overcome individual-level barriers. This study also revealed the overlapping 
influences that in many cases need to be in place simultaneously in order to bring about 
sustained programmatic change. These approaches and findings can be used by other 
CHCs seeking to expand naloxone access as a means to prevent opioid overdose deaths in 
their communities.   
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APPENDIX A: Letter to HIV Clinic Medical Directors Inviting Study Participation 
 
[Clinic Name; Clinic Email/Address] 
 
Dear [Clinic Medical Director]:        [Date] 
 
I received your name from [NAME] who recommended that I contact you about a project that I 
am working on. I am conducting a qualitative research study on barriers and facilitators faced by 
clinical care settings when implementing overdose education and naloxone prescribing for 
persons living with HIV who are at risk of potential overdose.  This study serves as my 
dissertation project at the Boston University School of Public Health where I am a Doctor of 
Public Health (DrPH) student.  
I am selecting approximately five different clinical care settings in Massachusetts that have more 
than two prescribers, provide dedicated care to PLWH in Massachusetts, and have initiated opioid 
overdose education and naloxone prescribing. [NAME] thought [CLINIC NAME] would be a 
great addition as a potential study site. I am writing to see if your clinic would be interested in 
participating in this project. 
The study has been approved by the Boston University Medical Center Institutional Review 
Board. Please see the attached research study summary. Your participation would entail the 
following, based on a discussion with you about what is most appropriate for your clinic’s 
staffing model: 
 Completion of a brief survey about your clinic 
 Interview with you by phone or in-person lasting about 30-50 minutes 
 Individual interview(s) and/or focus group(s) with your clinic staff involved in overdose 
education and naloxone prescribing, including physicians, nurses, social workers, 
pharmacists, case managers, and peer educators. 
 
I am hoping to learn about different strategies for providing overdose education and naloxone 
prescribing in HIV clinical settings-- what works, what doesn’t work, and what makes it 
challenging— or easier— in HIV clinical settings.   
 
I would come to your clinic for the interview(s) and focus group(s) at times convenient for you 
and your staff sometime between [DATES]. Findings from this study will be useful in supporting 
HIV clinic-based opioid overdose prevention and response strategies. 
 
Thank you very much for your consideration. I am happy to answer any questions about the study 
or your participation, and will follow-up with a call within the next week. You can reach me at 
mclark11@bu.edu or 617-997-2709. 
 
Best regards, 
Michele Clark, MPH 
 
Attached: Research Information Summary  
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APPENDIX B: Study Information Summary Sheets [Pilot and Main Studies] 
 
Research Information Summary 
Title of Project: Understanding the Context of Implementing Overdose Education and Naloxone 
Distribution (OEND) for Patients at Risk of Opioid Overdose in an Infectious Disease Clinic  
Principle Investigator: Michele Clark, MPH 
Background 
 
The _________________ has recently decided to train its providers on overdose education and 
naloxone kit distribution (OEND) and suggest prescribing naloxone to patients at high risk of 
overdose. As a formative step to a Boston University School of Public Health Doctor of Public 
Health student’s dissertation research in this area, we are interested in understanding what you 
and your colleagues think about implementing OEND in the clinic and what you anticipate as 
challenges and potential strategies.  
 
Purpose 
 
The goal of this formative study is to understand the context of implementing clinic-based 
overdose education and naloxone kit distribution for patients at risk of opioid overdose at the 
____ clinic. We are interested in understanding your current thinking around OEND in the clinic, 
as well as what makes it challenging and easier in clinical settings.  
 
You are being asked to participate in this research project because you work in the ____ clinic. 
Your voluntary participation will consist of taking part in an interview or focus group discussion 
lasting up to 50 minutes. If you chose not to participate, your job will not be impacted in any way. 
You are free to answer the questions in any way you choose. Again, your point of view or 
opinions will not impact your job in any way. You are free to not answer a particular question if it 
makes you feel uncomfortable. There is no cost to you for participation, and you will not receive 
anything in return. Your input will help guide future recommendations for opioid overdose 
prevention strategies in clinical settings. 
 
Confidentiality 
 
We will be audio-recording the conversation so that we can analyze the themes of what we 
discuss with you and the other staff we will be interviewing. After the taping is complete, the 
Principal Investigator will be transcribing the interview/focus group discussion. No identifying 
information will be associated with the audiotaped file. All audiotapes will be destroyed after we 
receive the transcripts.  
 
Who to Contact 
 
Please feel free to ask any questions you may have now, or at any time during the interview/focus 
group discussion. The contact information for the Principal Investigator of the study is Ms. 
Michele Clark, MPH (617-997-2709; mclark11@bu.edu). You may also contact the BUMC IRB 
at 617-638-7207 or medirb@bu.edu if you have questions about your rights as a research subject. 
 
 
Approved by the Boston University Medical Center IRB #: H-33572, 12/4/2014 
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Research Information Summary 
 
Title of Project: Implementation Study of Opioid Overdose Education and Naloxone Prescribing 
in Clinic Settings for People Living with HIV: Identifying Opportunities for Expanding Access 
and Saving Lives 
 
Principle Investigator: Michele Clark, MPH 
 
 
Background 
 
Michele Clark, MPH, a doctoral student at the Boston University of Public Health, is conducting 
her dissertation research on clinical approaches to opioid overdose education and naloxone 
prescribing for patients living with HIV (PLWH) who are at risk of potential overdose.  
 
Purpose 
 
The goal of this study is to examine the barriers and facilitators faced by HIV clinics in 
Massachusetts that are implementing varying strategies for providing overdose education and 
prescribing naloxone rescue kits to PLWH.  
 
Approximately five HIV clinic sites will be selected for participation. At each site, focus groups 
and interviews with clinic staff will focus on their current thinking and experiences regarding 
overdose education and naloxone prescribing in their clinic, plus any recommendations they 
might have for improving clinic-based overdose education and naloxone prescribing.  
 
You are being asked to participate in this research project because you work as a clinical provider 
or clinic staff member who may be involved in overdose education and/or naloxone prescribing. 
Your voluntary participation will consist of taking part in an interview or focus group discussion 
lasting up to 50 minutes.  
 
If you choose not to participate, your job will not be affected in any way. You are free to answer 
the questions in any way you choose. Your point of view or opinion will not impact your job in 
any way. You are free not to answer a question if it makes you feel uncomfortable.  
 
There is no stipend for your participation. Your input is important in helping guide future 
recommendations for opioid overdose prevention strategies in clinical settings. 
 
Confidentiality 
 
Interviews and focus groups will be audio-recorded for future review and analysis. Ms. Clark will 
be preparing a transcript of the discussion, after which she will destroy the audio recording.  
Individual names will not be associated with the transcripts or mentioned in the dissertation.  
 
Today’s discussion will remain as confidential as possible. The results of this interview/focus 
group will be summarized thematically. Your name will never be shared or linked with anything 
that you say. Focus group participants are also asked to help maintain the confidentiality of the 
process by honoring the request to keep this focus group discussion confidential. You can do this 
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by not talking about the content of this discussion with others outside of this room. Please be 
advised that although the moderator will take every precaution to maintain confidentiality of the 
data, the nature of focus groups prevents her from guaranteeing confidentiality.  
 
Whom to Contact 
 
Please feel free to ask any questions you may have now or at any time during the study by 
contacting information for the Principal Investigator of the study is Michele Clark (617-997-
2709; mclark11@bu.edu). You may also contact the Boston University Medical Center IRB at 
617-638-7207 or medirb@bu.edu if you have questions. 
 
 
Approved by the Boston University Medical Center IRB #: H-33572, 12/22/2015 
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APPENDIX C: Pilot Study Data Collection Tools 
 
Physician Interview and Focus Group Participant Information Questionnaire 
 
Understanding the Context of Implementing Overdose Education and Naloxone Kit 
Distribution (OEND) for Patients at Risk of Opioid Overdose in an  
Infectious Disease Clinic Setting 
 
1) What is your gender?   
1 Male   
2 Female    
2)  How old are you?   
1  < 25 years 
2 26-35 years  
3 36-45 years  
4 46-55 years   
5 56-65 years  
6  >65 years    
3) How many years have you worked at this HIV clinic?  
1 Less than 1 – 2 years  
2 3-5    
3 6-10     
4 More than 10 years  
4) On average, how many sessions per week do you work at this HIV clinic?  
1  1 session  
2  2 sessions  
3  3 or more sessions  
5) Have you ever received training on overdose education and naloxone kit distribution?  
1 Yes  
2 No   
6) If yes, please indicate the setting(s) where you received this training (check all that 
apply):  
1   Center for Infectious Diseases  
2    Emergency Department   
3    Community-based organization 
4    Medical school 
5   Other place please specify: ________________________________________________ 
7) Approximately what percentage of your patients at this HIV clinic do you think could 
be at risk of a future opioid overdose?  
1   10% or less  
2    11-25%   
3    26-50%  
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4    51-75%  
5    more than 75% 
8) Approximately what percentage of your patients at this HIV clinic do you prescribe 
opioids for chronic pain management?  
1   10% or less  
2    11-25%   
3    26-50%  
4    51-75%  
5    more than 75% 
9) Have you ever prescribed Narcan to your patient(s) at this HIV clinic?  
1 Yes   
2 No   
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Physician Interview and Focus Group Discussion Guide 
 
Understanding the Context of Implementing Overdose Education and Naloxone Kit 
Distribution (OEND) for Patients at Risk of Opioid Overdose in an 
Infectious Disease Clinic Setting 
 
INTRODUCTION         10 MINUTES 
A. Hello and welcome to our discussion, or focus group, today. Thank you for taking time to 
participate. We will keep the meeting to 50/60 minutes so that we finish by #:## am/pm. You 
should also feel free to get up and stretch, go to the bathroom, or help yourself to 
refreshments during the group if needed. 
 
B. My name is Michele Clark and I will act as the moderator for today’s discussion.  As you 
may have heard, I am a Doctor of Public Health student at the Boston University School of 
Public Health and doing my dissertation research.  Before we begin today’s focus group, I’d 
like to give you some background on why I am here and what I hope to learn from this 
discussion.  
 
I am conducting qualitative research on clinic approaches to opioid overdose education and 
naloxone rescue kit prescribing for patients living with HIV at risk of potential overdose. The 
study is taking place within different clinical settings in Massachusetts that have recently decided 
to implement overdose education and prescribe naloxone rescue kits.  
 
In order to learn about different strategies, as well as barriers and facilitators to overdose 
education and naloxone prescribing in clinical settings, I am talking with providers and plan to 
talk with patients, as well.  
 
The goal of this formative study is to understand the context of implementing clinic-based 
overdose education and naloxone kit distribution for patients at risk of opioid overdose at the 
____ clinic. We are interested in understanding your current thinking around OEND in the ___ 
clinic, as well as what makes it challenging and easier in clinical settings.  
 
You are being asked to participate in this research project because you work in the ___ clinic. 
Your voluntary participation will consist of taking part in an interview or focus group discussion 
lasting up to 50 minutes. If you chose not to participate, your job will not be impacted in any way. 
You are free to answer the questions in any way you choose. Again, your point of view or 
opinions will not impact your job in any way. You are free to not answer a particular question if it 
makes you feel uncomfortable. There is no cost to you for participation, and you will not receive 
anything in return. Your input is so helpful to guide future recommendations for opioid overdose 
prevention strategies in clinical settings. 
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Confidentiality 
We will be audio-recording the conversation so that we can analyze the themes of what we 
discuss with you and the other staff we will be interviewing. After the taping is complete, the 
Principal Investigator will be transcribing the interview/focus group discussion. No identifying 
information will be associated with the audiotaped file. All audiotapes will be destroyed after we 
receive the transcripts.  
 
ROLES AND LOGISTICS        5 MINUTES 
A. As a facilitator, my role is to make sure that we stay focused on the topic, that all the issues 
are touched upon as fully as possible within the time frame, and that everyone gets a chance 
to participate and express his or her opinion. We are here to learn about your experiences.  
I know you all have a lot of information and personal experiences to offer. At times, I may 
have to either gently interrupt and/or change the direction of the discussion so we can cover 
everything in the time we have. 
 
B. As participants, your role is to give your ideas, and share your experiences related to my 
questions and to comments made by other members of the group. I will ask a series of 
questions related to the topic, and ask for your opinions and ideas. Please remember that there 
is no right or wrong answers, and it is okay to have differences in opinions. The goal of 
today’s session is not to reach consensus, but to hear diverse perspectives. Everything you tell 
us is valuable. It is important that you speak loudly and clearly, and that one person speaks at 
a time. The first part of the group will focus on your understanding of the current challenges 
facing patients and the current role of health literacy and patient education in addressing 
those challenges. We will then shift to hearing what specific strategies— both with and 
without resources— that you would recommend to improve patient outcomes through health 
literacy and patient education interventions.  
 
C. I want to emphasize that the discussion today will remain confidential. The results of this 
focus group will be reported thematically. Your name will never be shared or linked with 
anything that you say. We also ask all participants to help us maintain the confidentiality of 
the process by honoring our request to keep this focus group discussion confidential. You can 
do this by not talking about the content of this discussion with others outside of this room.  
 
D. I also want to remind you that we are audiotaping the discussion group so we can remember 
the important ideas you have. The tape will give us the opportunity to review what you said at 
a later time when we prepare a summary report. Is this okay with you?  
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INTRODUCTIONS         5 MINUTES 
 
A. Let’s start with introductions. We have a lot to cover so please keep your introductions 
brief.  
 
B. Please tell us: 
 Your name (first names are fine) 
 What department or community health center you work at 
 Briefly what your role is 
 
QUESTIONS: CURRENT PRACTICE; DESCRIPTION OF CHALLENGES, 
SUCCESSES          35 MINUTES 
 
I. Questions [40 minutes] 
 
A. Role of Overdose Education and Narcan in Patient’s Lives  [20 minutes] 
 
1) What role do you see overdose education and Narcan playing in your patients’ lives? 
Probe: 
 To what extent do you see a need for overdose education and Narcan 
prescribing with the patients you see in the clinic? 
 
2) What patients could benefit the most from overdose education and getting a prescription 
for Narcan? 
Probe: 
 Approximately what percentage of your patients could benefit from 
overdose education and getting a prescription for Narcan? 
 Who else might benefit? Who else would you consider for this?  
 What about patients who are on opioids for chronic pain management? 
Could they benefit from this?  
 What criteria should determine if a patient should receive overdose 
education and Narcan? 
3) Thinking about patients on opioids for chronic pain management, what typically happens 
when opioids are prescribed?  
Probe: 
 What discussions, if any, happen with your patients related to their 
opioid use— both medical and non-medical?  
 
B. Implementing Overdose Education and Narcan Prescribing within the Infectious Disease 
Clinic [20 minutes] 
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Let’s talk about how feasible you think it would be to implement overdose education and Narcan 
prescribing in the ___ clinic—both what makes it difficult and could facilitate talking to patients 
about overdose education and prescribing Narcan in this clinic setting.   
 
4) What do you see as getting in the way of conducting overdose education with your 
patients and prescribing those at risk Narcan in the infectious disease clinic setting?  
Probes:  
 BMC policies 
 Work environment 
 Concerns about naloxone increasing risk 
 Overdose not seen as a risk 
 Lack of comfort discussing topic 
 Limited time/not the priority 
 Concerns about patient reaction 
 
5) What solutions can you suggest that might help overcome some of the challenges to 
implementing overdose education and Narcan in an infectious disease clinic setting? 
 
6) What about other team members’ roles in the infectious disease clinic (e.g., case 
managers and peer educators)— who could best provide overdose education and 
prescribe Narcan? 
Probes:  
 Who would best provide the overdose education?  
 Who should prescribe Narcan?  
 Who could offer referral and follow-up support?  
 
7) What about new models that aren’t in place, such as a nurse addictions specialist who 
provides the education and prescribing or the pharmacist? How would those models play 
out? 
Probes:  
 Let’s talk about the nurse addictions specialist model— how do you see 
that working with your patients and in your clinic setting? 
 What about the pharmacist? What if there was a standing order where 
patients could request Narcan from the pharmacist and/or a pharmacist 
could offer Narcan to patients on opioids— how do you see that model 
working? 
 
Additional Ideas for Preventing Overdose and Overdose Deaths in the Clinic Setting 
 
8) What further suggestions or recommendations do you have on how overdose education 
and Narcan prescribing might happen more in the ___ clinic?  
Probes:  
 Administrative/leadership support 
 Additional provider training 
 Patient education about overdose education and Narcan 
 Staff training and support 
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 Job aides 
 Integrated into EMR 
 
9) Other than overdose education and Narcan prescribing, what other prevention tools or 
interventions do you think are useful to reduce the risk of a person overdosing or dying 
from an overdose?  
 
II. Closing  [2 minutes] 
         Is there anything you want to discuss that has not already been discussed?  
 
 Summarize what was heard and thank participants for their time and sharing their 
experiences/ideas. 
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APPENDIX D: Pilot Study Findings 
 
Overdose Education and Naloxone Access:  
Barriers and Facilitators Among HIV Physicians (January 2015) 
 
The clinic site provided both HIV and routine primary care to PLWH. This setting 
differed from the study sample in several regards. First, it was an infectious disease clinic 
based within a large, urban academic medical center rather than a community health 
center. Second, the number of HIV patients seen (1,653 in 2015) was significantly greater 
than the average number of patients seen at the CHCs in the study sample. Third, in large 
part to the number of patients, the care team was much larger in both size (e.g., 13 FTE 
physicians compared to an average of 1.3 FTE), and composition, including infectious 
disease fellows, along with nurses, case managers, peer educators, and in-house 
pharmacist educators. About 25% of the patients were estimated to have injection drug 
use as a risk factor (compared to 32% of the study sample). Both the preliminary study 
and implementation study sites had an estimated 10% of patients prescribed opioids for 
chronic pain management. Approximately 15% of patients were thought to be misusing 
or abusing opioids, compared to approximately 20% of the patients in the implementation 
study sample.  
 
Similar to the study sites, the clinic was currently implementing outpatient individual or 
group counseling, buprenorphine treatment, naltrexone treatment, and OEND. Along 
with most of the study sites, this clinic also referred patients outside the organization for 
detox and methadone treatment services.  
 
Unlike the implementation study sites, the pilot study clinic had not yet implemented a 
plan for naloxone prescribing for patients.  At that time, primarily one physician— a 
buprenorphine provider and a champion of OEND, was prescribing naloxone. A clinic 
provider and staff training had been offered a few months prior, though was only 
attended by a couple of physicians, nurses, and case managers.  At the time of data 
collection, and at the end of the implementation study, an overdose education and 
naloxone prescribing policy, EMR field, and ongoing discussion during regular meetings 
had not yet been happened.  A standing order had just been implemented within one of 
the hospital pharmacies to allow for naloxone dispensing by patient request or at the 
pharmacists choice. Given the nascent stage of naloxone access activities at the time of 
the study, one of the providers noted that “we are on the steep side of the learning curve.” 
This timing made it particularly interesting to explore barriers and potential facilitators to 
broader implementation.  
 
Pilot Study Participants 
 
A summary of participant characteristics from this preliminary study phase can be found 
in Table 1. Nearly one-third of the participants (69%) were female, varying in age with 
almost half (46%) between 36-45 years of age. Almost half (46%) of the participants 
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worked at the clinic for three to five years, with 38% of them working there for over six 
years. The majority of physicians interviewed worked one clinic session/week, with a 
quarter working two sessions per week. Additional characteristics of the preliminary 
study participants will be described in the “Findings” chapter. 
 
Table 1. Summary of Preliminary Study Participant Characteristics, Physicians 
(N=13) 
Gender 
Male 
Female 
 
4 (31%) 
9 (69%) 
Age  
26-35 
36-45 
46-55 
56-65 
 
3 (23%) 
6 (46%) 
3 (23%) 
1 (0.8%) 
Years worked at clinic  
Less than 2  
3-5  
6-10 
More than 10 
 
2 (15%) 
6 (46%) 
2 (15%) 
3 (23%) 
Number of clinic 
sessions/week  
1 
2 
3 or more 
 
8 (62%) 
3 (23%) 
2 (15%) 
 
Pilot Study Participant Experience Related to Overdose Education and Naloxone 
Prescribing 
 
Table 2 summarizes participant experience related to overdose education and naloxone 
prescribing (OENP). Among the pilot study participants, 8 of the 13 physicians had 
attended an OEND training— half of them had participated in the clinic-based training, 
and the others had received training through residency program, state and city health 
department, or an online training program. Nearly half of the participants estimated that 
11-25% of their patients are at risk of a future overdose, whereas about a quarter 
estimated 26-50% and 15% estimated 51-75% of patients are at risk, a reflection of the 
patient panel seen by participating physicians. For example, one of the physicians 
oversees patients on Suboxone, an office-based medication treatment for opioid addiction 
treatment, and another treats several patients receiving methadone treatment. Note that 
these estimates of risk are higher compared to the implementation study participants’ 
estimates.  
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Table 2. Summary of Pilot Study Participant Characteristics, Physicians (N=13) 
Past OEND training receipt 
Yes 
No 
 
8 (62%) 
5 (38%) 
Location of past OEND training 
(n=8) 
Current clinic 
Other place 
 
4 (50%) 
4 (50%) 
Percentage of patients perceived to 
be at risk of future opioid overdose  
10% or less 
11-25% 
26-50% 
51-75% 
 
 
2 (15%) 
6 (46%) 
3 (23%) 
2 (15%) 
Percentage of patients prescribed 
opioids for pain management  
10% or less 
11-25% 
26-50% 
 
 
9 (69%) 
3 (23%) 
1 (8%) 
Ever prescribed Narcan at clinic  
Yes 
No 
 
3 (23%) 
10 (77%) 
 
All of the participants prescribed opioids to at least some of their patients, but the 
majority (69%) prescribe opioids to 10% or less or their patients, while about a quarter of 
the physicians reported prescribing opioids to 11-25% and only one 26-50% of patients—
similar percentages to the implementation study. Despite the training receipt and 
perceived risk of patients at risk of an overdose along with opioid prescribing to patients, 
less than one-quarter of participants ever prescribed Narcan to their patients at the 
clinic— a lower percentage compared to the implementation study which makes sense 
given that these sites theoretically were implementing naloxone access activities. At the 
time, other than the one nurse working with the provider who regularly prescribed 
naloxone, no other staff members in the clinic routinely provided overdose education or a 
naloxone prescription to patients.  
 
Pilot Study Interview and Focus Group Findings 
 
Several findings emerged from this preliminary study to inform the implementation study 
research aims and data collection tool development. Table 3 summarizes the identified 
barriers and current and potential facilitators to overdose education and naloxone 
prescribing in the clinic. A brief summary of the four major barriers and five major 
facilitators follows: 
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Table 3. Barriers and Facilitators to Physician Implementation of OENP 
Current Barriers 
 Minimal time with patient 
 Multiple clinical priorities 
 Coding and prescribing 
 Low knowledge on how to use 
naloxone 
 Challenging to have 
conversations with patients on 
chronic opioid pain medication 
 
Potential Facilitators 
 Internal champion 
 Awareness of opioid crisis and data 
 Provider and staff training on overdose 
education and naloxone use 
 Utilization of other team members to deliver 
intervention 
 Standardized screening tool in EMR 
 Clarification of coding  
 Easy electronic prescribing in EMR 
 Build alerts into EMR 
 Post signs in waiting room and/or exam rooms 
 Universalize education by framing discussions 
as “opioid safety”  
 
Barriers to Opioid Overdose Education and Naloxone Prescribing 
 
Limited time and competing clinical care priorities made it difficult for physicians 
to discuss overdose education and naloxone prescribing during the physician clinical 
encounter. All of the participants indicated that limited time and competing clinical 
priorities prevented them from talking about overdose risk and prescribing naloxone. “So 
I think why we haven't done it more is because of the time barriers…having the time to 
give the patients the education….We have a lot of time constraints. And there are a lot of 
administrative activities that are implemented at the same time, we have to push that 
button we have to complete this other piece of paper. We have a lot of competing 
priorities in that 20 minutes that we have with the patient. While I understand the benefits 
of it, it is yet another initiative that isn't done very easily.” Another physician spoke about 
the time barrier of raising overdose education, “It's not an easy conversation. I can 
imagine it being a 15-minute conversation or more to talk about that. Usually I've got to 
talk about six other co-morbid conditions and then that. And then 'Oh, I'm going to just 
raise Narcan.' You can't just do that in the time. I think that's a major barrier.” 
 
The physician participants also indicated that they conducted more overdose education 
and naloxone prescribing in primary care compared to the HIV clinic. While the burden 
of addiction per patient is likely to be higher within the HIV clinic, the volume of persons 
with opioid addiction or other substance use disorders is likely to be higher in primary 
care. Furthermore, there are more patients on buprenorphine in the primary care clinic. 
Therefore, innovations for overdose education and naloxone are also occurring in the 
primary care clinic context and through the Suboxone program, including a standing 
order in the primary care clinic pharmacy for naloxone that started during the time of 
these interviews. 
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Furthermore, physicians providing both HIV and primary care to patients are faced with 
multiple tasks. One physician explained the challenge of prioritizing multiple patient 
clinical needs during a single visit, “We do primary care for our patients, and that means 
that you have to do HIV and hepatitis C and everything else: cholesterol, hypertension, 
diabetes, meal sufficiency. And they are growing old, osteoporosis, vitamin D, and then 
addiction management-- sure it would be nice to do it, and STD testing and treatment-- 
but is there a real time for it? There really isn't. Because we see patients for HIV and 
primary care, that is a big difference from maybe a clinic where they do purely 
consultative work where they manage their HIV or hepatitis C and for everything else is 
say, ‘see your primary care doctor.’” 
 
Lack of clarity on how to bill, code, and prescribe for overdose education and 
naloxone impeded physician overdose education and naloxone prescribing. 
Physicians talked about their lack of clarity on how to bill for overdose education and 
naloxone. Furthermore, they were not sure how to prescribe naloxone in the current 
electronic prescribing system. One physician talked about the challenges she faces in a 
brief clinical interaction, “We are struggling to manage the medical side of things, so this 
is yet another thing that you should include in your visit, such as educating about how to 
use Narcan, taking the time to write the prescription, how do you write it, what’s the 
dose, how do you prescribe it? We know it needs to be done and if it were one button 
click away, I think I would do it for everyone.” 
 
Discussing opioid overdose and prescribing naloxone is harder for patients 
prescribed chronic opioids for pain management. There was consensus among the 
participants that patients with opioid abuse history, overdose history, who have witnessed 
an overdose, or who have friends or family members at risk of an overdose would be 
priority patients to receive overdose education and naloxone.  
Patients prescribed chronic opioids for pain management were also identified as those 
who should receive overdose education and naloxone, yet were not the always mentioned 
as high priority patients. One physician explained, “People on chronic meds are not in the 
front of my head as needing this, not because they don’t need it, but because it isn’t my 
default. Because of background of addiction, it is very easy for a patient to take a couple 
too many pills.” Another noted, “Sometimes after an interaction I'm thinking 'Oh I should 
have had that conversation.'” Some physicians expressed difficulty in reaching these 
patients with overdose messages for fear of stigmatizing their patients.   
 
At the same time, the focus on the opioid crisis in national and state news and policies 
has changed the practice environment for providers prescribing opioids for pain 
management. One physician explained, “In the past two years we have heard a lot more 
about it, so in effect I've changed my practice, my prescribing behavior…some of the 
testing that we do. My awareness has changed in the past two years so I'm kind of primed 
for a major intervention.” 
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Physicians not the most appropriate role to deliver and sustain overdose education 
and naloxone prescribing. The majority of physicians believed that physicians were not 
the most appropriate care team members to offer overdose education and prescribe or 
deliver naloxone. In fact, this strong sentiment was expressed by a few of the 
participants, and clearly stated by one participant as follows, “Leaving this up to the 
doctor is a sure thing to kill the initiative.” Many of the other barriers previously 
discussed, in part, explain this belief, including lack of time and need for ongoing 
training and education. One provider cautioned, “I think the actual piece of education 
means let’s open up the kit and look at it and see how we are going to do it. I definitely 
would not be able to do that. I think the pharmacy that is dispensing it would be a good 
place to do it because they will have to explain how to use it. And if we had test kits in the 
clinic we could have the nurses, our addictions nurse, demonstrate to patients how to use 
it.” While providers may do it sporadically, there was strong agreement that putting this 
initiative into the hands of other staff who could more universally implement this with 
patients (e.g., patients receiving chronic pain medication) would maintain and sustain 
naloxone access.  
  
While physicians did not see themselves as the primary educators, it should be noted that 
without a standing order in place, physicians would still need to be involved in the 
naloxone prescribing and potentially the referral to a team member— which would 
require an assessment to determine who should get referred for OEND. A team-based 
approach to overdose education and naloxone prescribing was recommended, taking it 
out of the hands of the physician. “I feel that the flu shot is a good corollary. So the flu 
shot in some ways has been taken out of the hands of the providers. Where they come to 
the clinic for any type of visit and they can get offered a flu shot and get it. I think 
something like that where not that we don't do it but it’s more of a team-based approach 
like with the flu vaccination.” 
 
There were differing opinions about the best team members to provide overdose 
education and naloxone to patients. Suggestions included:  
 HIV clinic pharmacists provide dedicated training to patients on a variety of 
medications. One provider explained, “The pharmacists cover almost every 
session and conduct HIV adherence counseling, and they will also do 
polypharmacy discussions, diabetes, smoking cessation. They could add Narcan 
to the discussion.”  
 Peer educators and case managers could talk patients about overdose prevention 
and naloxone, particularly given that they are trained to provide support around 
the “emotional” aspects of overdose and addiction.  
 A specialized addiction nurse on staff could offer overall prescription pain 
management education and monitoring for patients, along with overdose 
education and naloxone.  One noted, “I think practically it’s going to have to be a 
referral to a specialty teaching service, somebody who can train them, whose gets 
issues of expiration, technique, all that kind of stuff.  It’s like sending somebody to 
weight loss clinic, that's a specialty service which is really important but we can't 
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do that.” Another provider compared this specialist nurse educator role to nurse 
educators who conduct diabetes insulin or warfarin education to patients. Having 
a specialized educator would ultimately allow the providers to better manage pain 
medication. The challenges of prescribing opioids and managing addiction posed 
enormous challenges to one physician. She explained, “If the medical director 
came and she said make it the rule that all pain medicine has to go through this 
doctor and nurse who specialize in pain medicine, I would be the happiest 
person.” The provider did, however, acknowledge the current provider capacity 
issues with such a model and that patients would require patients to wait weeks to 
be seen. This is one of the challenges of the current model of having a solo 
provider champion who regularly integrates this into his practice.  
 Mental health counselors were thought to be well suited to discuss overdose with 
patients. One provider explained her thinking, “I would say the mental health 
counselors they do see the patients and interact with them a little bit more and 
have more time in general than the psychiatrists, so that may be another 
opportunity to at least bring it up under the category of safety at home.” She also 
spoke about the role of psychiatrists prescribing benzodiazepines to patients on 
prescription opioids, and that this would be an opportunity to talk to patients 
about overdose risk and naloxone. 
 
Facilitators to Opioid Overdose Education and Naloxone Prescribing 
A champion who is passionate about overdose prevention plays a major role in 
opioid overdose and naloxone prescribing. In this clinic setting, one physician in 
particular prescribed naloxone regularly to his patients. The role of a champion seemed to 
have two effects. First, these individuals can demonstrate that this practice can be done 
despite the identified barriers. One provider explained, “I think someone has to stand up 
and raise their hand and say, "I'm going to be the champion." That is what has happened 
elsewhere where it has been successful…It's got to be somebody who thinks it’s 
important. The case managers to some degree specialize in different patient populations, 
all of the attendings have their niche of patients that they get excited about.” This may 
mean that providers think of this one physician as the one to refer high-risk patients to, 
rather than trying the intervention themselves or diffusing the intervention across 
providers. One physician noted, “If I could refer all of my high-risk opioid user patients 
to [name of champion], that would make my job so much easier.” The challenge with this 
approach, as described by this same participant, is that patients are getting opioid-related 
support services based on one provider’s “…individual relationships as opposed to a 
systemic response. And I think this institution needs a systemic response.” Thus, 
strategies to diffuse a champion’s expertise and practice to the broader system are 
needed.  
Second, champions can heighten awareness about the importance and benefits of 
prescribing naloxone to other providers in the clinic. Another physician explained, “I 
think most physicians are not aware of the problem with overdoses, the solution for 
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overdoses, the ability of having naloxone be used very easily in the field by people who 
are minimally trained or with very little training. I think most physicians are not aware 
that this is happening…and it makes a difference. When you see the numbers. After 
seeing [name of champion] present the numbers… they are so shocking. You also then 
begin to become more in tune to your patients’ messages. This is how I kind of paid 
attention to the fact that a patient of mine that I see seldom told me how she basically 
overdosed in the street with her pain medicine, and then you realize this is happening, 
that people are probably using opioids, that other people in the household have access to 
their opioids.” 
 
Framing discussions with patients about opioid overdose risk in terms of “opioid 
safety” helps normalize risk. A couple of physicians spoke about the importance of 
addressing opioid safety rather than overdose risk with patients who do not have an 
acknowledged addiction: “It is better to really emphasize opioid safety, instead of 
overdose…when you are talking about an individual's risk who doesn't acknowledge that 
they have an addiction, it’s probably better to talk about opioid safety. We want to talk to 
patients about this as a safety issue and make it clear to patients that we are not 
assuming that they are going to overdose or that we are not assuming that they are not 
going to take their medication in anyway other than prescribed.” Coming at the 
importance of having a naloxone kit on hand from the perspective of the patient’s 
caregiver role was seen as particularly helpful in aiding communication— to protect their 
family members and friends. Physicians spoke about the importance of making overdose 
education a universal practice, “…like we are talking to everyone who is on a pain med... 
I think if you universalize it makes it a little bit less uncomfortable.” 
 
Training and education initiatives could expand provider and staff participation in 
overdose education and naloxone prescribing. As seen from the participant 
characteristics data, less than a quarter of the participants received OEND training. One 
provider noted that physician awareness and knowledge is individually-driven based on 
their interest. As a result of not having seen what is involved in overdose education, a 
couple of providers expressed concern about what to tell patients. One noted, “I mean I 
know what it does, and I know why it’s important, but that's not the questions that 
patients will ask me, …So actually I avoid it, which probably isn't constructive 
behavior.” A couple of other providers talked about the complexity of naloxone 
administration, noting that it required ongoing, hands-on learning with a mannequin and 
knowledge of how to use the syringe. One provider explained, “Epi-pen is easy, simple, 
not clinically complex like insulin, warfarin, or overdose.” This lack of self-efficacy in 
understanding the mechanics of using naloxone during an overdose posed barriers for 
several of the providers. One provider explained, “I have the education piece on my 
bulletin board, but I haven't gone to the training. And so I am kind of sketchy myself 
about what they are supposed to do in the field. I know it is something they are supposed 
to spray in the nose, but in fact the reason I still have that piece of paper there is because 
I am a little leery of how to do it myself. So currently I wouldn't be able to teach my 
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patients what to do with it [naloxone]. Well it is something you need to spray in the nose, 
is the extent of my knowledge, but I haven't touched a kit, I haven't literally seen a kit.” 
 
The EMR could support standardized patient overdose risk assessment.  Physicians 
talked about the need for more information from the EMR on patient’s risk, naloxone 
prescription status, and overdose history. A structured assessment could support 
providers or provider teams in ensuring overdose risk was assessed in a standardized way 
across patients. One physician explained, “We used to have a very structured intake 
process in the ID clinic, its morphed so many times that I don't know if tis done in a 
reliable way anymore over the past few years.” Another noted, “We need a system in 
place…for data, for keeping any data on health maintenance or things like that.” In 
addition to guiding assessment and documenting findings, physicians talked about how 
these alerts could support their patient discussions. 
 
Prompts may support providers in offering overdose education and prescribing 
naloxone to patients. Several participants talked about the need for decision tools to 
guide their patient overdose risk assessment activities. Different formats were suggested. 
Providers recommended an alert in the EMR to help identify need and/or past receipt of 
overdose education and naloxone. One explanation was, “It would be nice if there was a 
like a Logician pop-up. Now that we have those things they print out for us with the 
vaccine status, lit could include patient on opiates, naloxone status, or something like 
that…you know It’s hard to remember all these things when the patient comes in, with 
chest pain, they are bleeding, and you know. I think if there was some sort of automatic 
reminder system it would be helpful.” In fact, one provider explained how a patient’s 
medication facilitated her conversation about naloxone with a patient for whom she was 
prescribing pain medication: “I saw that she had naloxone on her list, and I asked if she 
had Narcan at home and do you know how to use it…She was very upfront about it. She 
answered questions and it was definitely this little alert that made me ask about it 
because it was in the record, in the medication list. It would be the kind of thing that 
would make me ask, ‘Do you need refills? Do you have refills?’ Kind of like an Epi-pen 
situation. Do you need refills? Have you used it? It’s a discussion opener.” Providers 
also suggested putting posters in the waiting and exam rooms to help engage both 
providers and patients.  As one provider noted, “If you put a poster up that said 'would 
you like to learn how to save someone's life from an overdose?’ That might catch a few 
people.” Others went on to talk about how such educational messages could engage 
patients who are not directly at risk, but may have a family member or friend who is at 
risk of an overdose. Furthermore, as another provider added to the discussion, such 
messages may help normalize discussions about overdose.  
 
Several (n=11) constructs from the CFIR emerged from these preliminary study findings, 
as documented in Table 3 below.  As can be seen in the next section, the findings from 
the implementation study both drew and expanded upon these initial findings due to the 
higher sample size and implementation experience of the selected sites.  
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Table 3. Relevant CFIR Constructs Emerged from Pre-implementation Study 
Construct Finding 
I. Innovation Characteristics 
 Complexity 
 
 Discussing overdose and naloxone perceived to be 
disruptiveness, lengthy in duration, and complicated 
II. Outer Setting 
 Needs and Resources of 
Those Serviced by the 
Organization  
 Easier to talk with patients with current or past 
opioid substance use disorder compared to patients 
prescribed opioids for chronic pain management 
III. Inner Setting 
 Structural Characteristics 
 Implementation Climate: 
Relative Priority 
 Readiness for 
Implementation: Available 
Resources 
 Access to Knowledge and 
Information 
 Utilization of interdisciplinary care team offers 
multiple opportunities for who can deliver 
intervention 
 Multiple clinical demands and priorities impede 
discussion 
 Limited time during patient encounter 
 Need for training on the mechanics of naloxone use; 
Decision tools, such as screening tools and prompts 
in the EMR  
IV. Characteristics of Individuals 
 Self-efficacy 
 
 Individual Stage of 
Change 
 Provider lack of confidence in their ability to 
implement overdose education and prescribe 
naloxone 
 Variation in provider passion, skill, and sustained 
overdose education discussions with patients and 
naloxone prescribing 
V. Planning 
 Champions 
 
 Key Stakeholders 
 
 Innovation Participants 
 Individual provider who prioritizes and focuses on 
overdose prevention within clinic 
 Availability of staff within clinic who could play a 
role in intervention delivery (e.g., nurses, case 
managers, peer educators, pharmacists) 
 Need for strategies (e.g., posters in exam rooms) to 
engage patients 
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APPENDIX E: Clinic Characteristics Survey 
Implementation Study of Opioid Overdose Education and Naloxone Prescribing 
in Clinic Settings for People Living with HIV:  
Identifying Opportunities for Expanding Access and Saving Lives 
 
Thank you for taking 10 minutes to complete this survey.  
 
The survey asks about your clinic’s characteristics with a focus on clinical care for 
persons living with HIV (PLWH) at your clinic. Specifically, this survey asks about 
opioid overdose and naloxone prescribing activities for patients with HIV at your clinic.  
 
Completion of this is completely voluntary, and you may skip any questions you’d prefer 
not to answer. Please feel free to send this to someone else in your clinic to complete if 
helpful. Please note that no reports or presentations will provide any information 
identified by clinic name.  
 
Thank you very much for participating in this project. The findings will be useful for 
supporting opioid overdose prevention activities within routine, outpatient clinical care 
settings for PLWH. 
 
 
A. HIV Clinic Background Information 
 
1. Which of the following best describes your clinic organization? (Select one) 
 Academic medical center clinic 
 Other hospital-based clinic  
 Federally Qualified Health Center/Community health center clinic 
 Other private, non-profit clinic 
 Other, please specify: ____________________________ 
 
2. Which of the following best describes how the majority of your HIV patients get primary 
and HIV care? (Select one) 
 HIV patients get both primary care and HIV care at this clinic site 
 HIV patients get primary care outside this HIV clinic, but within this organization 
 HIV patients get primary care outside this organization, and are referred here for HIV 
care 
 
3. What external funding sources, if any, does your clinic currently receive to support the 
care of patients with HIV? (Check all that apply) 
 Ryan White (state or federal) 
 Other federal, non-Ryan White 
 Other state, non-Ryan White 
 Private/foundation funding 
 Our clinic does not receive external funding for HIV services 
 Not sure 
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4. Please indicate the approximate full-time equivalency (FTE) of your clinic staff 
members, not including administrative staff, housed directly within your clinic, who 
support the care of patients with HIV. (Write “0” if staff type not providing HIV care at your 
clinic) 
 
HIV Clinic Staff Type FTE (0-1.0) 
Physician  
Nurse practitioner  
Physician’s assistant  
Nurse  
Case manager  
Social worker  
Patient/peer educator  
Community education specialist/outreach worker  
Patient navigator  
Pharmacist based within HIV clinic  
OtherPlease specify: 
_________________________ 
 
 
OtherPlease specify: 
_________________________ 
 
 
 
5. Please indicate the availability of opioid substance use services for your clinic patients 
with HIV. (Check all that apply) 
 
 Have 
within 
agency 
Do not have on-
site, but have a 
formal referral 
process with 
program  
Do not have on-site, 
but refer patients to 
program without a 
formal relationship 
with program 
Do not have 
on-site and 
do not refer 
patients 
Detox program     
Outpatient individual or 
group counseling 
    
Buprenorphine treatment      
Naltrexone treatment     
Methadone treatment     
Overdose education and 
naloxone distribution 
program 
    
 
6. When did your clinic begin offering overdose education and naloxone prescribing to 
patients with HIV seen during routine clinical care visits?  
 In the past 3 months 
 In the past 4-6 months 
 In the past 7-12 months 
 In the past 13-18 months 
 In the past 19-24 months 
 More than 24 months ago 
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7. Please indicate the implementation status of various overdose education and naloxone 
prescribing-related activities within your clinic providing routine care to patients with 
HIV. (Select one per row) 
 Have 
implemented  
Planning to implement 
in the next 6 months 
No plans to 
implement in the 
next 6 months 
Staff training on opioid overdose and 
naloxone prescribing 
   
Distribution of education materials to 
clinic staff  
   
Development of clinic protocol 
including opioid overdose and naloxone 
prescribing 
   
Stocking of naloxone within clinic 
pharmacy  
   
Established partnership with 
pharmacy to conduct overdose 
education and distribute naloxone  
   
Added electronic medical record field 
for naloxone prescribing 
   
Distribution of patient education 
materials about overdose education 
and naloxone  
   
Tracking and monitoring of naloxone 
prescribing data within clinic 
   
Regular, ongoing communication (e.g., 
during monthly staff meetings) with 
clinic staff about overdose education 
and naloxone prescribing activities 
   
 
 
B. Patient Information 
 
8. Approximately how many adult patients received HIV care at this clinic site in CY 
2015? __________________ 
 
9.    Please list the top three cities or towns where the majority of your HIV patients reside. 
If the majority comes from two or one city or town, then only list those places.  
1. __________________________________________________________________________ 
2. __________________________________________________________________________ 
3. __________________________________________________________________________ 
 
9. Please list the approximate percentage of your adult HIV patients covered by the 
following types of health insurance. Please provide your best estimate—percentages 
should add up to 100%. 
________% Medicare 
________% Mass Health 
________% Dually eligible for Medicare/Mass Health 
________% Commercially insured 
________% None/uninsured 
                100%   Total   
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10. Please list the approximate percentage of your adult HIV patients in each of the 
following age categories. Please provide your best estimate—percentages should add up to 
100%. 
________ % 18-24 years 
________ % 25-44 years 
________ % 45-64 years 
________ % 65 years and older 
            100%  Total   
 
11. Please list the approximate percentage of your adult HIV patients in each of the 
following gender categories. Please provide your best estimate—percentages should add 
up to 100%. 
________ % Male 
________ % Female  
________ % Transgender 
                    100% Total   
 
12. Please list the approximate percentage of your HIV patients in the following 
racial/ethnic categories. Please provide your best estimate—percentages should add up to 
100%. 
________ % Black/African American (not Hispanic or Latino) 
________ % White (not Hispanic or Latino) 
________ % Asian (not Hispanic or Latino) 
________ % Native Hawaiian/Pacific Islander (not Hispanic or Latino) 
________ % American Indian/Alaska Native (not Hispanic or Latino) 
________ % Multi-racial (not Hispanic or Latino) 
________ % Hispanic/Latino 
            100%  Total   
 
13. Approximately what percentage of your HIV patients has injection drug use as a risk 
factor? ____________ 
 
14. Approximately what percentage of your HIV patients are currently on a chronic opioid 
prescription for pain management?  _____________ 
 
15. Approximately what percentage of your HIV patients are currently misusing or 
abusing opioids? ____________ 
 
16. In the past six months, approximately how many HIV patients have been prescribed a 
take-home naloxone rescue kit from your clinic staff? _____________ 
 
17. Please feel free to add any comments or questions to clarify any of the responses.  
 
 
 
Thank you very much for taking the time to complete this survey. I look forward to 
meeting with you and your clinic team soon to learn more about your clinic’s overdose 
education and naloxone prescribing activities.  
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APPENDIX F: Participant Survey 
 
Clinic Staff Interview and Focus Group Participant Questionnaire 
 
Implementation Study of Opioid Overdose Education and Naloxone Prescribing  
in Clinic Settings for People Living with HIV:  
Identifying Opportunities for Expanding Access and Saving Lives 
 
3) What is your gender?   
1 Male   
2 Female 
3 Transgender 
   
4)  What is your age?   
1  < 25 years 
2 26-35 years  
3 36-45 years  
4 46-55 years   
5 56-65 years  
6 >65 years  
   
10) What is your role at this clinic? 
1 Physician  
2 Physician Assistant   
3 Nurse Practitioner   
4 Registered Nurse 
5 Case Manager  
6 Social Worker   
7 Patient Navigator 
8 Peer Educator 
9 Other Please specify: ________________________________________________  
  
11) How many years have you worked at this clinic?  
1 Less than 2 years  
2 3-5 years   
3 6-10 years    
4 More than 10 years 
  
12) In a typical week, how many patients with HIV do you see at this clinic?  ___________ 
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13) Have you ever received training on opioid overdose education and naloxone kit 
distribution?  
1 Yes  
2 No If no, skip to #8 below. 
 
14) If yes, please indicate the setting(s) where you received this training (check all that 
apply):  
1   Medical school or nursing school 
2   Current workplace  
3   Community-based organization 
3   Online webinar  
4   Other place Please specify: 
________________________________________________                                                                                                           
15) Approximately what percentage of patients with HIV whom you see at this clinic do 
you think could be at risk of a future opioid overdose?  
1    10% or less  
2    11-25%   
3    26-50%  
4    51-75%  
5    more than 75% 
 
16) Which of the following statements best captures your involvement with talking to your 
patients with HIV at this clinic about the risk of opioid overdose and prevention steps 
they can take? 
1   I have not thought much about it   
2   I have information about how to do this, but have not yet done it 
3   I have talked with other clinic staff about this, but have not yet done it  
4   I intend to try this in the next three months 
5   I have tried this but don’t do it regularly 
6   I do this regularly 
7   I have integrated this into my routine clinical care and have promoted it to other clinic 
staff  
 
17) For prescribers: Approximately what percentage of your patients with HIV who you 
see at this clinic do you prescribe opioids for chronic pain management?  
1   10% or less  
2    11-25%   
3    26-50%  
4    51-75%  
5    more than 75% 
 
18) For prescribers: Approximately how many naloxone prescriptions have you written in 
the past 12 months to patients with HIV in this clinic? ______________ 
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19) For prescribers: Which of the following statements best captures your involvement with 
prescribing naloxone to your patients at this clinic?  
1   I have not thought much about it   
2   I have information about how to do this, but have not yet done it 
3   I have talked with other clinic staff about this, but have not yet done it  
4   I intend to try this in the next three months 
5   I have tried this but don’t do it regularly 
6   I do this regularly 
7   I have integrated this into my routine clinical care and have promoted it to other clinic 
staff   
 
Thank you! 
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APPENDIX G: Interview/Focus Group Guide 
 
Implementation Study of Opioid Overdose Education and Naloxone Prescribing 
in Clinic Settings for People Living with HIV:  
Identifying Opportunities for Expanding Access and Saving Lives 
 
INTRODUCTION/STUDY BACKGROUND/CONSENT    
    
 
Thank you for taking time to participate in this study. We will keep the meeting to about [30-50 
minutes] so that we finish by [#:## am/pm].  
 
My name is Michele Clark and I am the interviewer/moderator for today’s discussion. I am a 
Doctor of Public Health student at the Boston University School of Public Health, and I am 
talking to you as part of my dissertation study.   
 
I am conducting qualitative research on clinic approaches to opioid overdose education and 
naloxone rescue kit prescribing for patients living with HIV who are at risk of potential overdose. 
The study is taking place at several primary care clinics in Massachusetts that provide routine, 
outpatient care to persons living with HIV.   
 
I have circulated an information summary sheet about this study, which has been approved by the 
Boston University Medical Campus IRB. Please let me know if you have any questions at any 
time, either now or after our interview. 
 
I am talking with providers and staff providing HIV care in order to learn about different 
strategies for providing overdose education and naloxone prescribing in clinical settings, plus the 
barriers and facilitators that affect your practice.  In particular, I am interested in understanding 
your current thinking about opioid overdose education and naloxone prescribing— what works, 
what doesn’t work— and what makes it challenging— or easier— to do this work in HIV clinical 
settings.  Because I am not an expert in this area, I may ask you to clarify your comments. 
 
Your participation is voluntary. If you chose not to participate, your job will not be impacted in 
any way. You are free to answer the questions in any way you choose, again with no impact on 
your job. You are free to not answer a particular question if it makes you feel uncomfortable.  
 
There is no cost to you for participation, and you will not receive anything in return. Your input 
will be helpful in guiding future recommendations for opioid overdose prevention strategies in 
clinical settings. 
 
I want to emphasize that our conversation today will remain confidential. The results of this 
interview will be summarized thematically. Your name will never be shared or linked with 
anything that you say.  
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[For focus groups] As a facilitator, my role is to make sure that we stay focused on the topic, that 
all the issues we need to cover are discussed as fully as possible within our allotted time, and that 
everyone gets a chance to participate and express their opinion.  
 
I am here to learn about your experiences. I know you all have a lot of information and personal 
experiences to offer. At times, I may have to gently interrupt or change the direction of the 
discussion so we can cover everything in the time we have. Also, because I am not an expert in 
this area, I may ask you to clarify your comments. 
 
As participants, your role is to share your ideas and experiences in response to my questions and 
comments made by other members of the group. Please remember that there is no right or wrong 
answers, and it is okay to have differences in opinions. The goal of today’s session is not to reach 
consensus, but to hear diverse perspectives. Everything you tell me is valuable. It is important 
that you speak loudly and clearly, and that one person speaks at a time. 
 
I want to emphasize that our discussion today will remain as confidential as possible. The results 
of this focus group will be summarized thematically. Your name will never be shared or linked 
with anything that you say. I also ask all participants to help us maintain the confidentiality of the 
process by honoring our request to keep this focus group discussion confidential. You can do this 
by not talking about the content of this discussion with others outside of this room.  Please be 
advised that although I will take every precaution to maintain confidentiality of the data, the 
nature of focus groups prevents me from guaranteeing confidentiality.  
 
*************************************** 
 
I also want to remind you that I am audiotaping the discussion group so I can remember the 
important ideas you have. The recording will give us the opportunity to review what you said at a 
later time when I prepare a summary report.  
 
Do you have any questions about the study or process?  
 
I wanted to confirm your consent for participating in this interview. 
 
Is it okay for me to begin the audio recorder? 
 
INTERVIEW/DISCUSSION QUESTIONS 
 
10) Please describe overdose education and naloxone prescribing activities currently 
going on at [clinic name] for patients with HIV receiving care here. First, I’m interested 
in hearing about overdose education activities, and then I’ll ask about naloxone 
prescribing.  
 
A) Opioid overdose education 
Probes: 
 What staff (roles) are doing overdose education with patients?  
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 What patients receive the overdose education? What criteria do you use? 
 How long does it take? 
 What is typically covered during that discussion? 
 Who is prescribing naloxone?  
B) Naloxone prescribing 
 Who in this clinic prescribes naloxone to patients?  
 What patients receive naloxone prescriptions? What criteria do you use? 
 Where do patients pick up their naloxone prescription [or if not a prescription 
approach, explain process for how patients access naloxone (e.g., in clinic, 
from pharmacy, from program)]? 
 
11) Thinking about your patients with HIV at this clinic, who do you think could benefit 
most from overdose education and a naloxone prescription? 
Probes: 
 To what degree is overdose a concern for you among your patients? 
 To what extent do providers know if patients have overdosed?  
 How is overdose risk assessed with your patients? 
 How frequently is that done with patients? 
 What patients in particular do you see at risk of an overdose?  
 How is overdose education and naloxone prescribing differently 
considered/implemented for patients who are using illicit drugs rather 
than patients on chronic opioid medicine for pain? 
 
[Summarize model described] 
 
12) Please summarize the process for how opioid overdose education and naloxone 
prescribing became introduced/integrated at this clinic. What were the key factors that 
went into the planning process and early stages of implementation? 
Probes: 
 Perceived need? 
 Patient and caregiver engagement/request? 
 Who participated in the decision to implement? 
 How were clinic staff engaged in the process?  
 How were patients engaged in the process? 
 What determined the model your clinic uses? 
 What supported implementation (e.g., training, champion provider, 
decision aides)? 
 
13) To what extent have policies— both external to your organization and internal to your 
organization-- influenced your HIV clinic’s adoption of overdose education and naloxone 
prescribing?  
Probes: 
 Federal policies, from SAMHSA, HHS, CMS? 
 State policies, naloxone access laws in Massachusetts; Governor’s 
Opioid Abuse Plan; prescribing guidelines? 
 Organizational policies, including clinic, hospital, commercial insurance 
providers? 
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14) What has your/your clinic’s experience been— both positive and negative— as you’ve 
worked to integrate overdose education and naloxone prescribing into your clinical care 
practice, particularly for PLWH? 
 
Let’s start with what has helped. What has supported your/your clinic’s integration of 
overdose education and naloxone prescribing for your patients? 
Probes: 
 Staff training? 
 Staffing models (e.g., case managers/peer educators/community outreach 
workers) 
 Support from other providers/ other clinic staff? 
 EMR prompts? 
 Job aides for providers? 
 Protocol/policy for all providers to follow? 
 Educational materials for patients? 
 In-house referral services for people addicted to opioids (e.g., 
buprenorphine program or other treatment services; OEND program)? 
 Support from caregivers of patients? 
 Partnership with pharmacist (in-house or community-based)? 
 
15) What has been challenging to conduct overdose education and naloxone prescribing for 
your patients?  
Probes: 
 Time? 
 Coordination across clinic staff? 
 Prescribing in EMR? 
 Cost? 
 Provider confidence— need for more information about effectiveness of 
intervention and need skills in naloxone use and talking to patients (e.g., 
training)? 
 Provider beliefs— concern of naloxone as “safety net” 
 Concern of stigmatizing patients? 
 Patient resistance? 
 Need to educate caregiver/friend if patient is at risk of overdose? 
 Board/community response? 
 Legal concerns? 
 Pharmacy process for getting naloxone? 
 
16) Thinking about how your clinic functions, who do you think should be providing 
overdose education and naloxone to your patients with HIV?  
 
Probes: 
 Clinical providers? 
 Case managers?  
 Peer educators?  
 Pharmacists? 
 Other? 
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17) How, if at all, does your clinic monitor the implementation of overdose education and 
naloxone prescribing activities? 
Probes: 
 Feedback from patients? 
 Feedback from providers? 
 Review of prescribing data at regular clinic provider/staff meetings? 
 Level of prescribing in clinic? 
 
18) What have been the outcomes of overdose education and naloxone prescribing to patients 
at your HIV clinic? In other words, what have you learned? 
Probes: 
 Provider impact? 
 Patient impact? 
 Time?  
 Costs? 
 
 
RECOMMENDATIONS  
 
19) What solutions can you suggest or are you thinking about for the future that might 
help overcome some of the challenges to implementing overdose education and naloxone 
prescribing in a routine primary care setting that provides care to PLWH? 
Probes:  
 Who would best provide the overdose education?  
 Who should prescribe naloxone?  
 Who could offer referral and follow-up support?  
 
20) What further suggestions or recommendations do you have regarding overdose 
education and naloxone prescribing, particularly for other clinics beginning to implement 
a program? 
Probes:  
 Administrative/leadership support? 
 Additional provider training? 
 Staff training? 
 Patient education about overdose education and naloxone? 
 Job aides (e.g., protocol, education sheet; education and counseling code 
provision)? 
 Integrated into EMR? 
 Monthly data and case reviews? 
 
21) Other than overdose education and naloxone prescribing, what other prevention tools 
or interventions within your clinic do you think can be useful for reducing the risk 
of a person overdosing or dying from an overdose?  
 
Probes: 
 Provision of medication-assisted treatment? 
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 In-house mental health and substance use counselors? 
 Implementing chronic opioid prescribing guidelines? 
 Use of PMP? 
 
CLOSING 
     
If relevant, ask: who else from your clinic would be appropriate for me to talk with to hear 
additional experiences about overdose education and naloxone prescribing within your clinical 
context?  
 
Suggest based on model: 
 Other clinical providers/prescribers 
 Suboxone providers 
 Social workers/peer educators/case managers/outreach workers 
 Pharmacists 
 Staff from other in-house program (e.g., OEND) 
 
Thank you for your time and sharing your experiences about overdose education and naloxone 
prescribing in your clinical care setting. I hope to be able to learn about implementation 
strategies across multiple clinic sites that I am talking with during the course of my dissertation 
research.  
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APPENDIX H: Document Summary Form* 
Study Site Code:  
Document Number:  
Date Received: __________________________ 
Document Date: _________________________ 
Name of Document: OENP Protocol 
Type of Document: 
o Clinic protocol 
o Provider job aide 
o Patient education material 
o Other, specify: 
_____________________________________________________________ 
 
Associated Event (if relevant):  
_______________________________________________________ 
 
 
 
Brief Summary of Document Contents: 
 
Significance, Purpose, Use, or Importance of Document: 
 
How Document Relates to Interview Questions and Study Constructs: 
 
Additional Comments/Reflections/Issues: 
 
 
 
 
 
*Adapted from: Miles MB, Huberman AM. Qualitative Data Analysis: An Expanded 
Sourcebook, 2nd Edition. 2nd edition. Thousand Oaks: SAGE Publications, Inc.; 1994. 
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APPENDIX I: Interview and Focus Group Summary Memo* 
Date: _____________   Time: ______    Interview/Focus Group Code: ___________ 
 
Type of Data Collection 
o Interview (In-Person) 
o Interview (Telephone) 
o Focus Group  Number of Participants:  _______ 
 
1. What observations did you make during your visit to the clinic? Specify 
setting and duration. 
 
 
 
2. What were the main issues or themes that struck you after this interview or 
focus group? Identify the salient points made, organized by CFIR constructs.  
 
 
 
3. Summarize the information learned from the responses to each question that 
was asked.  
 
 
 
4. What else stood out as salient, interesting, illuminating, or important? 
 
 
 
 
5. What new or remaining questions exist for this site, including any items for 
follow-up in future interview(s) or focus group(s)? 
 
 
 
 
6. What questions/probes/ideas should be explored with the other study sites?  
 
 
 
 
 
*Adapted from: Miles MB, Huberman AM. Qualitative Data Analysis: An Expanded 
Sourcebook, 2nd Edition. 2nd edition. Thousand Oaks: SAGE Publications, Inc.; 1994. 
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APPENDIX J: CFIR Codebook* 
* From www.cfirguide.org May 2016 
Note: This template provides inclusion and exclusion criteria for most constructs.  Please post 
additional inclusion and exclusion criteria, guidance, or questions to the CFIR Wiki discussion 
tab in order to help improve the CFIR.  
 
This template only includes CFIR definitions and coding criteria; codebooks may include other 
information, such as examples of coded text, rating guidelines, and related interview questions.  
 
I. Innovation 
Characteristics 
 
A. Innovation 
Source 
Definition: Perception of key stakeholders about whether the innovation is 
externally or internally developed.  
 
Inclusion Criteria: Include statements about the source of the innovation 
and the extent to which interviewees view the change as internal to the 
organization, e.g., an internally developed program, or external to the 
organization, e.g., a program coming from the outside. Note: May code 
and rate as "I" for internal or "E" for external. 
 
Exclusion Criteria: Exclude or double code statements related to who 
participated in the decision process to implement the innovation to 
Engaging, as an indication of early (or late) engagement. Participation in 
decision-making is an effective engagement strategy to help people feel 
ownership of the innovation. 
B. Evidence 
Strength & 
Quality 
Definition: Stakeholders’ perceptions of the quality and validity of 
evidence supporting the belief that the innovation will have desired 
outcomes. 
 
Inclusion Criteria: Include statements regarding awareness of evidence 
and the strength and quality of evidence, as well as the absence of 
evidence or a desire for different types of evidence, such as pilot results 
instead of evidence from the literature. 
 
Exclusion Criteria: Exclude or double code statements regarding the 
receipt of evidence as an engagement strategy to Engaging: Key 
Stakeholders. 
 
Exclude or double code descriptions of use of results from local or 
regional pilots to Trialability. 
C. Relative 
Advantage 
Definition: Stakeholders’ perception of the advantage of implementing the 
innovation versus an alternative solution.  
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Inclusion Criteria: Include statements that demonstrate the innovation is 
better (or worse) than existing programs. 
 
Exclusion Criteria: Exclude statements that demonstrate a strong need for 
the innovation and/or that the current situation is untenable and code to 
Tension for Change.  
D. Adaptability Definition: The degree to which an innovation can be adapted, tailored, 
refined, or reinvented to meet local needs. 
 
Inclusion Criteria: Include statements regarding the (in)ability to adapt the 
innovation to their context, e.g., complaints about the rigidity of the 
protocol. Suggestions for improvement can be captured in this code but 
should not be included in the rating process, unless it is clear that the 
participant feels the change is needed but that the program cannot be 
adapted. However, it may be possible to infer that a large number of 
suggestions for improvement demonstrates lack of compatibility, see 
exclusion criteria below.  
 
Exclusion Criteria: Exclude or double code statements that the innovation 
did or did not need to be adapted to Compatibility.  
E. Trialability Definition: The ability to test the innovation on a small scale in the 
organization, and to be able to reverse course (undo implementation) if 
warranted. 
 
Inclusion Criteria: Include statements related to whether the site piloted 
the innovation in the past or has plans to in the future, and comments 
about whether they believe it is (im)possible to conduct a pilot.  
 
Exclusion Criteria: Exclude or double code descriptions of use of results 
from local or regional pilots to Evidence Strength & Quality. 
F. Complexity Definition: Perceived difficulty of the innovation, reflected by duration, 
scope, radicalness, disruptiveness, centrality, and intricacy and number of 
steps required to implement.  
 
Inclusion Criteria: Code statements regarding the complexity of the 
innovation itself. 
 
Exclusion Criteria: Exclude statements regarding the complexity of 
implementation and code to the appropriate CFIR code, e.g., difficulties 
related to space are coded to Available Resources and difficulties related 
to engaging participants in a new program are coded to Engaging: 
Innovation Participants.  
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G. Design Quality 
& Packaging 
Definition: Perceived excellence in how the innovation is bundled, 
presented, and assembled.  
 
Inclusion Criteria: Include statements regarding the quality of the 
materials and packaging. 
 
Exclusion Criteria: Exclude statements regarding the presence or absence 
of materials and code to Available Resources.  
 
Exclude statements regarding the receipt of materials as an engagement 
strategy and code to Engaging.  
H. Cost Definition: Costs of the innovation and costs associated with 
implementing the innovation including investment, supply, and 
opportunity costs.  
 
Inclusion Criteria: Include statements related to the cost of the innovation 
and its implementation. 
 
Exclusion Criteria: Exclude statements related to physical space and time, 
and code to Available Resources. In a research study, exclude statements 
related to costs of conducting the research components (e.g., funding for 
research staff, participant incentives).  
II. Outer Setting  
A. Needs & 
Resources of 
Those Served by 
the Organization  
Definition: The extent to which the needs of those served by the 
organization (e.g., patients), as well as barriers and facilitators to meet 
those needs, are accurately known and prioritized by the organization. 
 
Inclusion Criteria: Include statements demonstrating (lack of) awareness 
of the needs and resources of those served by the organization. Analysts 
may be able to infer the level of awareness based on statements about: 1. 
Perceived need for the innovation based on the needs of those served by 
the organization and if the innovation will meet those needs; 2. Barriers 
and facilitators of those served by the organization to participating in the 
innovation; 3. Participant feedback on the innovation, i.e., satisfaction and 
success in a program. In addition, include statements that capture whether 
or not awareness of the needs and resources of those served by the 
organization influenced the implementation or adaptation of the 
innovation. 
 
Exclusion Criteria: Exclude statements that demonstrate a strong need for 
the innovation and/or that the current situation is untenable and code to 
Tension for Change.  
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Exclude statements related to engagement strategies and outcomes, e.g., 
how innovation participants became engaged with the innovation, and 
code to Engaging: Innovation Participants.   
B. Cosmopolitanism Definition: The degree to which an organization is networked with other 
external organizations.  
 
Inclusion Criteria: Include descriptions of outside group memberships and 
networking done outside the organization. 
 
Exclusion Criteria: Exclude statements about general networking, 
communication, and relationships in the organization, such as descriptions 
of meetings, email groups, or other methods of keeping people connected 
and informed, and statements related to team formation, quality, and 
functioning, and code to Networks & Communications. 
C. Peer Pressure Definition: Mimetic or competitive pressure to implement an innovation, 
typically because most or other key peer or competing organizations have 
already implemented or are in a bid for a competitive edge.  
 
Inclusion Criteria: Include statements about perceived pressure or 
motivation from other entities or organizations in the local geographic 
area or system to implement the innovation. 
 
Exclusion Criteria:  
D. External Policy 
& Incentives 
Definition: A broad construct that includes external strategies to spread 
innovations including policy and regulations (governmental or other 
central entity), external mandates, recommendations and guidelines, pay-
for-performance, collaboratives, and public or benchmark reporting. 
 
Inclusion Criteria: Include descriptions of external performance measures 
from the system. 
 
Exclusion Criteria:   
III.  Inner Setting  
A. Structural 
Characteristics 
Definition: The social architecture, age, maturity, and size of an 
organization. 
 
Inclusion Criteria: 
 
Exclusion Criteria:  
B. Networks & 
Communications 
Definition: The nature and quality of webs of social networks, and the 
nature and quality of formal and informal communications within an 
organization. 
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Inclusion Criteria: Include statements about general networking, 
communication, and relationships in the organization, such as descriptions 
of meetings, email groups, or other methods of keeping people connected 
and informed, and statements related to team formation, quality, and 
functioning. 
 
Exclusion Criteria: Exclude statements related to implementation leaders' 
and users' access to knowledge and information regarding using the 
program, i.e., training on the mechanics of the program and code to 
Access to Knowledge & Information.  
 
Exclude statements related to engagement strategies and outcomes, e.g., 
how key stakeholders became engaged with the innovation and what their 
role is in implementation, and code to Engaging: Key Stakeholders. 
 
Exclude descriptions of outside group memberships and networking done 
outside the organization and code to Cosmopolitanism. 
C. Culture Definition: Norms, values, and basic assumptions of a given organization. 
 
Inclusion Criteria: Inclusion criteria, and potential sub-codes, will depend 
on the framework or definition used for “culture.” For example, if using 
the Competing Values Framework (CVF), you may include four sub-
codes related to the four dimensions of the CVF and code statements 
regarding one or more of the four dimension in an organization.  
 
Exclusion Criteria:  
D. Implementation 
Climate 
Definition: The absorptive capacity for change, shared receptivity of 
involved individuals to an innovation, and the extent to which use of that 
innovation will be rewarded, supported, and expected within their 
organization.  
 
Inclusion Criteria: Include statements regarding the general level of 
receptivity to implementing the innovation. 
 
Exclusion Criteria: Exclude statements regarding the general level of 
receptivity that are captured in the sub-codes. 
1. Tension for 
Change 
Definition: The degree to which stakeholders perceive the current 
situation as intolerable or needing change.  
 
Inclusion Criteria: Include statements that (do not) demonstrate a strong 
need for the innovation and/or that the current situation is untenable, e.g., 
statements that the innovation is absolutely necessary or that the 
innovation is redundant with other programs. Note: If a participant states 
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that the innovation is redundant with a preferred existing program, 
(double) code lack of Relative Advantage, see exclusion criteria below. 
Exclusion Criteria: Exclude statements regarding specific needs of 
individuals that demonstrate a need for the innovation, but do not 
necessarily represent a strong need or an untenable status quo, and code to 
Needs and Resources of Those Served by the Organization.   
 
Exclude statements that demonstrate the innovation is better (or worse) 
than existing programs and code to Relative Advantage. 
2. Compatibility Definition: The degree of tangible fit between meaning and values 
attached to the innovation by involved individuals, how those align with 
individuals’ own norms, values, and perceived risks and needs, and how 
the innovation fits with existing workflows and systems.  
 
Inclusion Criteria: Include statements that demonstrate the level of 
compatibility the innovation has with organizational values and work 
processes. Include statements that the innovation did or did not need to be 
adapted as evidence of compatibility or lack of compatibility.  
 
Exclusion Criteria: Exclude or double code statements regarding the 
priority of the innovation based on compatibility with organizational 
values to Relative Priority, e.g., if an innovation is not prioritized because 
it is not compatible with organizational values. 
3. Relative Priority Definition: Individuals’ shared perception of the importance of the 
implementation within the organization.  
 
Inclusion Criteria: Include statements that reflect the relative priority of 
the innovation, e.g., statements related to change fatigue in the 
organization due to implementation of many other programs. 
 
Exclusion Criteria: Exclude or double code statements regarding the 
priority of the innovation based on compatibility with organizational 
values to Compatibility, e.g., if an innovation is not prioritized because it 
is not compatible with organizational values. 
4. Organizational 
Incentives & 
Rewards 
Definition: Extrinsic incentives such as goal-sharing, awards, performance 
reviews, promotions, and raises in salary, and less tangible incentives such 
as increased stature or respect. 
 
Inclusion Criteria: Include statements related to whether organizational 
incentive systems are in place to foster (or hinder) implementation, e.g., 
rewards or disincentives for staff engaging in the innovation. 
 
Exclusion Criteria:   
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5. Goals & 
Feedback 
Definition: The degree to which goals are clearly communicated, acted 
upon, and fed back to staff, and alignment of that feedback with goals.  
 
Inclusion Criteria: Include statements related to the (lack of) alignment of 
implementation and innovation goals with larger organizational goals, as 
well as feedback to staff regarding those goals, e.g., regular audit and 
feedback showing any gaps between the current organizational status and 
the goal. Goals and Feedback include organizational processes and 
supporting structures independent of the implementation process. 
Evidence of the integration of evaluation components used as part of 
“Reflecting and Evaluating” into on-going or sustained organizational 
structures and processes may be (double) coded to Goals and Feedback.  
 
Exclusion Criteria: Exclude statements that refer to the implementation 
team’s (lack of) assessment of the progress toward and impact of 
implementation, as well as the interpretation of outcomes related to 
implementation, and code to Reflecting & Evaluating. Reflecting and 
Evaluating is part of the implementation process; it likely ends when 
implementation activities end. It does not require goals be explicitly 
articulated; it can focus on descriptions of the current state with real-time 
judgment, though there may be an implied goal (e.g., we need to 
implement the innovation) when the implementation team discusses 
feedback in terms of adjustments needed to complete implementation. 
6. Learning 
Climate 
Definition: A climate in which: 1. Leaders express their own fallibility 
and need for team members’ assistance and input; 2. Team members feel 
that they are essential, valued, and knowledgeable partners in the change 
process; 3. Individuals feel psychologically safe to try new methods; and 
4. There is sufficient time and space for reflective thinking and evaluation.  
 
Inclusion Criteria: Include statements that support (or refute) the degree to 
which key components of an organization exhibit a “learning climate.” 
 
Exclusion Criteria:  
E. Readiness for 
Implementation 
Definition: Tangible and immediate indicators of organizational 
commitment to its decision to implement an innovation. 
 
Inclusion Criteria: Include statements regarding the general level of 
readiness for implementation.  
 
Exclusion Criteria: Exclude statements regarding the general level of 
readiness for implementation that are captured in the sub-codes. 
1. Leadership 
Engagement 
Definition: Commitment, involvement, and accountability of leaders and 
managers with the implementation of the innovation.  
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Inclusion Criteria: Include statements regarding the level of engagement 
of organizational leadership. 
 
Exclusion Criteria: Exclude or double code statements regarding 
leadership engagement to Engaging: Formally Appointed Internal 
Implementation Leaders or Champions if an organizational leader is also 
an implementation leader, e.g., if a director of primary care takes the lead 
in implementing a new treatment guideline. Note that a key characteristic 
of this Implementation Leader/Champion is that s/he is also an 
Organizational Leader. 
2. Available 
Resources 
Definition: The level of resources organizational dedicated for 
implementation and on-going operations including physical space and 
time. 
 
Inclusion Criteria: Include statements related to the presence or absence of 
resources specific to the innovation that is being implemented. 
 
Exclusion Criteria: Exclude statements related to training and education 
and code to Access to Knowledge & Information.  
 
Exclude statements related to the quality of materials and code to Design 
Quality & Packaging. 
 
In a research study, exclude statements related to resources needed for 
conducting the research components (e.g., time to complete research 
tasks, such as IRB applications, consenting patients).   
3. Access to 
Knowledge & 
Information 
Definition: Ease of access to digestible information and knowledge about 
the innovation and how to incorporate it into work tasks.  
 
Inclusion Criteria: Include statements related to implementation leaders' 
and users' access to knowledge and information regarding use of the 
program, i.e., training on the mechanics of the program. 
 
Exclusion Criteria: Exclude statements related to engagement strategies 
and outcomes, e.g., how key stakeholders became engaged with the 
innovation and what their role is in implementation, and code to 
Engaging: Key Stakeholders.  
 
Exclude statements about general networking, communication, and 
relationships in the organization, such as descriptions of meetings, email 
groups, or other methods of keeping people connected and informed, and 
statements related to team formation, quality, and functioning, and code to 
Networks & Communications. 
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IV.  Characteristics 
of Individuals 
 
1. Knowledge & 
Beliefs about 
the Innovation  
Definition: Individuals’ attitudes toward and value placed on the 
innovation, as well as familiarity with facts, truths, and principles related 
to the innovation. 
 
Inclusion Criteria: 
 
Exclusion Criteria: Exclude statements related to familiarity with evidence 
about the innovation and code to Evidence Strength & Quality. 
2. Self-efficacy Definition: Individual belief in their own capabilities to execute courses of 
action to achieve implementation goals.  
 
Inclusion Criteria: 
 
Exclusion Criteria:  
3. Individual 
Stage of 
Change 
Definition: Characterization of the phase an individual is in, as s/he 
progresses toward skilled, enthusiastic, and sustained use of the 
innovation. 
 
Inclusion Criteria: 
 
Exclusion Criteria:  
4. Individual 
Identification 
with 
Organization  
Definition: A broad construct related to how individuals perceive the 
organization, and their relationship and degree of commitment with that 
organization.  
 
Inclusion Criteria: 
 
Exclusion Criteria: 
5. Other 
Personal 
Attributes 
Definition: A broad construct to include other personal traits such as 
tolerance of ambiguity, intellectual ability, motivation, values, 
competence, capacity, and learning style. 
 
Inclusion Criteria: 
 
Exclusion Criteria:  
V. Process  
A. Planning Definition: The degree to which a scheme or method of behavior and tasks 
for implementing an innovation are developed in advance, and the quality 
of those schemes or methods. 
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Inclusion Criteria: Include evidence of pre-implementation diagnostic 
assessments and planning, as well as refinements to the plan. 
 
Exclusion Criteria:  
B. Engaging Definition: Attracting and involving appropriate individuals in the 
implementation and use of the innovation through a combined strategy of 
social marketing, education, role modeling, training, and other similar 
activities. 
 
Inclusion Criteria: Include statements related to engagement strategies and 
outcomes, i.e., if and how staff and innovation participants became 
engaged with the innovation and what their role is in implementation. 
Note: Although both strategies and outcomes are coded here, the outcome 
of engagement efforts determines the rating, i.e., if there are repeated 
attempts to engage staff that are unsuccessful, or if a role is vacant, the 
construct receives a negative rating. In addition, you may also want to 
code the "quality" of staff - their capabilities, motivation, and skills, i.e., 
how good they are at their job, and this data affects the rating as well. 
 
Exclusion Criteria: Exclude statements related to specific sub constructs, 
e.g., Champions or Opinion Leaders. 
 
Exclude or double code statements related to who participated in the 
decision process to implement the innovation to Innovation Source, as an 
indicator of internal or external innovation source. 
1. Opinion 
Leaders 
Definition: Individuals in an organization that have formal or informal 
influence on the attitudes and beliefs of their colleagues with respect to 
implementing the innovation. 
 
Inclusion Criteria: Include statements related to engagement strategies and 
outcomes, e.g., how the opinion leader became engaged with the 
innovation and what their role is in implementation. Note: Although both 
strategies and outcomes are coded here, the outcome of efforts to engage 
staff determines the rating, i.e., if there are repeated attempts to engage an 
opinion leader that are unsuccessful, or if the opinion leader leaves the 
organization and this role is vacant, the construct receives a negative 
rating. In addition, you may also want to code the "quality" of the opinion 
leader here - their capabilities, motivation, and skills, i.e., how good they 
are at their job, and this data affects the rating as well. 
 
Exclusion Criteria:  
  
236 
2. Formally 
Appointed 
Internal 
Implementati
on Leaders 
Definition: Individuals from within the organization who have been 
formally appointed with responsibility for implementing an innovation as 
coordinator, project manager, team leader, or other similar role.  
 
Inclusion Criteria: Include statements related to engagement strategies and 
outcomes, e.g., how the formally appointed internal implementation leader 
became engaged with the innovation and what their role is in 
implementation. Note: Although both strategies and outcomes are coded 
here, the outcome of efforts to engage staff determines the rating, i.e., if 
there are repeated attempts to engage an implementation leader that are 
unsuccessful, or if the implementation leader leaves the organization and 
this role is vacant, the construct receives a negative rating. In addition, 
you may also want to code the "quality" of the implementation leader here 
- their capabilities, motivation, and skills, i.e., how good they are at their 
job, and this data affects the rating as well. 
 
Exclusion Criteria: Exclude or double code statements regarding 
leadership engagement to Leadership Engagement if an implementation 
leader is also an organizational leader, e.g., if a director of primary care 
takes the lead in implementing a new treatment guideline. 
3. Champions Definition: “Individuals who dedicate themselves to supporting, 
marketing, and ‘driving through’ an [implementation]”, overcoming 
indifference or resistance that the innovation may provoke in an 
organization. 
 
Inclusion Criteria: Include statements related to engagement strategies and 
outcomes, e.g., how the champion became engaged with the innovation 
and what their role is in implementation. Note: Although both strategies 
and outcomes are coded here, the outcome of efforts to engage staff 
determines the rating, i.e., if there are repeated attempts to engage a 
champion that are unsuccessful, or if the champion leaves the organization 
and this role is vacant, the construct receives a negative rating. In 
addition, you may also want to code the "quality" of the champion here - 
their capabilities, motivation, and skills, i.e., how good they are at their 
job, and this data affects the rating as well. 
 
Exclusion Criteria: Exclude or double code statements regarding 
leadership engagement to Leadership Engagement if a champion is also an 
organizational leader, e.g., if a director of primary care takes the lead in 
implementing a new treatment guideline. 
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4. External 
Change 
Agents  
Definition: Individuals who are affiliated with an outside entity who 
formally influence or facilitate innovation decisions in a desirable 
direction.  
 
Inclusion Criteria: Include statements related to engagement strategies and 
outcomes, e.g., how the external change agent (entities outside the 
organization that facilitate change) became engaged with the innovation 
and what their role is in implementation, e.g., how they supported 
implementation efforts. Note: Although both strategies and outcomes are 
coded here, the outcome of efforts to engage staff determines the rating, 
i.e., if there are repeated attempts to engage an external change agent that 
are unsuccessful, or if the external change agent leaves their organization 
and this role is vacant, the construct receives a negative rating. In 
addition, you may also want to code the "quality" of the external change 
agent here - their capabilities, motivation, and skills, i.e., how good they 
are at their job, and this data affects the rating as well.  
 
Exclusion Criteria: Note: It is important to clearly define what roles are 
external and internal to the organization. Exclude statements regarding 
facilitating activities, such as training in the mechanics of the program, 
and code to Access to Knowledge & Information if the change agent is 
considered internal to the study, e.g., a staff member at the national office. 
If the study considers this staff member internal to the organization, it 
should be coded to Access to Knowledge & Information, even though 
their support may overlap with what would be expected from an External 
Change Agent. 
5. Key 
Stakeholders   
Definition: Individuals from within the organization that are directly 
impacted by the innovation, e.g., staff responsible for making referrals to 
a new program or using a new work process.  
 
Inclusion Criteria: Include statements related to engagement strategies and 
outcomes, e.g., how key stakeholders became engaged with the innovation 
and what their role is in implementation. Note: Although both strategies 
and outcomes are coded here, the outcome of efforts to engage staff 
determines the rating, i.e., if there are repeated attempts to engage key 
stakeholders that are unsuccessful, the construct receives a negative 
rating. 
 
Exclusion Criteria: Exclude statements related to implementation leaders' 
and users' access to knowledge and information regarding using the 
program, i.e., training on the mechanics of the program, and code to 
Access to Knowledge & Information.  
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Exclude statements about general networking, communication, and 
relationships in the organization, such as descriptions of meetings, email 
groups, or other methods of keeping people connected and informed, and 
statements related to team formation, quality, and functioning, and code to 
Networks & Communications.  
6. Innovation 
Participants 
Definition: Individuals served by the organization that participate in the 
innovation, e.g., patients in a prevention program in a hospital.  
 
Inclusion Criteria: Include statements related to engagement strategies and 
outcomes, e.g., how innovation participants became engaged with the 
innovation. Note: Although both strategies and outcomes are coded here, 
the outcome of efforts to engage participants determines the rating, i.e., if 
there are repeated attempts to engage participants that are unsuccessful, 
the construct receives a negative rating. 
 
Exclusion Criteria: Exclude statements demonstrating (lack of) awareness 
of the needs and resources of those served by the organization and 
whether or not that awareness influenced the implementation or 
adaptation of the innovation and code to Needs & Resources of Those 
Served by the Organization.  
C. Executing Definition: Carrying out or accomplishing the implementation according 
to plan.  
 
Inclusion Criteria: Include statements that demonstrate how 
implementation occurred with respect to the implementation plan. Note: 
Executing is coded very infrequently due to a lack of planning. However, 
some studies have used fidelity measures to assess executing, as an 
indication of the degree to which implementation was accomplished 
according to plan.  
 
Exclusion Criteria:  
D. Reflecting & 
Evaluating 
Definition: Quantitative and qualitative feedback about the progress and 
quality of implementation accompanied with regular personal and team 
debriefing about progress and experience. 
 
Inclusion Criteria: Include statements that refer to the implementation 
team’s (lack of) assessment of the progress toward and impact of 
implementation, as well as the interpretation of outcomes related to 
implementation. Reflecting and Evaluating is part of the implementation 
process; it likely ends when implementation activities end. It does not 
require goals be explicitly articulated; it can focus on descriptions of the 
current state with real-time judgment, though there may be an implied 
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goal (e.g., we need to implement the innovation) when the implementation 
team discusses feedback in terms of adjustments needed to complete 
implementation. 
 
Exclusion Criteria: Exclude statements related to the (lack of) alignment 
of implementation and innovation goals with larger organizational goals, 
as well as feedback to staff regarding those goals, e.g., regular audit and 
feedback showing any gaps between the current organizational status and 
the goal, and code to Goals & Feedback. Goals and Feedback include 
organizational processes and supporting structures independent of the 
implementation process. Evidence of the integration of evaluation 
components used as part of “Reflecting and Evaluating” into on-going or 
sustained organizational structures and processes may be (double) coded 
to Goals and Feedback.  
 
Exclude statements that capture reflecting and evaluating that participants 
may do during the interview, for example, related to the success of the 
implementation, and code to Knowledge & Beliefs about the Innovation. 
VI.  Additional 
Codes 
 
A. Code Name  Definition:  
 
Inclusion Criteria: 
 
Exclusion Criteria:  
B. Code Name   Definition:  
 
Inclusion Criteria: 
 
Exclusion Criteria:  
 
General Coding Rules: 
When two codes are in question for a passage, consider the primary meaning of the passage to 
assign code; consider what the participant is truly saying. Analysts may wish to err on the side of 
inclusion or double coding.  
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